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Ado I KAUI
Tardive dyskinesia is now widely recognised as a neurological disorder 
associated with the administration of antipsychotic drugs. 
Prevalence is higher among the elderly. The cause is unknown but 
the hypothesis of hypersensitivity of post-synaptic dopamine 
receptors is currently generally accepted. Many therapeutic 
approaches have been suggested but there is no completely 
satisfactory treatment at present.
The main purpose of this study was to undertake a survey of the 
prevalence of the disorder in a sample of elderly subjects who were 
resident in local authority homes for the elderly, and to determine 
what drugs were associated with the condition. A total of 500 elderly 
subjects were examined for dyskinetic movements and a prevalence 
rate of 15 per cent was identified. Association of. tardive dyskinesia 
with antipsychotic agents, antiparkinsonian agents and the benzo­
diazepines was investigated.
Preliminary work to the main subject included an evaluation of the 
various rating procedures, followed by a pilot study in a group of 
long-stay mental handicap patients.
Following earlier reports of the success of co-dergocrine in treating 
tardive dyskinesia, a double-blind study was carried out in a group of 
43 patients who had been hospitalised for many years and in whom 
the disorder was firmly established.
The implications for psychiatry of tardive dyskinesia are discussed 
and the current practices for management of the syndrome are 
considered. Research strategies are reviewed and, finally, 
recommendations are made for both the strategy to limit the 
incidence of tardive dyskinesia and the management of the problem if 
it arises.
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BACKGROUND. TO THE STUDY
"One of the first things I noticed about Old Granny Trill was that she 
always seemed to be chewing, sliding her folded gums together in a daylong 
ruminative cud. I took this to be one of the tricks of age, a kind of slowed- 
up but protracted feasting. I imagined her being delivered a quartern loaf - 
say, on a Friday night -  then packing the lot into her rubbery cheeks and 
chewing them slowly through the week”.
From: Cider with Rosie, by Laurie Lee
The tardive dyskinesia syndrome was overlooked for many years, probably 
because abnormal movements have been common in chronic psychiatric 
patients for centuries. A senile chorea manifested by chewing movements 
was observed in the elderly long before phenothiazines were ever used; and 
the line between some of the abnormal movements seen in patients with 
presumed tardive dyskinesia and the rocking movements seen in chronically 
institutionalised mental handicap patients and chronically psychotic 
patients in the predrug era is hard to define (Cole, 1976).
This project arises because of the concern over the association of tardive 
dyskinesia with long term antipsychotic medication,and the subsequent 
effect that this might have on the drug treatment of mental illness. The 
need for further research in this field has been advocated by many authors 
(Cole, 1976; Marsden, 1976a; Davis & Casper, 1978; Sovner, 1978; Lancet,
1979). The main objectives of this research are to establish further the 
relevance of tardive dyskinesia to antipsychotic drug therapy, to determine 
which antipsychotic drugs are associated with the disorder, and whether 
any particular drug is less likely to cause tardive dyskinesia.
It is also necessary to establish the extent to which established tardive 
dyskinesia can be treated, and one such therapeutic agent is investigated 
and reported. Recommendations are also made in respect of minimising 
the risks of producing tardive dyskinesia.
THE PREVALENCE OF ANTIPSYCHOTIC MEDICATION
From the introduction of chlorpromazine in 1952, antipsychotic medication 
has played a key role in the transformation that has taken place in the 
treatment of mental illness. Patients previously so unmanageable that 
they would perhaps have been immured in a mental institution for the rest 
of their lives have responded to drug treatment and, with suitable 
rehabilitation measures and adequate domicilary support, have returned to 
the community to lead relatively normal lives (Norton, 1978).
George (1978) stated that most doctors would agree that modern anti­
depressants and tranquillisers have revolutionised the management of 
psychiatric illness. Because of their effectiveness, and the frequency of 
mental illness in the community, antipsychotic drugs are now among the 
most widely prescribed groups of drugs in practice. Parkes (1976) 
estimated that 250 million prescriptions for antipsychotic drugs, anti­
depressants and minor tranquillisers are issued yearly in the United States, 
where 20 per cent of the population use them once or more each year.
ADVERSE EFFECTS OF ANTIPSYCHOTIC DRUGS
"You cannot have therapeutic roses without therapeutic thorns"
Sir Derrick Dunlop
Since their introduction into psychiatry in the early 1950’s the anti­
psychotic drugs have been shown to be remarkably safe compounds. Hall
(1977) stated that serious drug side effects are rare and are perhaps the 
only instances of which journals will publish a single case report. Certain 
antipsychotic drugs do occasionally cause serious side effects such as 
agranulocytosis and jaundice, and those of a less serious nature such as 
oculocutaneous changes, galactorrhoea, amenorrhoea, weight gain, 
constipation, and disturbances of the central nervous system which include 
somnolence, Parkinsonism, akathisia, dystonia and persistent dyskinesias 
(Shepherd, Lader & Lader, 1972; Davis & Casper, 1978).
In considering unwanted effects of antipsychotic drugs, Edwards (1977) 
observed that most treatment, whether medical or surgical, carries risks, 
and the price paid for progress in psychopharmacology has been a wide 
range of adverse effects. Hall (1977) in discussing the choice of medical 
treatment in schizophrenia concluded that treating a common, chronic and 
extremely crippling and tragic mental illness with an appalling untreated 
morbidity and, at times, mortality rate, justifies some therapeutic risks.
MOVEMENT DISORDERS ASSOCIATED WITH ANTIPSYCHOTIC
MEDICATION
Antipsychotic drugs, known also as neuroleptics, have been shown to 
produce a variety of movement disorders. These may be divided into the 
extrapyramidal side effects, such as hypokinesia, hyperkinesia, dystonia 
and myoclonus, and the delayed onset abnormal movements known as 
tardive dyskinesia.
1.4.1 Hypokinesia, Hyperkinesia, Dystonia and Myoclonus
Extrapyramidal reactions are the most dramatic of the CNS side 
effects of antipsychotic drugs. The characteristic syndromes 
which these drugs produce, probably by acting on higher EP 
centres, are as follows:
hypokinesia associated with rigidity and tremor, as seen in the 
classical Parkinsonian syndrome;
hyperkinesias of different kinds; choreiform, athetoid and ballistic 
movement disorders;
dystonia and other dyskinetic states similar to those found in 
dystonia musculorum deformans (torsion dystonia) and myoclonus 
(Hornykiewicz & Klawans, 1978).
These side effects are discussed in greater detail in Chapter 2 
(2.5.2), and generally speaking they occur within the first few days 
of treatment and most can be controlled by the addition of anti­
parkinsonian drugs (benztropine, procyclidine, diphenhydramine, 
trihexyphenidyl, orphenadrine, chlorphenoxamine, etc.) (Davis Sc 
Casper, 1978).
More recently considerable attention has been focussed on a long­
term extrapyramidal syndrome which occurs late in the course of 
treatment with antipsychotic drugs, and because of the delay in 
onset of involuntary movements the term "tardive dyskinesia" has 
been applied.
1.4.2 Tardive Dyskinesia
In a leading article, (Lancet, 1979) tardive dyskinesia is described 
as a syndrome, or several syndromes, of involuntary movement 
arising in psychiatric patients taking antipsychotic drugs; in order 
to meet the definition the disorder must be persistent and must not 
have preceded the onset of antipsychotic medication. Most of the 
patients are chronic schizophrenics and the condition begins 
insidiously with exaggerated and persistent chewing movements, or 
variations such as sucking and smacking movements, tongue 
protrusion, grimacing and grunting.
Whilst the cause of tardive dyskinesia is unknown (Task Force,
1980) it has been suggested that antipsychotic drugs produce a 
chronic blockade of post-synaptic dopamine receptors which 
increases sensitivity of these receptors to a hyper or super- 
sensitivity state (Rubovits & Klawans, 1972; Klawans 1973a; 
Gerlach, Reisby & . Randrup, 1974; Curzon, 1976; Lader, 1978).
Clinical reports began to appear in the middle 1950's describing 
involuntary movement disorders in psychiatric patients undergoing 
treatment with antipsychotic drugs (Ey, Faure & Rappard, 1956; 
Hall, Jackson & Swain, 1956; & Schonecker, 1957). A review of 
these reports, and the increasing number of publications reporting 
many further cases, follows in Chapter 2. Despite the frequency of 
reports little attention was given to the syndrome.
THE EFFECT OF TARDIVE DYSKINESIA ON THE USE OF ANTI-
PYSCHOTIC DRUGS
An editorial in the Lancet (1979) observed that although.tardive dyskinesia 
was first described more than 20 years ago, for a long time recognition of 
the syndrome had little impact on prescribing habits. Some psychiatrists 
seemed reluctant even to accept that the mainstay of the treatment of 
schizophrenia, the antipsychotic drugs, might have irreversible side- 
effects; others saw the dyskinesia as a reasonable price to pay for good 
control of psychosis.
Gibson (1978a) mentioned that in treating nearly 400 patients with depot 
antipsychotics over a 5 year period, 63 of them developed tardive 
dyskinesia. He observed that depot injections had allowed many people to 
lead reasonably normal lives outside hospital and that it was surely better 
to have involuntary movements of the lower face and tongue than to suffer 
the disturbing perceptions of uncontrolled schizophrenia.
Lader (1970) observed that irreversible dyskinesias are a serious drawback 
to antipsychotic therapy. This is emphasised by the fact that a wide 
variety of drugs have been used to treat the symptoms of tardive 
dyskinesia, and the results have been disappointing (Lancet, 1979).
The relative lack of appreciation of their symptoms by patients suffering 
from tardive dyskinesia was mentioned in a review article by Granacher
(1978), who stated that most chronically psychotic or institutionalised 
patients showed little or no concern for their malady. The patients who 
were most likely to be embarrassed by the movements were the neurotic or 
those with personality disorders. Some individuals were likely to have 
sufficient truncal and extremity dyskinesia to interfere with their jobs.
This opinion was supported by Gibson (1978b) who in reporting a 22 per cent 
prevalence of tardive dyskinesia in a study of 374 psychiatric out-patients, 
stated that in three-quarters of those affected, symptoms were mild and 
that whilst mild tardive dyskinesia may pass unnoticed among the socially 
handicapped population of a long-stay hospital ward, its presence in a 
patient in the community can be distressing to observers.
Paulson (1968) in an investigation involving nearly 500 patients, observed 
that complex dyskinesias despite their unpleasant appearance rarely disturb 
patients. The movements usually continue in the absence of awareness and 
are often worse after exertion. Secondary difficulties may arise such as 
the inability to retain dentures, or erosion and dryness of the tongue.
Sovner (1978) in presenting filmed records of patients showing tardive 
dyskinesia, commented that the disorder was one of the most critical 
problems facing psychiatry in the coming decade. He drew attention to the 
fact that several law suits were pending in the United States, initiated by 
people who had become alarmed at the appearance of tardive dyskinesia in 
their relatives who had been treated with antipsychotic drugs. In 
conclusion he stated that if the therapeutic gains which have been made in 
the treatment of psychosis over the past 20 years were not to be undone, 
then the entire mental health community must address the clinical issues 
of tardive dyskinesia.
TARDIVE DYSKINESIA AND SPONTANEOUS DYSKINESIA
One criticism of the concept of tardive dyskinesia is that dyskinesia 
frequently occurs spontaneously among chronic psychiatric patients, 
especially the elderly - the group that is also most prone to develop tardive
dyskinesia (Jeste & Wyatt, 1981). Abnormalities of posture and movement 
were reported in schizophrenic patients before the use of antipsychotic 
drugs (Marsden, Tarsy & Baldessarini, 1975).
In reviewing 12 major studies, involving a total of 4340 patients comparing 
the prevalence of dyskinesia among antipsychotic-treated and non- 
antipsychotic-treated patients, Jeste & Wyatt (1981) reported that 10 of 
these 12 studies found a significantly higher prevalence among anti­
psychotic-treated patients. All of the studies were done with chronic 
patients in psychiatric hospitals or nursing homes. When all 12 studies 
were taken together, the overall weighted mean prevalence of dyskinesia 
for chronically institutionalised individuals was 3.25 times greater in 
the antipsychotic-treated patients.
STUDY OBJECTIVES
In view of the impact of tardive dyskinesia on the use of antipsychotic 
medication in the treatment of mental illness, the purpose of the studies 
described in this thesis was to study methods of assessing tardive 
dyskinesia, determining prevalence rates in the non-hospitalised elderly and 
evaluating the effectiveness of a drug in the treatment of the syndrome.
1-7.1' Review of Literature
Chapter 2 outlines the impact of antipsychotic drugs on the 
treatment of mental illness. The range of effects and side effects 
observed following administration of these compounds is presented. 
The emergence of tardive dyskinesia as a late and gradually 
appearing neurological side effect syndrome is reviewed and its
importance concerning the future use of antipsychotic medication 
is considered.
1.7.2 Methods of Assessing Tardive Dyskinesia
The fact that there is no currently accepted standard for diagnosis 
of tardive dyskinesia has meant that it has been nearly impossible 
to specify precise prevalence rates (Task Force, 1980). In Chapter 
3, the various methods employed in assessing tardive dyskinesia are 
considered. The use of videotapes to test inter-rater and intra- 
rater reliability is described, and the technique chosen for 
subsequent studies is detailed, together with a small pilot study to 
test its reliability.
1.7.3 Pilot Study to Test Rating Technique
Chapter 4 reports on a pilot study carried out in a ward for 
mentally handicapped patients by two raters in order to establish 
the reliability and validity of the rating technique for subsequent 
work.
L7.4 Prevalence of Tardive Dyskinesia in the Elderly
‘ The aim of this part of the study (Chapter 5) was to examine 500 
elderly subjects who were either resident in or attending each day 
a home for the elderly to establish the prevalence rate of tardive 
dyskinesia in a moderate sized population sample, and to determine 
the difference between those treated with antipsychotic drugs and 
the non-antipsychotic treated group.
1.7.5 Evaluation of Co-dergocrine in the Treatment of Tardive Dyskinesia
Chapter 6 describes a double-blind evaluation of co-dergocrine in 
the treatment of 43 patients showing signs of tardive dyskinesia. 
This was an attempt to confirm earlier promising open, 
uncontrolled studies with the compound (Gomez, 1977; Hajioff,
1978).
1.7.6 General Discussion and Recommendations
The implications of these studies are outlined in Chapter 7 
together with suggestions for further work. Recommendations are 
made for preventing tardive dyskinesia, and progress in the 
development of compounds less likely to cause the syndrome is 
discussed.
SUMMARY
This chapter introduces the subject of the study. It outlines the 
importance of antipsychotic medication in the treatment of mental 
disorders, and how the antipsychotic drugs have contributed to the 
rehabilitation of the mentally ill from isolated institutions to the 
community. The safety of antipsychotic drugs is described and their 
serious and less serious side effects are listed. The emergence of tardive 
dyskinesia as a major problem in the long-term use of antipsychotic 
medication is introduced and its effect on current and future use of 
antipsychotic drugs is considered.
The main study objectives are set out and the reasons stated as to why they 
should be undertaken.
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HISTORICAL BACKGROUND TO THE TREATMENT OF MENTAL
ILLNESS
Disorders of the mind have been the subject of study throughout recorded 
history and there have been many theories on both the causes and 
treatment. For the most part these theories have been based on a 
combination of ignorance and fear of the unknown, and it is only very 
recently that rational thought has been applied to psychiatric problems.
From Neolithic times when trepanning involving the drilling of holes in the 
skulls of insane patients to let out evil spirits, the history of psychiatry in 
Western civilisation has been characterised by the imposition of physical 
suffering on the patient - whether the approach was active, for example 
whipping; or passive, such as manacling and the use of the strait-jacket 
(Sargant 1967; Hamilton, 1978).
The mentally ill were subjected to treatments which included blood letting, 
dousing with cold water, and centrifugalisation, and evidence of these 
latter methods is to be seen in the museum set up at Brookwood Hospital, 
Surrey. Restraint was frequently used and many of those responsible for 
the care of ’’the insane" were concerned only with ensuring custody and 
control, often by crude physical restraint (Office of Health Economics,
1979). In a lecture at the Institute of Psychiatry, Allderidge (1979) 
observed that from at least 1348 it was lawful to beat one’s mad kinfolk 
with a rod if with nothing else; and that from some time before 1482 it was 
lawful to imprison a lunatic provided you could be fairly sure he was going 
to burn down a house; and that from the end of the sixteenth century these 
two circumstances began to appear in the Justices’ manuals. In the manual
of 1581 it is stated that "Every man also may take his kinsman that is mad, 
and may put him in a house, and bind him and beat him with rods, without 
breach of the Peace" (Lambard, 1581). Allderidge added that the beating 
with rods was considered to be one of the appropriate remedies for 
insanity at that time. In suggesting that the care of the mentally ill has 
been going round in circles for at least the last 750 years, Allderidge (1979) 
observed that the received version of the history of the care of the insane 
consists largely of myth and folklore, tempered by a strong dash of wilful 
ignorance, and is capable of absorbing any number of incongruous features. 
Depending on where the version was received, nothing happened at all, or 
the mentally disordered were indiscriminately exorcised, or burnt, or left 
to wander at will, or chained up and beaten, or all four.
The modern approach can be said to have its beginning in the early 19th 
century, and it is significant that the main feature of the methods used by 
Tuke in England and Pinel in France was an attitude of humane sympathy. 
In 1835 Dr. Gardiner Hill began to remove mechanical restraints in Lincoln 
Asylum and Dr. John Conolly abolished all mechanical restraint in Hanwell 
Asylum, Middlesex in 1839 (Hamilton, 1978). An Act of Parliament in 1845 
provided legislation for the establishment of County Asylums. These were 
generally built in rural areas, out of sight and out of mind of a supposedly 
respectable community (Norton, 1978). The complex of five hospitals to 
the west of Epsom illustrates this philosophy as three of these had 
catchment areas in London. Many of these asylums were built on the tops 
of hills e.g. Epsom Common, because this was believed to lessen the 
incidence of tuberculosis which decimated the 19th century institutional 
occupants (Lader, 1981). These asylums each built to accommodate more 
than 1,000 patients were essentially custodial and wards were securely 
locked to prevent escape. Patients who were less disturbed were engaged
in agricultural work which was both therapeutic to the patient and 
beneficial in terms of produce to the hospital. Additionally patients were 
involved in work in the asylum launderies, bakeries and workshops, and the 
asylums themselves were practically self-sufficient. Most of these 
Victorian asylums are our major psychiatric hospitals of today.
Figure 2.1 illustrates how the numbers of patients resident in psychiatric 
hospitals steadily rose from 1860 when the 1845 Act was coming to 
fruition, to a peak in the mid - 1950fs. A steady decline then occurred 
following the introduction of the antipsychotic drugs and changes in 
attitudes to the treatment of mental illness.
The Office of Health Economics (1979) commented that the close 
conjunction of the availability of the antipsychotic drugs and drops in the 
number of people in hospital both in this country and abroad is reasonably 
firm evidence in favour of the hypothesis that medicines were of 
considerable significance around the start of this transition from closed to 
open care. There is clearly a degree of correlation between these two 
f actors , although many would dispute this.
The Department of Health and Social Security, White Paper (1975) "Better 
Services for the Mentally 111", in setting out further long-term plans for the 
mentally ill, recognised that although most of the mental hospitals were 
old, treatment methods had been revolutionised, and a considerable part 
had been played by antipsychotic drugs discovered in the 1950’s . Hordern 
(1961) mentioned that in mental hospitals, these drugs have reawakened the 
interest of the staff in the whole resident population. He added that as a 
result staff morale in mental hospitals has improved, and treatments 
always considered by some as punishments have been replaced by remedies 
of a demonstrably "medical" nature.
Figure 2.1
In-patients resident in mental illness hospitals,
England and Wales 1860-1978 (Office o f H ealth Economics. 1979)
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Cohen and Pillsbury (1960) treated 200 'deteriorated' schizophrenics, who 
had been continuously hospitalised for an average of over 15 years, with 
the phenothiazine, thioridazine and 39.5 per cent improved sufficiently to 
be discharged, sent to foster homes or to reside on open wards. In a four 
year study Leger (1966) treated 1225 mainly chronic psychiatric patients 
with thioridazine and was able to discharge 477 from hospital.
THE DISCOVERY OF THE ANTIPSYCHOTIC DRUGS
In the latter third of the last century in the city of Heidelberg, two events 
occurred that were destined to revolutionise psychiatry. In 1883, August 
Bernthsen synthesised phenothiazine, the progenitor of a group of drugs tha t 
have since been demonstrated to be of value in the treatment of schizo­
phrenia; and, in 1896, Emil Kraepelin defined the psychiatric syndrome 
which he called "dementia praecox", and which is now called "schizo­
phrenia". These important discoveries were made.in the same city within 
13 years of each other, and yet it was some 70 years later when they came 
together when the phenothiazine drug chlorpromazine was first used in the 
treatment of schizophrenia. The identification and synthesis of pheno­
thiazine took place in the course of a series of chemical analyses that 
Bernthsen was conducting on two dyes that had been synthesised in 1876, 
Lauth's violet and methylene blue (Swazey, 1974).
In a description of the development of phenothiazines, Swazey (1974) noted 
that in 1937, Daniel Bovet and A.M. Staub, at the Institut Pasteur, 
demonstrated the antihistamine properties of compound 929F (thymoxy- 
ethyldiethylamine), one of a series of phenolic ether amines first 
synthesised in 1910 by E. Fourneau. The development of synthetic 
antihistamines rested on three decades of research, notably by Sir Henry
Dale and his colleagues, that had defined the pharmacologic actions of 
histamine. The first synthetic antihistamine both powerful and nontoxic 
enough for therapeutic use in the treatment of allergies was phen- 
benzamine, an aniline derivative developed by Mosnier and Halpern at 
Rhone-Poulenc in 1942. Two years later a Rh&ne-Poulenc chemist, Paul 
Charpentier, synthesised a new line of phenothiazine amines in an 
unsuccessful effort to obtain a series of antimalarial, trypanocidal or 
anthelmintic drugs. Phenothiazine itself was used as a veterinary 
vermifuge (Knipling, 1938; Taylor & Sanderson, 1940).
Phenothiazine chemistry merged with research on synthetic antihistamines 
in 1943 when Halpern and Ducrot discovered the strong antihistamine 
properties of compound 3013 RP, one of the phenothiazine amines that 
Charpentier had synthesised the previous year.
A French surgeon, Henri Laborit, in a personal interview (Swazey, 1974) 
described how in 1949 he was doing what every other surgeon was doing - 
trying to protect or substitute for the organism’s natural defences. He had 
first used a combination of four drugs to combat shock by lowering or 
inhibiting the activity of the autonomic nervous system; procaine, a local 
anaesthetic; curare; atropine; which blocked the action of acetylcholine on 
muscarinic effector organs; and tetraethylammonium, the ganglion 
blocking drug. Then, after his experimental study of the irritation 
syndrome, a fifth  type of drug, antihistamines, was added to his pharma­
codynamic regimen. In fact Laborit was so struck with how effectively 
promethazine relieved anxieties that he asked an army psychiatrist to watch 
him operate on some of his tense, Mediterranean type patients. The 
psychiatrist agreed that after surgery, the patients were remarkably calm 
and relaxed.
In October 1950, Dr. Pierre Koetschet of Rhone-Poulenc drafted a research 
memorandum which set in motion the work which culminated in the 
synthesis of 4560 RP -  chlorpromazine - in December 1950. The compound 
was subjected to a test in rats involving conditioned avoidance response to 
stimuli. The loss of response to stimuli without impairment of muscular 
strength was considered to indicate consistent central activity (Swazey, 
1974). In considering the lines of influence that first led psychiatrists to 
test chlorpromazine, Swazey (1974) observed that Henri Laborit, through 
informal personal contacts, and through his publications on artificial 
hibernation played a pivotal role. Soon after he began working with
chlorpromazine, Laborit sought to implement his belief that the drug would
/
find applications in psychiatry. On April 6th 1951 the first clinical trial of 
chlorpromazine began and the compound was marketed in November 1952 
under the trade name of Largactil.
THE CHEMISTRY AND ANIMAL PHARMACOLOGY OF THE ANTI­
PSYCHOTIC DRUGS
By definition these are drugs that are used in the treatment of the 
psychoses. They have many other names and Lader (1977) suggested that 
this demonstrates the lack of concensus on their clinical action. The 
following list shows the variety of synonyms used in describing anti­
psychotic drugs.
Antischizophrenics Neurotropics
Ataractics Psycholeptics
Major tranquillisers Psycholytics
Neuroleptics Psychoplegics
Neuroplegics Psychotropics
The term ’’tranquilliser” appears to have developed from the early 
observations of the French surgeon Henri Laborit, who noted that patients 
who had received phenothiazines were more tranquil after surgery than 
other comparable surgical patients. Delay and Deniker (1957) proposed the 
term "neuroleptic” on the basis of their clinical observations of the action 
of chlorpromazine and related compounds, in that the drugs produced a 
reduction in nervous activity rather than a paralysis.
The antipsychotic drugs are divided into three main classes, viz the 
phenothiazines , the thioxanthenes and the butyrophenones.
2.3.1 The Phenothiazines
This group of antipsychotic drugs was developed following the 
discovery of the tranquillising activity of chlorpromazine. Several 
hundred phenothiazine compounds have been synthesised and there 
are twelve phenothiazines currently available for routine 
prescription as antipsychotics in Britain. There are others, e.g. 
promethazine and thiethylperazine, which are not antipsychotics. 
They all have the same basic three ringed structure in which two 
benzene rings are linked by a sulphur and a nitrogen atom. The 
structure is numbered as shown in Figure 2.2.
The basic structure has been modified by substitutions at position 
10 (R^) and position 2 (R2) e.g. (Figure 2.3) with the objective of 
achieving safer and more effective antipsychotic compounds. 
Whilst the former objective has been met (Sandison, Whitelaw & 
Currie (1960) in a two year study involving 174 patients concluded 
that thioridazine had fewer side-effects than any other of the 
phenothiazine compounds) there has been some debate on the
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latter as some workers consider that the antipsychotic potency of 
the many phenothiazines is equivalent (Cole, 1976).
2.3.2 The Thioxanthenes
The synthesis and pharmacology of the first thioxanthene 
compounds was reported by Petersen, Lassen, Holm, Kopf & Mj&ler 
Nielsen (1938), and although M/&iler Nielson, Hougs, Lassen, Holm & 
Petersen (1962) described the pharmacological properties of 66 hew 
thioxanthenes, only 4 have been marketed in Britain.
The basic structure of the thioxanthenes is very similar to the 
phenothiazine nucleus except that the nitrogen atom at position
10 in the phenothiazine nucleus is replaced by a carbon atom 
(Figure 2.4).
As with the phenothiazines, substitutions can be made at positions 2 
and 10 of the basic thioxanthene structure to produce different 
antipsychotic compounds (Figure 2.5).
The profile of the thioxanthenes is similar to those of other 
antipsychotic compounds in terms of pharmacological variables 
that include decreased mobility, selective inhibition of conditioned 
avoidance responses, antagonism of amphetamine-induced stereo­
typies and of apomorphine-induced emesis, production of 
catalepsy, potentiation of analgesics and hypnotics and a taming 
effect (Simpson &  Lee, 1976).
2.3.3 The Butyrophenones
The synthesis of the butyrophenone, haloperidol (Figure 2.6) 
resulted from the search for a pethidine-like analgesic. The
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compound induced cataleptic immobility, inhibited exploratory and 
self-stimulating behaviour, interfered with apomorphine-induced 
vomiting and amphetamine-induced stereotyped chewing, and 
Janssen (1970) suggested that the compound could therefore have 
antipsychotic properties.
The butyrophenones are monophenylbutylpiperidines. Replacement 
of the carbonyl in the propylene chain of the butyrophenone 
structure by a fluorophenyl resulted in a chemically new group of 
drugs, usually referred to as diphenylbutylpiperidines. Common 
characteristics of this class of antipsychotic drugs are their long 
duration of action, and the best known of the diphenylbutyl- 
piperid ins series is the oral antipsychotic  pimozide (Figure 2.7) 
which has a duration of action of 24 hours (Ban & Pecknold, 1976).
THE CLINICAL USE OF ANTIPSYCHOTIC DRUG5
2.4.1 Use in Non-Psychiatric Indications
The antipsychotic drugs, and in particular the phenothiazines, have 
been used in a number of non-psychiatric indications:^
0 Use in Vomiting
In patients with psychogenic vomiting, considerable 
symptomatic relief followed treatment with phenothiazines 
(Hill, 1968). The phenothiazines, notably chlorpromazine and 
prochlorperazine, inhibit vomiting caused by stimulation of 
the chemoreceptor trigger zone which is situated on the 
surface of the medulla. They are thus indicated in the 
symptomatic treatment of vomiting in hypertensive
Figure 2.7
Structure of pimozide, a diphenylbutylpiperidine 
compound
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encephalopathy, cerebral tumour, and certain other 
conditions such as encephalitis, meningitis and subarachnoid 
and cerebral haemorrhage (British Medical Journal, 1970).
ii) Use in Alcoholism
Chlorpromazine and mesoridazine each produced 
improvement which was most marked in the first week, in a 
controlled study of 40 patients in alcohol withdrawal states. 
Agitation, tremor, anxiety and hallucinations were relieved 
or reduced (Frost, 1973). In addition to its property of not 
suppressing vomiting, another favourable aspect of the use of 
thioridazine in chronic drinkers with severe liver disease, is 
its low hepatotoxicity (Cohen, 1964). The use of thioridazine 
in treating alcohol withdrawal symptoms has also been 
reported (Huot, 1966; Ehik, 1968) and Acton (1968) treated 
more than 11,000 prison hospital alcoholics with thioridazine 
until a regular eating pattern was established.
iii) Use in Premedication
A total of 173 patients with duodenal ulcer were pre­
medicated with chlorpromazine, atropine and phenobarbitone, 
prior to gastric freezing (Hitchcock, Ruiz, Sutherland & 
Bitter, 1966).
iv) Use in Dentistry
The phenothiazine derivative promethazine, is often used in 
dentistry. Its property of receptor antagonism,
potentiation of barbiturate action and/or sedative effects, 
and antiemetic action partially explain its popularity in i/v 
sedation combined with analgesics which are known histamine 
releasers (Hayden, 1978).
2.4.2 Use in Psychiatric Indications
The antipsychotic drugs have been widely prescribed over the past 
twenty years for a variety of mental and emotional disturbances, 
particularly where anxiety, tension and agitation are presented. 
They have been used in acute, sub-acute and chronic schizophrenia, 
manic depressive psychoses, acute and chronic neuroses, 
conf usional states, especially in the elderly, the disturbed mentally 
handicapped, and behaviour disorders in children with epilepsy.
i) Use in Schizophrenia .
The target symptoms of the schizophrenic states are the 
prime indication for the phenothiazines. Disturbances of 
thought, emotion, perception and behaviour are all 
moderated. The acute psychoses are most quickly influenced, 
but chronic processes can also be ameliorated (Cohen, 1964).
Some of the best designed, most carefully controlled, large 
sample studies have been the Veterans Administration inter- 
hospital cooperative projects and those carried out by the 
National Institute of Mental Health. In one project (Lasky, 
Klett, Caffey, Bennett, Rosenblum & Hollister, 1962) 512 
chronic schizophrenics were given one of six drugs "blind" 
over a 24 week period. At the end of the study f luphenazine, 
thioridazine and chlorpromazine were superior to reserpine at 
the 5 per cent level of statistical significance or better. The 
National Institute of Mental Health (1964) reported a 
double-blind study involving over 400 acutely ill schizo­
phrenic patients treated at 9 collaborating hospitals. The
results demonstrated tne clinical etticacy of drug therapy in 
acute schizophrenic psychoses. Ninety-five per cent showed 
some degree of improvement within six weeks - over 75 per 
cent showed marked to moderate degrees of improvement.
Core symptoms of schizophrenia (e.g. apathy, withdrawal, 
retardation, hebephrenic giggling and grimacing) show the 
greatest drug-placebo differences in acute studies, whilst 
secondary symptoms (e.g. delusions, hallucinations, hostility) 
show some change on placebo but substantially more on 
antipsychotic drugs (Cole, 1976). The degree of overall 
improvement in drug-treated patients is nevertheless greater 
for the secondary symptoms (Goldberg, Klerman & Cole, 
1965).
Use in Other Psychiatric Indications
Leger (1966) reported impressive results in mania using 
thioridazine and there is good evidence that chlorpromazine 
and thioridazine may be effective in some kinds of 
depression. Chlorpromazine seems to be particularly 
effective in agitated depressions (Klein & Davis, 1969) and 
thioridazine in anxious depressions (Hollister, 1973). In the 
neuroses, thioridazine was compared with diazepam in 27 
patients under double-blind conditions. Significantly more 
patients receiving thioridazine experienced relief from 
tension (Loff t & DeMars, 1974).
There is modest evidence that phenothiazines are better than 
placebo in the treatment of geriatric patients with such 
psychotic behaviour as agitation, restlessness, delusions or
hallucinations, or thought disorder (Cole & Stotsky, 1974). 
Felger (1966) found that thioridazine had a calming effect 
without dulling or extrapyramidal effects in eight geriatric 
patients suffering from behaviour disorders, and Krai (1961) 
reported that confusion of thought, restlessness and agitation 
were improved by thioridazine in 29 out of 37 patients 
resident in an old peoples home. In treating paranoid 
syndromes in the elderly with thioridazine, only 6 of 71 
patients failed to show any beneficial effects: 22 improved 
and 43 achieved complete immediate remissions (Post, 1965). 
In the management of disturbed, mentally handicapped 
patients the phenothiazines can be used in the control of 
behaviour disorders (Bicknell & Blowers, 1980a), and 
thioridazine was found to be effective in controlling 
symptoms of senseless physical overactivity, aggressiveness, 
rage and tantrum outbursts, disturbance of sleep rhythm, 
agitation, self-injury and noisiness (Le Vann, 1961). Where 
behaviour disorders were present in epileptic children, 61 of 
100 randomly selected patients showed a marked 
improvement in behaviour, and moderate improvement was 
seen in a further 28 following treatment with thioridazine. 
There was a decrease in the number of seizures in 41 patients 
and in a further 23 patients no seizures were recorded after 
the addition of therapy (Pauig, Deluca & Osterheld, 1961).
SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
There are many side effects of antipsychotic drugs and whilst this work
concentrates on one aspect of the CNS side effects, the non-CNS side
effects are also of importance.
2.5.1. Non-CNS Side Effects
i) Allergic Reactions
(a) Jaundice
Chlorpromazine-induced jaundice was one of the earliest 
noted and more dramatic of the phenothiazine-induced side 
effects. The jaundice generally occurs within 1 - 5  weeks
after initiation of therapy, and on a clinical basis it is
difficult to differentiate from infectious hepatitis (Davis & 
Casper, 1978). Sherlock (1962) observed that about 1 per 
cent of patients receiving chlorpromazine develop intra- 
hepatic obstructive jaundice, usually within 4 weeks of 
starting the drug and unrelated to dosage. Over recent years 
there has been a steady decline in chlorpromazine-induced 
jaundice, and the present incidence in probably well under 0.5 
per cent (Davis & Casper, 1978). The decline is unexplained.
(b) Agranulocytosis
This is a serious, though rare, side effect of phenothiazines. 
It is not dose related and generally occurs within the first 
6 - 8  weeks of treatment. Its onset is extremely abrupt, 
consisting of the sudden appearance of sore throat, 
ulcerations and fever (Davis & Casper, 1978). If a fall in the
leucocyte count is found, the drug must be stopped 
immediately and a full course of antibiotic treatment 
commenced.
(°) Skin Reactions
Davis & Casper (1978) noted that a variety of skin eruptions 
have been associated with chlorpromazine treatment, 
including the urticarial, maculopapular, petechical and 
eczematous type. These reactions usually occur during the 
first 5 weeks of treatment. Allergic skin reactions due to 
chlorpromazine were reported by Tszycka (1961) following a 
survey of three neuropsychiatric hospitals. This revealed 
allergic reactions in both patients and staff. Sixteen 
members of staff developed contact dermatitis and this 
presented either in the form of scarlatiniform rash, local 
oedema, or small, itchy vesicles on the hands, forearms, face 
or eyelids. Davis & Casper (1978) also referred to the 
occurrence of a contact dermatitis in personnel who handle 
chlorpromazine. Chlorpromazine is unique among the pheno­
thiazines for causing marked photosensitivity. Patients 
receiving chlorpromazine in the summer are likely to develop 
severe sunburns after relatively short exposure to the sun 
(Cole, 1976). Acute photosensitivity with chlorpromazine has 
been the subject of a number of reports (Greiner & Berry, 
1964; Feldman & Freirson, 1964; Greiner & Nicholson, 1964; 
Cairns, Capoore & Gregory, 1965; Satanove, 1965). 
Treatment consists of protecting the patient from sunlight, 
either by use of barrier creams, protective clothing, or by 
restriction of patients to wards or covered areas.
ii) Autonomic Side Effects
(a) Antiadrenerqic
Postural (orthostatic) hypotension can occur during pheno­
thiazine therapy and when it does appear it usually does so in 
the first few days of treatment. Tolerance of this side effect 
generally develops quickly (Davis & Casper, 1978). Pheno­
thiazines, particularly thioridazine, can postpone, or 
eventually prevent, ejaculation without interfering initially 
with erectile potency (Cole, 1976). This side effect responds 
to a reduction in dosage (Davis & Casper, 1978).
(b) Anticholinergic
A variety of anticholinergic side effects occur in patients 
treated with phenothiazines, including dry mouth and throat, 
blurred vision, nasal congestion and constipation (Davis & 
Casper, 1978).
iii) Long Term Skin and Eye Effects
Long-term high dosage chlorpromazine therapy has 
occasionally produced skin and eye changes (Davis & Casper, 
1978). The skin changes consist of a blue-grey metallic 
discolouration of the skin over areas exposed to sunlight, such 
as the face and nose, the neck and collar area of the chest, 
and the dorsum of the hand. Eye changes are described as 
bilateral whitish-brown granular deposits concentrated in the 
subcapsular area, which in more severe cases may also be 
found in the anterior lens cortex as well as in the posterior 
cornea. Retinal damage is not seen and, in general, vision is 
not impaired.
Thioridazine has produced a pigmentary retinopathy in 
patients who Were receiving 1,600 mg or more per day, and to 
provide a margin of safety the dose level has been restricted 
to 800 mg per day. This side effect can be produced by other 
phenothiazines in very rare instances, and this effect is 
different from ocular deposits arid not related to the anterior 
lens opacities (Davis & Casper, 1978).
Endocrine and Other Side Effects
Weight gain is a well-documented side effect of pheno­
thiazines, particularly of chlorpromazine. The aetiology of 
this weight gain, which often occurs rapidly when the drug is 
started and comes to a halt on continuous treatment, remains 
obscure (Davis & Casper, 1978). Phenothiazines can produce 
galactorrhoea and gynaecomastia, most commonly in pre­
menopausal women, although it does occur in postmenopausal 
women and in men. It can occur as early as the first or 
second week of antipsychotic therapy. This side effect was 
first described in patients being treated with chlorpromazine, 
but also can occur with other phenothiazines, such as 
thioridazine, trifluoperazine, prochlorperazine and 
fluphenazine. It has been suggested that phenothiazines 
block the inhibitory action of dopamine on prolactin 
secretion, thus accounting for the galactorrhea. 
Amenorrhoea, a frequent occurrence with psychiatric 
patients, has been reported in a small percentage of schizo­
phrenic patients under phenothiazine treatment (Davis & 
Casper, 1978).
2.5.2
An electrocardiographic abnormality of uncertain 
significance, consisting of broadened, flattened, or inverted 
T-waves, has been observed in patients treated with pheno­
thiazines, particularly thioridazine. Although not associated 
with clinical electrolyte disturbance, it is said to be 
reversible by potassium supplements, discontinuation of the 
drug, isorbide dinitrate and ergotamine tartrate. S-T 
segment depression has also been observed in patients treated 
with phenothiazines. In addition, bradycardia, tachycardia or 
palpitations may occur. A cardiomyopathy consisting of a 
thickening of cardiac vessels less than 0.1 mm in diameter 
has been found in patients treated with phenothiazines for 
long periods, including some patients who died suddenly or 
unexpectedly whilst on these drugs. It is unclear whether 
sudden death occurs more frequently in phenothiazine treated 
patients than in non-drug patients (Davis & Casper, 1978).
CNS Side Effects
i) Extrapyramidal Side Effects
Drug induced extrapyramidal side effects may be divided into 
two groups, the reversible syndromes and the generally 
irreversible syndromes. The former comprise Parkinsonian 
reactions, akathisia and dystonia, and the latter are the 
dyskinesias (Lader, 1970).
(a) Reversible Syndromes
Parkinsonism: Although this drug induced extrapyramidal
effect is frequently called ’pseudo-Parkinsonism', the clinical
features closely resemble those of idiopathic Parkinsonism. 
The mildest form presents as bradykinesia and loss of 
associated movements, with weakness especially marked in 
those muscles used in repetitive movements such as walking 
(Lader, 1970). In moderate cases the classical triad of 
tremor, rigidity and akinesia is present together with facial 
and pharyngeal immobility, drooling of saliva, 'pill-rolling' 
movements and seborrhoea (Lader, 1970).
Tremor is both one of the main signs and one of the main 
symptoms of Parkinsonism, and usually affects distal muscle 
groups such as those of the hand, forearm and foot. It is 
characteristically present at rest, and it is made worse by 
nervousness, excitement, or fatigue. It is sometimes seen 
when the patient is walking (Pallis, 1971). Rigidity is another 
common feature and is detected clinically as resistance to 
passive manipulation of the limbs and trunk. The examiner 
encounters uniform resistance throughout the range of 
passive movement, hence the terms "plasticity" and "lead- 
pipe rigidity". When tremor is present the rigidity is broken 
up, producing "cog-wheel rigidity" - a jerking sensation often 
experienced by the examiner on passively stretching a hyper­
tonic Parkinsonian muscle (Pallis, 1971; Marsden, 1977). 
Postural abnormalities also occur and rigidity contributes to 
the characteristic flexed posture. However, other abnor­
malities of postural stability are evident, such as the 
festinating (hurrying) gait, the inability to withstand a push 
or pull, and frequent falls without attempts to avoid injury 
(Marsden, 1977). As far as the patient is concerned, akinesia 
is the most disabling of all the main features of
Parkinsonism. A slowness of initiation and execution of 
movements, and a general poverty of spontaneous and auto­
matic or associated movements, are characteristic. Akinesia 
is not merely the result of rigidity; it is an inability to 
generate movement. Along with rigidity and postural abnor­
malities it accounts for many of the characteristic features 
of Parkinsonism - the masked face, the loss of blinking, the 
absence of arm swinging when walking, the small hand­
writing, the soft monotonous speech (Marsden, 1977).
The incidence of extrapyramidal side effects caused by 
antipsychotic drugs varies considerably. Cohen (1966) 
mentioned that fluphenazine and trifluoperazine had a high 
incidence of extrapyramidal side effects and that there was a 
lower incidence with thioridazine. Cole & Clyde (1961) 
estimated the relative incidence figures to be 36 per cent for 
fluphenazine and 3 per cent for thioridazine. The 
thioxanthenes resemble thioridazine in their paucity of extra­
pyramidal reactions, and the butyrophenones are similar to 
the piperazine-type phenothiazines (e.g. trifluoperazine) 
(Lader, 1970).
The true incidence of extrapyramidal side effects is masked 
by the administration of antiparkinsonian drugs. Researchers 
typically administer antiparkinsonian agents with anti­
psychotic drugs routinely, thus clouding the statistics on side 
effect incidence which are usually based on the entire time 
period of the study (Davis & Casper, 1978).
Akathisia: This syndrome is characterised by motor
restlessness. The patient appears agitated, experiences a 
compulsion to move about and may complain of anxiety or of 
the "jitters". He constantly shuffles his feet, paces up and 
down, stands up and sits down repeatedly, changing his 
position. When standing, he rocks continuously back and 
forwards, shifting from one foot to the other. Wringing of 
the hands, twisting and interlocking of the fingers, and 
smacking of the lips may also occur (Lader, 1970).
Acute Dystonic Reactions: These reactions, sometimes
termed acute dyskinesias, are the most dramatic of the 
extrapyramidal syndromes. There is an abrupt onset of 
features such as torticollis, retrocoilis, facial grimacing and 
distortions, dysarthria, and laboured respiration. Other 
phenomena include scoliosis, lordosis, opisthotonus, 
tortipelvis, and sinuous writhing movements resembling those 
seen in dystonia musculorum deformans. Bizarre movements 
of the tongue ("flycatcher") and jaw may occur; trismus, 
severe tongue injuries and dislocation of the temporo­
mandibular joint have occurred. Spasms may be very wide­
spread, involving most muscle groups including the bladder 
(Lader, 1970).
Another form of dystonic reaction described by Lader (1970) 
is the oculogyric crisis, in which the attack begins with a 
fixed stare, soon followed by upwards and sideways rotation 
and fixation of the eyeballs. The head is tilted backwards, 
the mouth opened wide and the tongue protruded. Attacks 
last a few minutes to several hours.
Other CNS Effects: In normal subjects, high doses of the
more sedative phenothiazines such as chlorpromazine cause 
sedation. In patients, mild or moderate drowsiness usually 
disappears after the first or second week, and patients should 
be cautioned about driving or operating machinery while 
taking phenothiazines. If the effect proves troublesome, it 
can be controlled by lowering the dosage (Davis & Casper, 
1978). Occasionally disturbed body temperature, paroxysmal 
or focal EEG slowing, and respiratory depression may be seen 
with phenothiazine therapy (Davis & Casper, 1978), though 
variations are seen with individual phenothiazines. Taeschler 
& Cerletti (1958) found that thioridazine reduced the body 
temperature of rats only when given at 10 times the dosage 
required for a similar effect with chlorpromazine.
(b) Generally Irreversible Syndromes
Tardive Dyskinesia: The syndrome of antipsychotic-induced 
tardive dyskinesia includes a variety of abnormal movements, 
from lingual-facial-buccal dyskinesias to dyskinesias and 
choreiform movements of the limbs and trunk. The subject is 
considered in greater detail in this chapter (See 2.7)
PHARMACOLOGY OF ANTIPSYCHOTIC DRUGS
"The value of a hypothesis lies not so much in whether it is right or wrong,
but in its capacity to stimulate attempts to refute it".
Karl Popper.
This can be truly said of the Dopamine Hypothesis of Schizophrenia. The 
hypothesis states that, since many behavioural effects of the 
amphetamines are due to increased central dopamine release, and since 
most neuroleptic compounds are antagonists at central dopamine receptors, 
the symptoms of schizophrenia may be due to an abnormal increase in 
central dopamine release and the effects of this increase are diminished by 
partial blockade of the receptor site (Crow, Deakin, Johnstone & Longden, 
1976).
The observations that led to the hypothesis are:-
i) The psychosis associated with amphetamine misuse resembles 
acute paranoid schizophrenia and experimental work demonstrates 
that amphetamines increase brain dopamine activity (Connell, 
1958; Ellinwood, 1967; Griffith, Cavanaugh, Held & Oates, 1972). 
Biochemical, pharmacological and histochemical evidence suggests 
that amphetamines stimulate increased dopamine release in the 
CNS (Randrup &  Munkvad, 1966; Scheel-Kruger & Randrup, 1967; 
Christie &  Crow, 1971).
ii) The drugs that control schizophrenic symptoms can be shown to 
decrease brain dopamine activity (Crow, Deakin, Johnstone & 
Longden, 1976; Iversen, 1977; Snyder, 1978).
2.6.1 Dopamine Receptor Blockade
The majority of the drugs that have been found to be effective in 
the treatment of schizophrenic symptoms act by blocking receptors 
for the CNS transmitter dopamine. Reserpine and oxypertine
however, prevent dopamine storage. The dopamine neurones are 
arranged in two prinicipal systems, one originating from cells in 
the substantia nigra and innervating various regions of neostriatum, 
and a second originating from cells in the ventral tegmentum (the 
so-called AIO group) whose fibres project to various limbic 
structures, including nucleus accumbens, olfactory tubercle, 
medial frontal cortex and cingulate cortex (Iversen, 1977). The 
physiology of dopamine in the main brain dopamine tracts is 
illustrated in Figure 2.8. .
Dopamine blockade of various central systems has a number of 
different consequences, e.g. in the nigrostriatal system, 
Parkinsonism and other extrapyramidal effects may result; in the 
tubero-infundibular system, elevation of plasma prolactin occurs; 
in the mesolimbic and mesocortical system, dopamine blockade 
may underlie antipsychotic actions. There is much evidence to 
suggest that various antipsychotic drugs have differential actions 
on these various systems. For example, clozapine and thioridazine 
have a much stronger effect on dopamine turnover in the limbic 
system than in the striatum, relative to haloperidol; clinically 
these drugs are associated with a low incidence of extrapyramidal 
effects. Conversely haloperidol and perphenazine seem to affect 
the striatum more than the limbic system with a correspondingly 
high incidence of Parkinsonian symptoms (Brain Biochemistry, 
1980) Figure 2.9 illustrates the balance relating to the increase or 
decrease of Parkinsonian symptoms resulting from dopamine 
blockade.
Physiology of brain dopamine tracts
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Whereas the antipsychotic effects and the elevation in plasma 
prolactin concentrations persist as long as the drug is continued, 
the extrapyramidal effects tend to diminish. This has been 
attributed to diminution in the feedback response. The other long­
term effect is receptor supersensitivity which refers to variations 
of receptor response according to the availability of the neuro- 
transmitter. Thus, dopamine-receptor blockade by antipsychotic 
agents increases the number of receptors, an adaptive mechanism 
to overcome the blockade. Such a mechanism is believed to 
underlie tardive dyskinesia which appears to be due to 
dopaminergic overactivity in the striatum. Drugs which increase 
dopamine, such as levodopa or amphetamine, exacerbate tardive 
dyskinesia whereas reserpine and the antipsychotic drugs (in the 
short-term) ameliorate the condition by blocking the extra 
receptors. On the other hand, physostigmine and deanol, drugs 
which increase acetylcholine, improve the condition, whereas anti­
cholinergics, including the antiparkinsonian drugs, exacerbate it. 
The benzodiazepines and sodium valproate can help alleviate the 
dyskinesia by increasing GABA inhibition on the nigrostriatal 
dopaminergic neuron (Brain Biochemistry, 1980). Figure 2.10 
illustrates the balance situation in tardive dyskinesia resulting 
from dopamine blockade.
Dopamine released within the CNS acts on specific dopaminergic 
postsynaptic receptors. CNS dopamine receptors are potently 
stimulated by the drug apomorphine and are not antagonised by ^  
or j l  adrenoceptor antagonist drugs. Amphetamine appears to 
elicit many of its behavioural effects indirectly by causing a 
release of endogenous dopamine in the brain, since selective lesions 
of CNS dopaminergic pathways abolish its behavioural effects 
(Creese and Iversen, 1975).
Figure 2.10
Evidence from dopaminergic blockade: tardive dyskinesia
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Decrease acetylcholine: cholinolytics 
e.g. antiparkinsonian drugs
Increase acetylcholine: 
physdstigmine, deanol
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movements
Worse
Decrease dopamine:
increase antipsychotics 
give reserpine
Increase dopamine: 
levodopa, amphetamines 
withdraw antipsychotics
Ach—acetylcholine DA—dopamine
Source : Brain Biochennstry, Mental Disorders and Antipsychotic Agents (1980)
Amphetamine psychosis is alleviated by drugs known to be 
effective in the treatment of schizophrenia (Iversen, 1977) and 
such drugs also block the behavioural stimulant effects of 
amphetamine in animals and this is such a consistent property that 
this test has been used to predict new compounds likely to exhibit 
antipsychotic actions in man (Randrup & Munkvad, 1974). The 
hypothesis that antipsychotic drugs of many different chemical 
classes share a common ability to block CNS dopamine receptors is 
supported by other lines of evidence (Iversen, 1977). All such drugs 
cause a selective stimulation of the rate of synthesis and 
metabolism of dopamine in the animal brain, apparently as an 
adaptive response to dopamine receptor blockade (Sedvall, 1975).
The most direct evidence for dopamine-blocking properties of anti­
psychotic drugs has come from studies of CNS dopamine receptor 
mechanisms in vitro. Many antipsychotic drugs act as potent 
inhibitors of the ability of dopamine to stimulate cyclic AMP 
formation in homogenates of dopamine-rich areas of brain (Iversen, 
1975). The actions of antipsychotic drugs on the dopamine 
stimulated adenylate cyclase are, however, anomalous, in that 
certain potent antipsychotic drugs (notably pimozide and the 
related butyrophenone series) are only weakly active on this test 
(Iversen, 1977).
There is evidence for Dopamine^ and Dopamine2  receptor sites 
(Kebabian and Caine, 1979), and it has been shown in animal 
experiments that continuous administration of neuroleptics to rats 
for up to a year induces behavioural and biochemical super- 
sensitivity of striatal dopamine mechanisms, including an enhanced
response of striatal adenylate cyclase to dopamine, which persists 
for a further six months after drug withdrawal. Adenylate cyclase 
is linked with D^ dopamine receptor systems, and selective D^ 
receptor antagonists such as flupenthixol certainly cause tardive 
dyskinesia (Jenner & Marsden, 1979), and whilst it is suggested that 
D 2  antagonists such as the substituted benzamides sulpiride, 
tiapride and oxiperomide should theoretically reduce the likelihood 
that tardive dyskinesia will ensue (Lancet, 1979), there are so far no 
data to support this hypothesis (Jenner & Marsden, 1979).
A more recently developed test system depends on measurements 
of the saturable high affinity binding of the radioactively labelled 
butyrophenones, haloperidol or spiroperidol to specific membrane 
sites in brain homogenates (Creese, Burt & Snyder, 1976). Such 
sites occur only in dopamine-rich areas of brain and appear to 
represent CNS dopamine receptors. There is good correlation 
between the rank order of potencies of various antipsychotic drugs 
in clinical use and their potencies in competing for the binding of 
labelled haloperidol or spiroperidol in vitro (Iversen, 1977). 
Spiroperidol also binds to 5-HT receptors which complicates inter­
pretation of binding studies.
2.6.2 Dopamine Receptor Actions
Long term therapy with any drug which causes dopaminergic 
blockade can,, give rise to the risk of tardive dyskinesia (see 2.7.5). 
Blockade of dopamine receptors can give rise to a number of 
actions additional to antipsychotic activity.
i) Antiemesis
Blockade of dopamine receptors in the chemoreceptor trigger 
zone located in the area postrema of the medulla oblongata 
can cause antiemetic effects (Richelson, 1980), and most 
phenothiazines have been used to control vomiting.
ii) Prolactin Rise
Any substance with dopamine-blocking actions elevates the 
secretion of prolactin. Substantial parts of these effects are 
exerted directly at pituitary level although there may also be 
dopaminergic inhibition at the hypothalamic level, possibly 
mediated by a polypeptide (Horrobin, 1977). Thus treatment 
of patients with antipsychotic drugs results in increased 
levels of prolactin, which may result in galactorrheoa 
accompanied by amenorrhoea (Sachar, 1978).
iii) Parkinsonism
Drugs which block dopaminergic receptors such as the pheno­
thiazines, butyrophenones and diphenylbutylpiperidines can 
induce Parkinsonism (Caine, 1976). Because of the clinical 
analogy between the neurological syndrome of akinesia, 
muscular rigidity and tremor produced by dopaminergic 
antagonists and other antipsychotic drugs and that seen in 
Parkinson's disease, the former has been regarded as a classic
example of drug-induced Parkinsonism, serving as one of the
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experimental models for the latter (Hornykiewicz, 1975).
iv) Body Temperature Regulation
The evidence that dopamine plays a role in thermoregulation 
was demonstrated by Fuxe & Sjoqvist (1972) who injected
mice with apomorphine. Falls in body temperature of about 3 
to 4°C were observed after 13 minutes, and after 2 hours the 
body temperature was still below its normal level. The 
apomorphine action was completely prevented by the 
dopamine receptor agonist pimozide. Similar findings were 
obtained in the rat (Kruk, 1972).
v) Sleep Induction and Sedation
Intramuscular administration of apomorphine to 12 human 
volunteers produced sedation in 8 subjects, 4 of whom also 
showed sound sleep. The sedative and sleep-inducing effects 
of apomorphine were prevented by haloperidol, pimozide and 
by sulpiride (Corsini, Del Zompo, Manconi, Piccardi, Onali 
and Mangoni, 1977). A relationship between the 
dopaminergic system and sleep was also suggested by Bassi, 
Albizzati, Frattola, Passerini & Trabucchi4 (1979), who 
induced sleep in healthy volunteers after the administration 
of apomorphine, but failed to show significant effect on a 
group of Parkinsonism patients who had received long term 
treatment with L-dopa.
vi) ' Gastric Emptying
In man, dopamine reduces gastric motility and consequently 
delays gastric emptying. The dopamine antagonists 
domperidone and metoclopramide stimulate gastric phasic 
activity, increase pyloric dilatation and promote gastric 
emptying (Weihrauch, Fbrster & Krieglstein, 1979).
2.6.3 Other Pharmacological Actions
0 Muscarinic Block
Klawans (1973) found two main classes of drugs to be 
effective in the treatment of movement disorders, and this 
was considered to illustrate the antagonistic effect of the 
dopaminergic and cholinergic influences in the extra­
pyramidal system (Miller & Hiley, 1975). The relationship 
between muscarinic and dopaminergic activity was 
investigated by Kelly & Miller (1975), who tested the effects 
of muscarinic and antipsychotic drugs on the turning 
behaviour induced by methylamphetamine and apomorphine in 
rats with unilateral lesions of the substantia nigra. Turning 
towards the side of the lesion induced by methylamphetamine 
was inhibited by o^-flupenthixol and <jf-clopenthixol, but not 
by high doses of their ( I  - enantiomers. Turning was also 
inhibited by chlorpromazine and pimozide. These finding 
correlate well with the dopamine receptor-blocking potencies 
of these agents in vitro (Miller, Horn & Iversen, 1974) and 
support the view that the rat-turning model is a measure of 
dopaminergic-blocking activity. The antimuscarinic 
potencies of various antipsychotic drugs were measured by 
Miller and Hiley (1975) and they found an inverse correlation 
between the antimuscarinic potencies of the drugs and their 
ability to produce drug- induced Parkinsonism. Thioridazine 
and clozapine, which give the lowest incidence of drug- 
induced Parkinsonism, were found to be the most powerful 
antimuscarinics, whereas flupenthixol and spiroperidol, which 
produce the highest incidence of drug-induced Parkinsonism, 
were found to have poor antimuscarinic activity.
ii) Alpha-adrenoceptor Block
Symptoms of autonomic blockade, such as orthostatic 
hypotension and tachycardia, are side effects often 
associated with antipsychotic treatment, and compounds with 
a low norepinephrine antagonism to amphetamine antagonism 
ratio have the highest adrenergic blocking potential (Janssen 
& Van Bever, 1978). In summarising the receptor-blocking 
properties of antipsychotic drugs, Carlsson (1976) observed 
that chlorpromazine, thioridazine and chlorprothixene 
blocked central o£-adrenergic receptors as well as dopamine 
receptors.
iii) Antihistaminic Action
Antipsychotic drugs also possess antihistaminic properties, 
and because those with histamine-H^ receptor blocking 
action cause drowsiness they are frequently used clinically as. 
sedatives and hypnotics (Richelson, 1980). Additionally, the 
histamine-H^ receptor blockade by antipsychotics may play a 
role in the appetite stimulating effect of these drugs 
(Richelson, 1979).
Antipsychotic drug antagonism of histamine-b^ receptors has 
been studied with the use of histamine-stimulated adenylate 
cyclase activity (Kanof & Greengard, 1978). In the assay 
system they employed thioridazine was found to be more 
potent than cimetidine as an h^-receptor antagonist.
iv) Serotonin Antagonism
A number of dopamine-related and serotonin-related drugs 
were compared for their ability to displace spiroperidol 
binding from rat striatum and frontal cortex (Quik, Iversen, 
Larder & Mackay, 1978). Spiroperidol was found to bind with
high affinity not only to dopamine- related sites in the 
striatum, but also with an almost equal affinity to serotonin 
sites in the frontal cortex. It was concluded that dopamine- 
related drugs are more potent in displacing spiroperidol 
binding from the striatum than from the cortex, whereas 
serotonin-related drugs are more potent in displacing from 
the medial frontal cortex than from the striatum. Iversen 
(1978) observed that some neuroleptics, including 
o£-flupenthixol, are remarkably potent not only as dopamine 
blockers but also as serotonin antagonists.
Using a mouse climbing model Costall and Naylor (1977) 
found that dopamine agonistic effects of clozapine, 
thioridazine and sulpiride were reduced by the serotonin 
antagonist methysergide, and they suggested that the use of 
the mouse climbing model with methysergide may aid the 
search for antipsychotic drugs lacking undesirable side 
effects.
TARDIVE DYSKINESIA 
2.7.1 History
In the late 1950s clinical reports described an involuntary 
movement disorder in psychiatric patients undergoing treatment 
with antipsychotic drugs. The persistence of involuntary 
movements of the lower part of the face 6 months after stopping 
medication with chi or promazine was reported by Ey, Faure & 
Rappard (1956). In this case the dyskinesia disappeared 2 years 
after cessation of antipsychotic therapy. In the same year,
neurotoxic reactions resulting from antipsychotic medication were 
also described (Hall, Jackson & Swain, 1956) and in their group of 
90 patients who received chlorpromazine for about 2 months, 6 
patients showed persisting neurological signs 60 days or more after 
administration of the drug was completed.
Schonecker (1957) reported three cases of dyskinetic movements as 
a complication of long term phenothiazine therapy, and this was 
followed by similar observations by Sigwald, Bouttier, Raymond &  
Piot (1959) who reported four cases of dyskinesia and introduced 
the descriptive term "facial bucco-linguo-masticatory dyskinesia". 
The condition was described in detail in a review of neurological 
complications of antipsychotic drugs (Sigwald, Bouttier & 
Courvoisier, 1959). The term "tardive dyskinesia" was first used by 
workers in Set. Hans Hospital, Roskilde, Denmark, who referred 
initially to the fact that the syndrome occurred more frequently in 
elderly persons and in patients with organic brain diseases 
(Uhrbrand & Faurbye, 1960). In a later publication they stated that 
tardive dyskinesia occurred only after treatment for a long time, 
and that it was seldom observed during the first 6 months and it 
may occur even after several years of symptom-free treatment 
(Faurbye, Rasch, Peterson, Brandborg •& Pakkenberg, 1964).
The early reported tardive dyskinesias are listed in Table 2.1 
together with a number of further reports of persistent dyskinesias 
resulting from antipsychotic medication.
The tardive dyskinesia syndrome has been the subject of reviews 
and a number are shown in Table 2.2.
TABLE 2.1
CLINICAL REPORTS OF TARDIVE DYSKINESIA
Ey, Faure &  Rappard, 1956.
Hall, Jackson & Swain, 1956.
Schonecker, 1956.
Sigwald, Bouttier, Raymond & Piot, 1959.
Uhrbrand &  Faurbye, 1960.
Kruse, 1960.
Chatagnon, Chatagnon, Wilkin, Fournier & Lacey, 1961. 
Druckman, Seelinger & Thulin, 1962.
Faurbye, Rasch, Peterson, Branborg & Pakkenberg, 1964. 
Hunter, Earl & Thornicroft, 1964.
Evans, 1965.
Morphew & Barber, 1965.
Heathfield, 1965.
Rosin & Exton-Smith, 1965.
Schmidt & Jarco, 1966.
Degkwitz, 1967.
Crane, 1968a & 1970.
Brandon, McClelland & Protheroe, 1971.
Kennedy, Hershon & McGuire, 1971.
Fann, Davis & Janowsky, 1972.
Crane & Smeets, 1974.
Merriett, 1975.
Asnis, Leopold, Du Voisin <5c Schwartz, 1977.
Mehta, Mehta & Mathew, 1977.
Gibson, 1978a & 1978b.
TABLE 2.2
REVIEW ARTICLES ON TARDIVE DYSKINESIA
Faurbye, Rasch, Peterson, Brandborg &  Pakkenberg, 1964. 
Ayd, 1967.
Crane, 1968b & 1975.
Schiele, Gallant, Simpson, Gardner & Cole, 1973.
Marsden, Tarsy & Baldessarini, 1975.
Tarsy &  Baldessarini, 1976.
Gerlach, 1979.
Klawans, Goetz & Perlik, 1980.
Task Force, 1980.
Clinical Description
Tardive dyskinesia is a well defined clinical entity, although 
occasionally it is confused with acute drug reactions (Parkes, 
1976). The most conspicuous and frequent disorder is in the oral 
region and may be sufficiently severe to affect the function of 
speech and deglutition (Crane, 1968a) and even life-threatening by 
respiratory and gastro-intestinal complications (Casey & Rabins,
1978). The first sign of tardive dyskinesia to appear is often a 
vermicular movement of the tongue, followed by repetitive 
movements of the lip, jaw and cheeks, which result in constant 
sucking, licking, chewing , blowing and tonguing. There is little or 
no regular rhythm to these movements which almost always affect 
the lower face more than the upper, although the periorbital 
muscles may be involved. Many patients also have choreic 
movements of the extremities and swaying or rocking of the 
trunk, torsion of the axial skeleton and particularly the head and 
neck, legs and disturbances of respiratory rhythms. When extreme, 
the appearance is characteristic and bizarre. As with most 
involuntary movements, those of tardive dyskinesia are increased 
with physical stress and disappear during sleep (Parkes, 1976).
Generally, patients are unaware or only slightly emotionally 
disturbed by their tardive dyskinesia, but the movements are 
particularly striking to those around them, and can therefore 
become a considerable problem on discharge from hospital 
(Gerlach, 1979).
Tardive dyskinesia in its pure hyperkinetic, hypotonic or normotonic 
form, may become clinically evident after antipsychotic treatment 
for several months, sometimes following the reduction or with­
drawal of the drug, or during supplementary anticholinergic
the antipsychotic treatment, it appears in the course of a few days 
up to 2 to 3 weeks. In young subjects the movements then usually 
disappear, while in older subjects they often either persist 
(irreversible tardive dyskinesia) or disappear only slowly in the 
course of some months to a year (Gerlach, 1979).
2.7.3 Prevalence
The reported prevalence of tardive dyskinesia varies between 0.3 
per cent and 50 per cent (Lancet, 1979), although a number of 
individual studies show higher rates.
In a sample of 332 patients, tardive dyskinesia was present in 186 
(56 per cent), and when the patients were distributed into 3 age 
groups, the prevalence in those over 70 was 75.6 per cent (Jus, 
Pineau, Lachance, Pelchat, Jus, Pires & Villeneuve, 1976). The
prevalence of tardive dyskinesia in 65 chronic schizophrenic
\
inpatients was 55 per cent (Barnes & Kidger, 1979a), and in a 
group of 41 female mentally handicapped patients, with a mean 
period of hospitalisation of 31.6 years, the prevalence was 84 per 
cent in the 50 to 69 years age group, and 86.7 per cent in the 70 
years and above group (Blowers & Bicknell, 1980).
Estimates have in fact a very limited value, as they depend on 
varying factors such as the age of the subjects examined, the 
psychopharmacological treatment and the validity and sensitivity 
of the assessment employed (Gerlach, 1979).
.7.4 Aetiology
The permanent nature of tardive dyskinesia may be due to drug- 
induced structural changes in the central nervous system although
tnese nave not Deen convincingly oem unstrateu in man ^rarKes,
1976). As stated in the History (see 2.7.1.) there is considerable 
evidence that antipsychotic drugs can induce tardive dyskinesia. 
Both the dosage (Crane, 1970 & 1974; Gibson, 1978b), and the 
duration of treatment (Faurbye, Rasch, Peterson, Brandborg & 
Pakkenberg, 1964; Crane, 1974; Allen &  Stimmel, 1977), appear to 
play a role.
Prospective clinical studies cannot be carried out, however, as 
dosage and duration of treatment must be adjusted to the mental 
state of the patient. Furthermore, the various predisposing factors 
are just as important as the antipsychotic treatment. It is thus 
impossible to establish fixed risk boundaries for dosage and 
duration of treatment (Gerlach, 1979). It  should be mentioned that 
in one report, one patient developed a crippling tardive dyskinesia, 
having received no more than 10 mg of trifluoperazine daily for less 
than one year, which did not remit on withdrawal of medication. A 
further 2 patients treated with small dosages of antipsychotic 
medication were unable to dress themselves or function in the 
outside world because of their dyskinesias. All 3 patients were 
female and of Eastern European Jewish background, which raises 
the question of increased susceptibility to this syndrome (Simpson,
1973).
Brain Damage
Some reports show a correlation between tardive dyskinesia and 
brain damage (Uhrbrand & Faurbye, 1960; Faurbye, Rasch, 
Peterson, Brandborg & Pakkenberg, 1964; Edwards, 1970; Blowers 
& Bicknell, 1980), but others have been unable to repeat this 
finding (Brandon, McClelland & Protheroe, 1971; Fann, Davis & 
Janowsky, 1972). Specific lesions in the basal ganglia could 
probably promote the development of tardive dyskinesia, but with
the methods of investigation available it would hardly be possible to 
identify such a lesion in the living subject (Gerlach, 1979). It may 
be that brain damaged patients have higher doses of antipsychotics, 
although in a small survey of tardive dyskinesia in a group of 
mentally handicapped patients, 9 who- were treated with anti­
psychotic drugs had received dosages well below the 
manufacturer’s recommended maximum (Bicknell & Blowers, 
1980b).
Age
Uhrbrand & Faurbye (1960) were the first to observe that tardive 
dyskinesia is more frequent in the elderly, and Kruse (1960) 
suggested that in patients of 50 years and above the presence of 
vascular changes in the extrapyramidal system might predispose 
towards the development of the syndrome. It has also been 
postulated the sensitivity to drugs in aged patients varied from 
that in young adults (Paulson, 1968). It could be that most older 
patients will have received more drugs. The positive relationship 
between age and tardive dyskinesia has been further supported 
(Crane, 1971; Tarsy & Baldessarini, 1976; Mehta, Mehta & 
Mathew, 1977; Simpson, Varga, Lee & Zoubok, 1978).
Sex
Female patients have been considered more prone to the syndrome 
than males (Hunter, Earl & Thornicroft, 1964; Simpson, Varga, Lee 
& Zoubok, 1978), and in particular chorea was more common in 
women than in men (Kennedy, Hershon & McGuire, 1971). Whilst 
this observation has not always been consistent in published work 
(Crane, 1970; Fann, Davis & Janowsky, 1972; Jus, Pineau, 
Lachance, Pelchat, Jus, Pires & Villeneuve, 1976), there have not 
been any reports of a higher incidence in males.
2.7.5 Drugs Causing Tardive Dyskinesia
i) Antipsychotics
All effective antipsychotic drugs in common use have been 
implicated as causing tardive dyskinesia (Schiele, Gallant, 
Simpson, Gardner, Cole, Crane, Chase, Ayd, Levine & 
Ochota, 1973) and although this is most commonly due to 
long-term phenothiazine or butyrophenone treatment, it is 
extremely rare with reserpine (Parkes, 1976). The dopamine 
depleting antipsychotic oxypertine has not been assoicated 
with causing tardive dyskinesia, and has been used in its 
treatment (Kazamatsuri, 1980; Freeman, Soni & Carpenter, 
1980) (See 2.7.7).
Piperazine derivatives may be especially liable to cause 
tardive dyskinesia (Uhrbrand & Faurbye, 1960), but many 
different phenothiazine compounds, including chlorpromazine 
and trifluoperazine, the thioxanthenes, thiothixene and chlor- 
prothixene, and haloperidol and droperidol may be responsible 
(Parkes, 1976). The depot antipsychotics have also been 
implicated, and seem more likely than oral medication to be 
associated with tar dive dyskinesia (Drug and Therap. Bull., 
1979). In 374 chronic schizophrenics receiving depot anti­
psychotics the syndrome appeared with steadily increasing 
frequency and had affected about a quarter of them in 3 
years (Gibson, 1978b). In this latter study 6 out of 167 
patients developed generalised chorea within months of 
starting flupenthixol, and a national survey was then 
undertaken. The proportion of cases reported as developing 
chorea were, depot flupenthixol, 1 in 230, depot fluphenazine, 
1 in 400, and oral antipsychotics, 1 in 1800 (Gibson, 1979). 
The severity of tardive dyskinesia correlated significantly
with both total dose and average daily dose of fluphenazine 
decanoate in the examination of a group of 22 psychiatric 
outpatients (Csernansky, Grabowski, Cervantes, Kaplan & 
Yesavage, 1981).
ii) Anticholinergics
Cases of tardive dyskinesia have been associated with 
treatment with a variety of anticholinergic drugs (Committee 
on Safety of Medicines, 1979). Anticholinergic treatment can 
uncover latent tardive dyskinesia and accentuate existing 
tardive dyskinesia (Klawans, 1973a; Gerlach, Reisby & 
Randrup, 1974; Klawans & Rubovits, 1974). In milder cases 
this response may be delayed, while in severe cases there 
may be a momentary fluctuation in condition from hypo­
kinesia to hyperkinesia, e.g. following intravenous injection 
of physostigmine and scopolamine (Gerlach, Reisby & 
Randrup, 1974). It has been suggested that patients in a 
study who developed tardive dyskinesia were erroneously 
treated with anticholinergic drugs which impaired their 
condition and accounted for the finding of a significant 
relationship between severity of tardive dyskinesia and the 
amount of anticholinergic drug. (Perris, Dimitrijevic, 
Jacobsson, Paulsson, Rapp & Froberg, 1979).
iii) Other Drugs
Although tardive dyskinesia is generally regarded as a 
complication of antipsychotic drug therapy, the condition has 
been reported as a complication of treatment with other 
drugs.
Lavy, Melamed & Penchas (1978) reported a case of severe 
involuntary movements after chronic use of high doses of 
metoclopramide which were identical to the syndrome of 
tardive dyskinesia. The drug had been prescribed for 
persistent nausea without vomiting or other gastrointestinal 
symptoms. Metoclopramide has been reported to cause extra­
pyramidal reactions in man (Casteels-Van Daele, Jaeken & 
Van Der Schueren 1970), and has been shown to induce 
catalepsy and increase striatal homovanillic acid content in 
mice (Ahtee & Buncombe, 1974). This latter property has 
been shown to occur with antipsychotics (O'Keefe, Sharman & 
Vogt, 1970).
Fann, Sullivan & Richman (1976) described two cases of the 
dyskinetic syndrome occurring during the administration of 
amitryptyline therapy. Whilst it is recognised that 
amitriptyline is structurally similar to the phenothiazines, it 
should be mentioned that both patients did receive some 
phenothiazine medication during their treatment period. In 
describing a case of oral-buccal dyskinesia following low dose 
diazepam and flurazepam over a period of 13 months, it was 
noted that the patient had been treated earlier with 
amitriptyline (Kaplan & Murkofsky, 1978), and whilst 
Rosenbaum and De La Fuente (1979) referred to a clear 
temporal association between the use of benzodiazepines and 
tar dive dyskinesia in six patients only two of these received 
diazepam alone, the other four had their benzodiazepine 
therapy complicated by earlier treatment with either anti­
psychotic or anti depress ant drugs.
The occurrence of oral facial dyskinesia associated with 
prolonged use of antihistamine decongestants was reported by
2.7.6
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observed a progressive left-sided facial dyskinesia in a 
patient who had received chlorpheniramine for 10 years. A 
further case of tardive dyskinesia was reported in a patient 
who had taken a variety of antihistamine preparations 
intermittently for 30 years and continuously for 10 years 
(Hale & Heins, 1978). Tardive as well as permanent 
dyskinesias have been described in three young drug addicts 
taking narcotics and marihuana (Marshall, 1972), although it 
is notoriously difficult to obtain full drug histories from many 
subjects and these patients may conceivably have taken many 
different drugs (Parkes, 1976). A case of dyskinesia in which 
body rocking and fly-catching movement of the tongue were 
featured occurred following the discontinuation of a 
compound analgesic containing oxycodone (Gardos, 1977).
Dyskinesias have also been reported following the 
administration of methylphenidate (Fann, Davis & Wilson, 
1973; Platatucci, 1974), dextroamphetamine (Mattson & 
Calverley, 1968), anti-convulsants (Chadwick, Reynolds & 
Marsden, 1976), and levodopa (Williams & Caine, 1981; Le 
Witt & Caine, 1981).
Spontaneous Dyskinesia
Whilst it is generally accepted that tardive dyskinesia occurs as a 
result of long-term antipsychotic medication there is evidence to 
suggest that the disorder can appear in persons who have never 
received these compounds. Brandon, McClelland & Protheroe 
(1971), in a study of the total population of a psychiatric hospital 
observed that 20 men (5 per cent) and 36 women (7 per cent) who
showed facial dyskinesia had never been exposed to phenothiazines.
2.7.7
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Crane & Smeets (1974) were of the opinion that naturally occurring 
involuntary movements might be diagnosed as tardive dyskinesia 
and offered this as an explanation for the unusually high prevalence 
of the disorder in some studies of drug and non-drug treated 
patients. In a study in a retirement home 38 (18 per cent) of 211 
residents who had never been treated with an antipsychotic drug 
showed dyskinetic movements (Bourgeois, Bouilk, Tignol & 
Yesavage, 1980).
Treatment of Tardive Dyskinesia
i) Withdrawal of Medication
If possible, the antipsychotic drug should be discontinued at 
the first sign of tardive dyskinesia. The syndrome will then 
become temporarily intensified, but after a few weeks it will 
diminish. In young patients it will usually disappear 
completely, while in elderly patients it may persist, possibly 
in a weakened form. In view of present possibilities of 
treatment, and as long as the patient has no subjective 
discomfort, there is no indication for any antihyperkinetic 
treatment (which would merely accentuate the syndrome on 
the longer view). If psychotic symptoms recur or become 
intensified, it may be necessary to reinstitute the anti­
psychotic treatment, possibly employing an antipsychotic 
with a weak striatal dopamine receptor-blocking effect 
(Gerlach, 1979).
Dopamine blocking drugs
Paradoxically the most effective treatment for suppressing 
tardive dyskinesia is the administration of antipsychotics 
(Jeste & Wyatt, 1979). Increasing of the dosage of an 
antipsychotic drug whenever signs of tardive dyskinesia 
appeared provided additional dopamine receptor-blockade and 
there was an alleviation of dyskinetic symptoms 
(Kazamatsuri, Chien & Cole, 1972a; Crane, 1973; Klawans,
1976). However dyskinetic symptoms reappear, and on 
repeating the process, the patient becomes subjected to an 
escalating dosage of antipsychotic drug with ultimately an 
increasing level of dyskinesia (Klawans, 1976; Lader, 1978).
In double-blind interrupted cross-over trial in two established 
cases of oral dyskinesia, thiopropazate was found to be highly 
effective (Roxburgh, 1970). It was suggested that the use of 
the compound required caution and justification. Thio­
propazate was also used by Singer & Cheng (1971) who found 
it to be significantly more effective than a placebo in 
relieving dyskinesia in 23 patients. Eighteen patients 
improved and further research was advised to determine the 
long-term effectiveness of the drug.
In 10 hospitalised psychiatric patients who had shown 
persistent dyskinesia for a minimum of 4 years, one patient 
improved following a 12 week placebo controlled, cross-over 
study with thiopropazate (Ananth, Ban & Lehmann, 1977).
Haloperidol was used in the treatment of tardive dyskinesia 
which had been exacerbated by levodopa, and although a
decrease in dyskinesia was obtained, doubt was expressed as 
to whether the improvement would be permanent (Klawans & 
McKendall, 1971). In treating a group of 10 patients who 
showed typical signs of tardive dyskinesia, Frangos & 
Christodoulides (1975) obtained improvement using increasing 
doses of haloperidol, and were prepared to recommend its 
further use. Kazamatsuri, Chien & Cole (1972b) reported 
improvement with both haloperidol and thiopropazate, and 
were of the opinion that partial reblockage of hypersensitive 
dopamine receptors should suppress dyskinesia.
Widroe and Heisler (1976) in addition to using deanol in the 
treatment of tardive dyskinesia recommended the 
continuation of, and if necessary, the increasing of pheno- 
thiazine medication. This approach was however considered 
unwise and potentially harmful if it led to a further increase 
in dopamine receptor sensitivity (Curzon, 1976).
A double-blind study of the antipsychotic pimozide was 
undertaken in 24 patients with tardive dyskinesia (Caine, 
Claveria, Teychenne, Haskayne & Lodge-Patch, 1974). 
Results indicated that pimozide achieved a significant 
therapeutic action on dyskinesia, although pimozide dosage 
required limitation due to the development of parkinsonism. 
In a study of 374 outpatients receiving antipsychotic depot 
injections, tar dive dyskinesia developed in 84. Of these 84 
patients 33 were selected for pimozide administration, and 
over a period of 6-18 months 29 patients showed dramatic 
improvement in their dyskinesia. A follow up 12 months later 
showed that of the group of 29 patients who had improved, 19
had the condition in a mild form with constant, though slight 
movements of the lower face and tongue. In 9 of the 
remaining 10 who had received pimozide, dyskinesia was 
found to be still apparent after the pimozide had been 
discontinued for a period of 5 weeks (Gibson, 1977).
Sulpiride, a selective type-2 dopamine receptor antagonist, 
was evaluated in a blind, placebo-controlled trial in 11 
patients with tardive dyskinesia (Casey, Gerlach & 
Simmelsgaard, 1979). There was a significant suppression of 
tardive dyskinesia, although scores returned to their baseline 
level during the final placebo phase. Similar results were 
obtained in a group of six chronic schizophrenics with 
pronounced tardive dyskinesia. Dyskinetic signs were 
diminished unrelated to dosage, but returned to the starting 
level, two weeks after the discontinuation of sulpiride 
(Haggstrom, 1980).
The dibenzodiazepine derivative clozapine has been shown to 
be effective in the treatment of tar dive dyskinesia. In a 
study to evaluate its effect as an antipsychotic agent in 9 
chronic schizophrenics, it was observed that two patients who 
showed tardive dyskinesia during the placebo phase lost these 
symptoms when the active clozapine was administered 
(Simpson & Varga, 1974). In a further study clozapine was 
used to treat 12 chronic schizophrenic patients with tardive 
dyskinesia. Seven patients completed the study and all 
showed a steady improvement in their dyskinesia after 18 
weeks on clozapine. When they were then given placebo 
medication the dyskinetic symptoms returned. Problems
encountered during the study included neutropenia in two 
patients (Simpson, Lee & Shrivastava, 1978). Clozapine 
differs from the classic antipsycho tics in that it is able to 
antagonise dopamine-receptor hypersensitivity by a 
mechanism other than blockade of the dopamine receptors 
themselves (Sayers, Burki, Ruch & Asper, 1978), and it is 
suggested that clozapine has an antihyperkinetic effect 
without increasing the risk of a recurrence of tardive 
dyskinesia after the withdrawal of the treatment (Gerlach & 
Simmelsgaard, 1978). However the occurrence of agranulo­
cytosis as a side effect with clozapine (Lancet, 1975), has led 
to this compound being no longer available in the United 
Kingdom. The worldwide incidence of this side effect was 
reviewed by Griffiths & Saameli (1975).
Jeste & Wyatt (1979) suggested that the use of anti psycho tics
to treat antipsychotic-induced tardive dyskinesia may be
compared to the use of opiates in the treatment of opiate
•
dependence. Increasing the dose of antipsychotics generally 
abates the abnormal movements, but can aggravate the 
pathogenesis by further denervation and subsequent hyper­
sensitivity, and is clearly contraindicated (Klawans, Goetz & 
Perlik, 1980).
Papaverine, a smooth-muscle relaxant used in the treatment 
of cerebral arteriosclerosis has been found to antagonise 
dopamine in the caudate nucleus of the rat (Gonzalez-Vegas,
1974). Dopamine blocking properties of papaverine were also 
suggested by Duvoisin (1975) who showed that papaverine
administration produced relapse in levodopa-treated 
patients with Parkinson’s disease. In a pilot study 3 
chronic female hospitalised patients with moderately severe 
dyskinesia were treated with papaverine in doses of 300-600 
mg for 3 weeks. Orofacial dyskinesia improved in all three 
patients (Gardos &  Cole, 1975). A further study in 9 patients 
showed a modest 20 to 25 per cent improvement in oral 
dyskinesia (Gardos, Cole & Sniffin, 1976).
In a larger sample of 23 psycho geriatric patients and 18 
chronic schizophrenic patients, a single blind study which 
included a 6 week no drug period was undertaken. Whilst 
orofacial dyskinesia was significantly reduced by papaverine 
in the psycho geriatric group during the first 6 weeks, only a 
few patients reached a 50 per cent improvement of 
dyskinesia scores. The authors concluded that overall the 
drug effects were modest (Gardos, Granacher, Cole & Sniffin, 
1979).
Oxiperomide, a new dopamine-receptor antagonist, in dosage 
of 5 to 10 mg daily, decreased drug-induced dyskinesias 
without increasing Parkinsonian symptoms of akinesia and 
rigidity in 6 patients with idiopathic Parkinson's disease 
(Bedard, Parkes & Marsden, 1978). The same compound was 
evaluated in a blind, placebo-controlled trial in 10 patients 
with tardive dyskinesia. Significant results in reducing 
dyskinetic movements were obtained in 8 patients 
during the oxiperomide treatment phase, and the dyskinesia 
returned to the pretreatment level during the placebo phase 
(Casey & Gerlach, 1980).
Alpha-methyl-para-tyrosine (AMPT) reduces the formation of 
dopamine by inhibiting the rate-limiting enzyme tyrosine 
hydroxylase (Gerlach, Reisby & Randrup, 1974), and was 
shown to be effective in reducing dyskinesia in all 8 patients 
in a 3 day study. A further 3 day study showed improvement 
in dyskinetic signs in 10 patients of 24 treated with AMPT 
(Gerlach & Thorsen, 1976).
Dopamine depleting drugs and dopamine synthesis blockers
Reserpine, a dopamine blocking agent, and methyldopa, a 
blocker of catecholamine synthesis, were used in treating 37 
patients with tardive dyskinesia (Villeneuve & Boszormenyi, 
1970). Within the limitations of an open study, improvement 
was seen in approximately half of the patients in each group. 
In a double-blind, placebo-controlled study in 3 groups of 10 
patients, receiving reserpine, alpha-methyldopa and placebo 
respectively, statistically significant improvement of the 
tardive dyskinesia symptomatology with the two active 
preparations was noted when compared with the results 
obtained with the placebo (Huang, Wang, Hasegawa & 
Alverno, 1980). Methyldopa was found to be more effective 
than a placebo in relieving tremor, rigidity and orofacial 
dyskinesia in 15 chronic psycho geriatric patients who were 
studied during a 4 week double-blind experiment (Viukari & 
Linnoila, 1975). The dopamine-depleting agent tetra- 
benazine, an analogue of reserpine, was used in an open study 
to treat 4 cases of drug-induced tardive dyskinesia (Brandrup, 
1961). The dyskinetic movements disappeared in all 4 
patients and recurred when the tetrabenazine was 
experimentally discontinued for a period of 8 days during the
study. In a small double-blind study with 6 dyskinetic 
patients treated with tetrabenazine, abnormal movements 
were abolished in 3 patients and there was some improvement 
in 2 others (Godwin-Austen & Clark, 1971). A longer-term 
open study in 6 patients treated with tetrabenazine at a dose- 
level of 100 mg a day gave promising results initially but 
required a doubling of dosage after 15 weeks. The effect of 
dosage increase was transient as by the 18th week an 
increase in oral dyskinesia was observed (Kazamatsuri, Chien 
& Cole, 1973). A further single case open study in which 
tetrabenazine was successful when combined with choline has 
also been reported (Snell, Cleary & Sambrook, 1980).
Oxypertine, an indole derivative dopamine depleter, was used 
to treat tardive dyskinesia in 10 chronic hospitalised patients. 
Seven patients improved but it was necessary to continue 
antipsychotic medication to prevent the worsening of 
psychotic symptoms (Kazamatsuri, 1980). In a double-blind, 
placebo-controlled study involving 28 patients from whom 
previous medication was withdrawn, more of the 14 patients 
receiving oxypertine improved than those receiving placebo, 
though the difference did not reach statistical significance 
(Freeman, Soni & Carpenter, 1980).
Cholinergic agents
Among the hypotheses advanced to explain tardive 
dyskinesia, the suggestion of dopaminergic/cholinergic 
imbalance in the extrapyramidal system, has gained 
considerable acceptance (Baldessarihi & Tarsy, 1976). A
number of studies have been undertaken with the objective of 
restoring the balance between the dopaminergic and 
cholinergic systems, and attempts have been made to 
increase cholinergic activity with drugs such as deanol, 
physostigmine, choline and lecithin. Miller (1974a) reported 
the complete disappearance of levodopa-induced dyskinesia in 
8 of 11 patients treated with deanol, 500 to 900 mg daily for 
4 weeks. When the patients were transferred to placebo, 
dyskinetic signs returned within 3 to 8 days. In the same 
year he reported the successful treatment of 2 cases of 
tardive dyskinesia with deanol at doses up to 600 mg' daily 
(Miller, 1974b).
Deanol, the 2-dimethylamino-ethanol salt of para-acet ami do- 
benzoic acid, is thought to be a precursor of acetylcholine 
and once it crosses the blood-brain barrier it is probably 
converted to acetylcholine (Klawans, Topel & Bergen, 1975). 
In their own study in 18 cases of levodopa-induced 
dyskinesias, these authors failed to confirm the observations 
of Miller (1974a), and observed improvement in only 4 
patients, and in none were the dyskinesias completely 
eliminated. Other studies under open conditions also failed 
to confirm Miller's results (Escobar & Kemp, 1975; Crane, 
1975; Laterre .& Fortemps, 1975). Positive results however 
were obtained in all 10 deanol treated cases of tardive 
dyskinesia (Fann, Sullivan, Miller & McKenzie, 1975) and in all 
4 treated cases (De Silva & Huang, 1975). In a detailed single 
case study, severe orofacial dyskinesia was completely 
relieved although within a week of stopping deanol because of 
occipital headaches, dyskinetic movements returned (Casey &
Denney, 1975). In a review article (Re, 1975), reference was 
made to the conflict and controversy as to the effects of 
deanol in the management of dyskinesias, and the conclusion 
was drawn that different results seemed to be related to the 
integrity of receptor sites in the striatum and to proper 
diagnostic selection.
This theme was supported by Granacher, Baldessarini & Cole 
(1975), who advocated that until it was possible to distinguish 
cases of tardive dyskinesia that would respond to deanol, the 
drug should be used empirically. Ayd (1975) urged the setting 
up of studies involving large numbers of dyskinetic patients 
treated with deanol for many months to determine that the 
anti dyskinetic efficacy of the drug does not diminish with 
time or interfere with the efficacy of antipsychotic therapy. 
In a subsequent double-blind study some therapeutic effect in 
oral hyperkinesia was seen in 5 of a group of 20 patients 
treated with deanol (Bockenheimer & Lucius, 1976). However 
3 placebo controlled, double-blind studies in 10 patients, 25 
patients and 14 patients respectively showed no statistical 
differences in dyskinetic scores between the deanol therapy 
period and that when placebo medication was administered 
(Simpson, Voitashevsky, Young & Lee, 1977; Jus, Villeneuve, 
Gautier, Jus, Villeneuve, Pires & Villeneuve, 1978; Penovich, 
Morgan, Kerzner, Karch & Goldblatt, 1978).
An antihyperkinetic effect was obtained by intravenous 
administration of the cholinergic drug physostigmine 
(Klawans & Rubovits, 1974), but its duration of action is 
short, and it can produce nausea, vomiting and impaired
cognitive functioning (Davis, Berger, Hollister & Simonton,
1977). Choline chloride administration has been shown to 
increase blood choline, brain choline, and brain acetylcholine 
levels in rats (Cohen & Wurtman, 1975 & 1976). On this basis 
choline chloride was administered to 4 patients with tardive 
dyskinesia. All 4 patients had significantly less abnormal 
movements during the choline treatment (Davis, Berger, 
Hollister & Simonton, 1977). In a * double-blind, placebo- 
controlled, crossover study, choline was administered to 20 
patients with tardive dyskinesia. Blood choline levels rose 
during the period of choline therapy in all patients and 9 were 
significantly improved (Growdon, Hirsch, Wurtman & Wiener,
1977).
Adverse reactions to choline included a "fishy" body odour 
and gastrointestinal irritation (Gelenberg, 1979), and double­
blind trials with choline chloride are made difficult because 
the fishy odour indicates which patients are receiving choline 
chloride (Davis, Hollister, Vento & Simonton, 1978).
Lecithin, another precursor of acetylcholine, and a major 
source of dietary choline, has been shown to be more 
effective in raising serum choline levels than choline 
chloride, and this increase is more prolonged (Wurtman, 
Hirsch & Growdon, 1977). In a double-blind, placebo 
controlled study in 8 chronic schizophrenic patients with 
moderate to severe tardive dyskinesia, Branchey, Branchey, 
Bark & Richardson (1979) were unable to confirm earlier 
promising results of others, and found no difference between 
the severity of tardive dyskinesia observed during lecithin
treatment and that observed during placebo administration. 
Using double the dose of lecithin than that employed in the 
previous study, significant improvement was seen in the 
dyskinesia of 6 long-term patients with moderate or severe 
tardive dyskinesia, who participated in a double-blind, 
placebo controlled trial (Jackson, Nuttall, Ibe & Perez-Gruet,
1979).
GAB A minerqic agents
Gamma-aminobutyric acid (GABA), an inhibitory neuro- 
transmitter, has been linked with nigrostriatal dopaminergic 
functions in both electrophysiological and behavioural studies 
(Stevens, Wilson & Foote, 1974). On this basis it was 
hypothesised that GABAminergic agents such as sodium 
valproate might be useful for treating tardive dyskinesia 
through their inhibition of the dopamine neuronal super- 
sensitivity in the nigrostriatum (Linnoila, Viukari & Hietala,
1976). In their double-blind crossover study in 32 chronic 
psychiatric patients, orofacial dyskinesias were totally or 
significantly relieved in 17 cases. These results were not 
confirmed in an open study in which 25 schizophrenic patients 
with tardive dyskinesia were given sodium valproate for 1 
month. Films for each patient taken before and after 
treatment were screened side by side as a randomly allocated 
pair and viewed by a multidisciplinary audience of 9, who 
tried to identify the ’after1 film. A majority made the 
correct adjudication in only 8 cases, and it was concluded 
that the treatment was unsuccessful (Gibson, 1978c). In the 
former trial sodium valproate was administered at a level of 
300mg thrice daily and in the latter the dosage was 200mg
thrice daily. Muscimol (3-hydroxy-5-amino-methylisoxazole), 
thought to be a GABA agonist was administered to 7 chronic 
schizophrenics with symptoms of tardive dyskinesia. Whilst 
dyskinetic movements were improved, the psychotomimetic 
properties of the drug limited its value as a treatment agent 
in tardive dyskinesia (Tamminga, Crayton & Chase, 1979).
The benzodiazepines are thought to have central GABA 
minergic action, and clinically they exert sedative and 
muscle relaxant effects. It is however uncertain whether 
these drugs act specifically or merely as sedatives in 
controlling the symptoms of tardive dyskinesia (Jeste & 
Wyatt, 1979). O'Flanagan (1973) described the use of 
diazepam in controlling dyskinesia. Diazepam in doses of 10 
mg 3 times a day was effective, but patients became drowsy 
and dulled. In a later report, (O'Flanagan 1975), clonazepam 
was used in place of diazepam to control dyskinesia, and in 42 
patients who had been given clonazepam in doses of 0.5 mg 
twice daily to 1 mg 3 times a day, there had been a distinct 
improvement, without drowsiness in all cases. These results 
were not repeated in an open study with 18 chronic 
psychiatric patients with tardive dyskinesia. Only 2 showed 
noticeable improvement, and side effects included 
drowsiness, behavioural changes, confusion and ataxia 
(Sedman, 1976). ^  "
The parachlorophenyl analogue of GABA, baclofen, induces 
biochemical changes similar to GABA agonists (Fuxe, 
Hokfelt, Ljungdahl, Agnati, Johansson & de la Mora, 1975). 
In a double -blind crossover trial in 20 female patients
suffering from antipsychotic-induced tardive dyskinesia, 15 
patients showed improvement on baclofen (Korsgaard, 1976). 
Side effects observed included sedation, muscular hypotonia, 
dizziness, vomiting and muscular rigidity. Similar results 
were obtained in a further double-blind crossover study, but 
the authors considered that side effects limited the practical 
usefulness of baclofen in the treatment of tardive dyskinesia 
(Gerlach, Rye & Kristjansen, 1978). Whilst no statistically 
significant changes were found between baseline scores and 
those at the end of baclofen and placebo periods, in a double­
blind study in 10 chronic schizophrenic patients (Nair, Yassa, 
Ruiz-Navarro & Schwartz, 1978), the results cannot be 
compared with the 2 previously mentioned studies as in this 
trial all antipsychotic medications were withdrawn for at 
least 3 months prior to entry.
Dopamine agonists
If the hypothesis that tardive dyskinesia is related to an 
abnormal hypersensitivity of dopaminergic receptors to 
normal or relatively normal levels of brain dopamine 
(Klawans, Ilahi & Shenker, 1970; Klawans, 1970) it might be 
expected that dopamine agonists would markedly exacerbate 
these abnormal movements. This was confirmed in a short - 
term trial in which levodopa (L-3, 4-dihydroxyphenylalanine) 
was given for 2 weeks to a patient who had developed tardive 
dyskinesia following chlorpromazine and haloperidol therapy 
(Klawans & McKendall, 1971). The dyskinesia worsened 
strikingly and after discontinuation of the levodopa, the
condition was only improved by the administration of 
haloperidol, and whilst the authors observed that it was 
unclear at that time whether the reinstitution of an anti­
psychotic drug would bring about permanent improvement in 
the dyskinesia, the procedure was subsequently condemned 
(Klawans, Goetz & Perlik, 1980).
Confirmation of a worsening of dyskinetic symptoms 
following levodopa treatment in a 36 year old female patient 
was reported by Carroll, Curtis & Kokmen (1977); however on 
a reduced dosage, improvement was observed. The authors 
postulated that this paradoxical and unexpected improvement 
may have been due to a stimulation of presynaptic dopamine 
receptors. Improvement was also reported using 
apomorphine, a directly acting dopamine agonist in the 
treatment of tardive dyskinesia in an undisclosed number of 
patients, although in the same study, d-amphetamine, an 
indirectly acting dopamine agonist, increased dyskinetic 
movements (Smith, Tamminga, Haraszti, Pandey and Davis,
1977).
In a single-blind study comparing the effects of 2 dopamine 
agonists, levodopa and bromocriptine and an anticholinergic 
(trihexyphenidyl), on antipsychotic induced tardive dyskinesia 
in 3 groups of 16 patients, bromocriptine was effective in 30 
to 70 per cent of those treated and schizophrenia was not 
exacerbated. Levodopa was found to be unsuitable as, 
although it had a slight effect on kinetic disorders, side 
effects such as hallucinations and excitation were observed. 
With trihexyphenidyl improvement was noted in 10 of the 16 
patients treated (Ringwald, 1978).
Iivanainen, Kaste, Juntunen, Kruus, Ranta & Seppala (1978) 
investigated the effect of bromocriptine in a double-blind, 
placebo controlled crossover study in 10 mentally retarded 
patients. No beneficial effect on dyskinesia was observed. 
Bromocriptine and another dopamine agonist (CF 25-397) were 
administered to 8 schizophrenic patients with tardive 
dyskinesia. Neither agent significantly improved the 
dyskinesia (Tamminga &  Chase, 1980). Earlier studies with 
bromocriptine were carried out with a relatively high daily 
dosage. A mean daily dosage of 32mg (range 20-50mg) was 
used by Ringwald (1978) and in the study above (Iivanainen et 
al, 1978) up to 50mg a day was given. It has been postulated 
that a low dose of bromocriptine may lead to predominant 
stimulation of the presynaptic inhibitory dopaminergic 
receptor thus reducing pre-synaptic dopamine release 
(Barnes, Kidger & Taylor, 1978), but 7 patients in the 
Tamminga and Chase study referred to above failed to 
improve after 3 weeks treatment with bromocriptine with a 
maximum daily dosage of lOmg. This study had the dis­
advantage that antipsychotic medication was discontinued 
prior to patients entry into the trial.
An alternative viewpoint on dosage of dopamine agonists was 
put forward by List & Seeman (1979) who suggested that 
short term high dose therapy with dopamine agonists might 
be of some value in alleviating antipsychotic-induced tardive 
dyskinesia clinically. They had shown that dopamine agonists 
could reverse antipsychotic - induced elevation of brain anti­
psychotic drug binding, by a 5 day administration of bromo­
criptine or levodopa + carbidopa to rats who had previously 
been subjected to chronic administration of large doses of 
haloperidol for 21 days.
Lithium
Gerlach,'Thorsen & Munkvad (1975) demonstrated an anti- 
hyperkinetic effect with lithium in antipsychotic induced 
tardive dyskinesia. In a double-blind, placebo controlled, 
crossover study in 20 patients they found a slight, but 
significant reduction in the dyskinesia. Eleven patients 
showed improvement, 3 patients were excluded from the 
study because of toxic reactions to lithium, and a further 2 
refused to continue medication. Some improvement in 
dyskinesia was also reported in an open study in 6 patients 
(Reda, Escobar & Scanlan, 1975) but in a single-blind pilot 
study, followed by a placebo controlled double-blind trial 
with lithium, no improvement in dyskinesia was observed 
(Simpson, Branchey, Lee, Voitashevsky & Zoubok, 1976). This 
result was confirmed in 23 patients with tardive dyskinesia 
who were given lithium for an 8 week period. No significant 
improvement in dyskinetic movement was obtained, and in 2 
patients there was an aggravation of the dyskinesia (Jus, 
Villeneuve, Gautier, Jus, Villeneuve, Pires & Villeneuve, 
1978). This latter observation was also made by Beitman 
(1978) who treated a 56 year old female patient, who had 
previously shown signs of tardive dyskinesia, with lithium for 
depression. Within a few weeks of lithium therapy dyskinesia 
reappeared.
viii) Pyridoxine
Pyridoxine (Vitamin B )^ was used in treating 11 patients with 
tardive dyskinesia, because it had been observed earlier to 
diminish the effects of L-dopa in parkinsonian patients, but 
only 1 patient showed any improvement (Crane, Turek & 
Kurland, 1970). However, in an open study in 5 patients with 
tardive dyskinesia, oral doses of pyridoxine ranging from 1000 
to 1400mg daily, was found to reduce the frequency and the 
severity of the dyskinesia (DeVeaugh-Geiss & Manion, 1978).
ix) Cyproheptadine
Conflicting results have been obtained using the serotonin 
antagonist cyproheptadine in tardive dyskinesia. In open 
studies Goldman (1976) reported good results in all 3 patients 
treated; Kurata, Hosokawa & Koshino (1977) observed marked 
amelioration of dyskinesia in 4 of 11 patients treated, with 
lesser degrees of improvement in 4 others, but Gardos & Cole 
(1978) were unable to demonstrate any lasting effects in 5 
patients treated with cyproheptadine.
x) Oestrogens
Raymond, Beaulieu, Labrie & Boissier (1978) demonstrated 
that chemical synaptic transmission can be influenced by 
hormones, namely oestrogens. In an open pilot study in 20 
male patients with tardive dyskinesia, 16 patients showed 
varying degrees of improvement in dyskinetic scores 
(Villeneuve, Cazejust & C & te , 1980). The authors were, 
however, cautious in drawing definite conclusions, as in some 
instances the improvement was very slight.
xi) Clonidine
In an open study in 2 patients showing tardive dyskinesia, 
clonidine was observed to have a beneficial effect on both 
the psychotic condition and the dyskinesia (Freedman, Bell & 
Kirch, 1980). The authors noted that the hypotensive effect 
of clonidine was a particular disadvantge.
xii) Propranolol
Low-dose (20 to 40 mg per day) of the beta-adrenoceptor 
blocking agent, propranolol, was added to current anti­
psychotic medication to treat tardive dyskinesia in a group of 
10 chronic, psychiatric male patients. Seven showed 
significant improvement in their dyskinetic movements, 
which reappeared in 2 patients when propranolol therapy was 
stopped. These results were supported by a further study in 
which 3 psychotic patients with tardive dyskinesia, showed 
improvement in both dyskinetic movements and extra- 
pyramidal side effects, when treated with propranolol in 
doses of 30 to 60 mg per day (Kulik & Wilbur, 1980).
xiii) Manganese chelate
Postulating that tardive dyskinesia was associated with a 
deficiency of manganese, doses of manganese chelate were
- “administered "t (TT5~patients with the syndrome. Four patients 
responded dramatically, and a further 9 patients showed a 
definite improvement in 2 to 5 days (Kunin, 1976). Similar 
responses were reported "in a smaller number of cases" 
(Hoff er, 1977) and in 6 cases (Norris & Sams, 1977).
xiv) Fusaric acid
Fusaric acid, a selective and potent dopamine-/^ -hydroxylase 
inhibitor, has been shown to decrease noradrenaline and 
increase serotonin, but not to alter dopamine concentrations 
in the brain (Hidaka, 1971), The effect of fusaric acid on 
tardive dyskinesia and mental state was studied in 15 chronic 
psycho geriatric patients. Fusaric acid significantly relieved 
oro-facial dyskinesia, tremor and rigidity, and it improved 
the mental state of patients (Viukari & Linnoila, 1977).
xv) Co-derqocrine
It has been suggested that co-dergocrine is a dopamine 
agonist, a serotonin agonist and a noradrenaline antagonist 
(Loew, Vigouret & Jaton, 1979). In an uncontrolled study, 7 
out of 10 schizophrenic patients showed improvement in their 
dyskinetic movements (Gomez, 1977).
This observation was supported in a further open study in 
which all 6 patients with tardive dyskinesia, treated with co- 
dergocrine improved (Hajioff, 1978). In a group of 9 
psychotic patients with tardive dyskinesia treated with a 
placebo for 1 week, followed by active co-dergocrine for 7 
weeks and then placebo for a final 2 weeks, all 9 patients
showed highly significant improvement during the period of
 :  ^ : / _______
active medication (Arranz^Munecas, Ganoza Garcia &
Forcadell Puyo, 1979). These findings were not confirmed in
a small open study in 5 patients, as although 2 patients
showed some improvement, 3 worsened (Mohamed, Kazarian,
Merskey & Thompson, 1980). In a preliminary report on a
double-blind study in 8 patients, superiority of co-dergocrine
over placebo was noted (Chien, Marder, Van Putten & 
Escobar, 1980). Work with co-dergocrine is reported in 
greater detail in Chapter 6.
xvi) Electroconvulsive Therapy
Although the. effects of ECT on the dyskinetic process are 
unclear, and 1 report suggested that tardive dyskinesia had 
resulted from ECT (Uhrbrand & Faurbye, 1960), reports on 
the benefits of ECT in Parkinson’s disease (Lebensohn & 
Jenkins, 1975; Asnis, 1977) suggested that tardive dyskinesia 
might improve following ECT treatment. However only 1 of 
4 patients treated with ECT showed any improvement in 
dyskinetic scores, and the authors concluded that ECT had a 
negligible effect on the dyskinetic process (Asnis & Leopold,
1978). An improvement in a single patient was seen following 
7 sessions of ECT with a concomitant improvement in 
depressive symptoms (Price & Levin, 1978).
2.7.8 Conclusions
In reviewing methods that have so far been used in the treatment 
of tardive dyskinesia, Jeste & Wyatt (1979) observed that it is
interesting to note that most of these investigations have been
-
based on some theoretical rationale about the mechanism of action 
of the treatments being tested, and yet the neuropathology under­
lying tardive dyskinesia, as well as the mode of action of the 
treatments used to combat it, so far has eluded understanding.
Most of the treatment methods reviewed in this chapter have 
yielded inconclusive results. Early enthusiasm produced by
apparent improvement in open studies has been tempered by 
disappointing results under double-blind, placebo controlled 
conditions. Numbers of patients in most of the studies have been 
small, and the period of treatment has been short. Improvements 
reported have not been maintained when the treatment has been 
stopped. Results are also difficult to interpret when in many 
instances antipsychotic medication has been stopped whilst the 
tardive dyskinesia is being treated. Factors influencing poor 
results also include age, chronicity of psychotic illness, length of 
hospitalisation and the variety and duration of antipsychotic 
medication.
IMPLICATIONS FOR PSYCHIATRY
In considering issues in tardive dyskinesia, Gardos & Cole (1980), stated 
that public health concern over tardive dyskinesia has been rising, but the 
magnitude of the problem has been undetermined. Incidence (as distinct 
from prevalence) refers to the number of new cases emerging in a well- 
defined population during a given time period, and in respect of tardive 
dyskinesia the true incidence is unknown. Prevalence rates yield 
conflicting and misleading estimates, and Gardos & Cole (1980) stated that 
it is premature to draw alarming conclusions from high and seemingly 
increasing prevalence rates. The major public health concern is the real 
possibility that with each passing year of widespread antipsychotic drug 
use, increasing numbers will develop tardive dyskinesia. Gathering reliable 
incidence figures from a wide-range of populations at risk over a long time 
period appears to be the only direct method of clarifying this issue.
In the Task Force report of the American Psychiatric Association (1980), 
on late neurological effects of antipsychotic drugs, the observation is made 
that while the problem is serious, an alarmist view is not warranted, 
especially since many cases are detected early and improve spontaneously. 
The best approach currently is to use antipsychotic drugs thoughtfully for 
clear indications, the best supported of which, scientifically, is chronic 
schizophrenia.
The subject is considered in greater detail in Chapter 7.
SUMMARY
The historical background to the treatment of mental illness, which has 
been characterised by the imposition of much physical suffering on the 
patient, is traced. The transformation that occurred following the 
discovery and introduction of antipsychotic drugs is then described, 
followed by consideration of the chemistry and animal pharmacology of 
these drugs. Clinical use, side effects and pharmacology of the anti­
psychotic drugs is outlined.
Tardive dyskinesia is then reviewed following its first observation in 1956, 
including a description of its clinical manifestations, its prevalence and the 
aetiology of the condition. The various agents, including antipsychotics as 
well as other drugs which have been implicated in the syndrome are listed, 
and attention is drawn to the occurrence of spontaneous dyskinesias.
The many methods so far used in the treatment of tardive dyskinesia,
including their rationale, are reviewed, and reasons suggested for the many
disappointing results obtained. Preliminary comments are made on the 
implications for psychiatry of tardive dyskinesia.
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INTRODUCTION
Much of the current confusion about the prevalence, incidence and
seriousness of tar dive dyskinesia grows out of confusion as to how to
diagnose the condition and how to measure its intensity (Cole, 1975). He
was of the opinion that the descriptive statement contained in the special 
report of the Task Force of the American College of .Neuropsycho­
pharmacology and the Food and Drug Administration (Schiele, Gallant, 
Simpson, Gardner, Cole, Crane, Chase, Ayd, Levine & Ochota, 1973) made 
the situation even more complicated. This descriptive statement which 
was recommended as a definition of the condition is here given in full:
'Tardive dyskinesia as usually seen in older, more chronic
patients is characterised by stereotyped, repetitive, involuntary 
movements of the mouth, lips and tongue and sometimes 
accompanied by choreiform movements of the limbs or trunk’.
'The most widely described symptoms make up the 'bucco-linguo- 
masticatory' (BLM) triad; this consists of sucking and smacking 
movements of the lips, lateral jaw movements, and the tongue 
will thrust, roll, or have fly catching movements. This 
movement may be carried out with the mouth closed, in which 
case the tongue will hit the inside of the cheek and a chewing- 
the-cud type of movement will be seen. While the BLM 
syndrome is the most frequently described and seen, it is by no 
means the only mode of onset. Sometimes tic-like movements 
involving the lips and eyes may antedate these symptoms and 
other parts of syndrome to be described later may also appear 
first. The oral movements usually worsen under emotional 
tension; they disappear during sleep.'
'The extremities may show choreiform movements which are 
variable, purposeless, involuntary quick movements. They 
sometimes intensify on attention but are irregular in occurrence. 
Frequently associated with these symptoms are athetoid 
movements which are continuous arrhythmic worm-like slow 
movements in the distal parts of the limbs. The choreo-athetoid 
movements particularly affecting the arms and fingers are to be 
differentiated from schizophrenic stereotyped movements.'
'Another feature of the syndrome may be axial hyperkinesis, i.e. 
a to-and-fro clonic movement of the spine in the antero­
posterior direction, a rare symptom, but one that has been seen 
as the only manifestation of the syndrome. Ballistic movements 
can also occur, as can rhythmical swaying movements of the 
body from one side to the other which can take on a rocking 
quality if the patient sits down. All of these features are seldom 
present at the same time, but the BLM signs, plus choreo- 
athetoid movements of the limbs with an inability to stand or sit 
still, are a frequent grouping of signs in severe cases. All 
involuntary movements disappear during sleep.'
'Parkinsonian symptoms can coexist with tardive dyskinesia'.
Tarsy and Baldessarini (1976) suggested that the diagnosis of tardive 
dyskinesia should be considered in any patient displaying chorea, athetosis, 
dystonia, orofacial dyskinesia, facial grimacing, or tic-like disturbances, 
who have been taking phenothiazines or butyrophenones for a period of at 
least several months. Differential diagnosis between tardive dyskinesia
and other syndromes induced by antipsychotic drugs is discussed in Chapter 
2, and recently attention has been drawn to the existence of 'subsyndromes' 
of tardive dyskinesia (Milavic & Gaind, 1980). Jus, Pineau, Lachance, 
Pelchat, Jus, Pires and Villeneuve (1976) distinguished four subgroups on a 
phenomenological basis, and Jeste, Potkin, Sinha, Feder & Wyatt (1979) 
differentiated two clinical categories of reversible and persistent tardive 
dyskinesia, and attributed different discriminant variables to each 
category. Barnes &  Kidger (1979b) observed that on the basis of a factor 
analysis of abnormal movements in a population of chronic schizophrenics, 
tardive dyskinesia is not a single syndrome. They proposed that orofacial 
movements would constitute a central component, and the dyskinetic trunk 
and limb movements would constitute peripheral tardive dyskinesia. It 
appears that different subtypes of tardive dyskinesia may exist which are 
phenomenologically and neurochemically distinct (Barnes & Kidger, 1979b; 
Mackay & Sheppard, 1979).
The Task Force (1980) drew particular attention to the wide range of 
abnormal movements that are encountered clinically and may be called 
tardive dyskinesia. These abnormalities include minor movements that 
may be difficult to distinguish from habit spasms, other tics of unknown 
cause, psychotic mannerisms, manifestation of senescence, or even normal 
movements with ill-fitting dentures. Factors to be considered in 
differential diagnosis include schizophrenic reversible neuroleptic 
syndromes, and dyskinesias induced by other drugs (Table 3.1). It is nearly 
impossible to specify precise prevalence rates of tardive dyskinesia since 
there is no currently accepted standard for diagnosis (Task Force, 1980).
Table 3.1
DIFFERENTIAL DIAGNOSES TO CONSIDER IN EVALUATING 
TARDIVE DYSKINESIA
1. Neuroleptic withdrawal-emergent dyskinesias or other transient 
acute dyskinesias associated with neuroleptics.
2. Late and persistent "classical” tardive dyskinesia itself. *
3. Stereotyped movements of schizophrenia. *
4. Spontaneous oral dyskinesias of advanced age or senility. *
5. Oral dyskinesias related to dental conditions or prostheses.
6. Idiopathic torsion dystonia.
7. Focal dystonia (oromandibular dystonia, blepharospasm, 
spasmodic torticollis) and habit spasms (tics).
8. Huntington's disease. *
9. Gilles de la Tourette's syndrome.
10. Wilson's disease (hepato-cerebral-lenticular degeneration due 
to abnormal copper metabolism), manganism, and other 
disorders due to heavy metal poisoning. *
11. Fahr's syndrome and other disorders with calcification of the 
basal ganglia.
12. Postanoxic, postencephalitic and encephalitic extrapyramidal 
syndromes. *
13. Rheumatic chorea (Sydenham's chorea, St Vitus' dance).
14. Drug intoxications involving L-dopa and amphetamines and, less 
commonly, anticholinergics, anti depressants, lithium and 
phenytoin. *
15. CNS complications of systemic metabolic disorders, such as 
hepatic or renal failure, hyperthyroidism, hypoparathyroidism, 
hypoglycemia and vasculitides. *
16. Brain neoplasm (thalamic, basal ganglia).
*  both psychiatric disorder and dyskinesia may be present.
Source: Task Force, 1980.
Granacher (1981) whilst suggesting that research studies on the incidence 
or prevalence of tardive dyskinesia have included patients with movements 
completely unrelated to that disorder, was of the opinion that most cases 
of dyskinesia in chronic psychiatric patients who have been exposed to 
antipsychotic drugs will, in fact, be true tardive dyskinesia.
The methodological problems inherent in survey research are formidable 
(Gardos & Cole, 1980), and include the f ollowing:-
1. Arbitrary definitions of tardive dyskinesia.
2. Measurement problems (particularly questionable reliability of
rating scales).
3. Generalisability (study populations often consist of elderly,
hospitalised patients, and the findings do not apply to drug-treated
schizophrenic patients in the community).
4. The confounding effect of concurrent antipsychotic treatment,
which may influence the level of observed dyskinesia.
SUBJECTIVE ASSESSMENT
The severity of dyskinesias may be expressed in very simple terms, such as 
mild, moderate or severe or may be defined by more extensive and 
complex rating scales. The latter can take into account not only the 
severity of the abnormal movements at a given site, but can also document 
the movements at various sites throughout the body. Both approaches have 
been used to rate a number of dyskinesias, but there is no general 
agreement as to whether complex rating scales are more efficient or 
sensitive than simpler techniques (Marsden & Schachter, 1981). These two
authors have found that rating dyskinesias at different body sites (face, 
neck, trunk, each arm and each leg) on a simple 0 - 3  scale (nil, mild, 
moderate and severe) is the most satisfactory way of approaching the 
problem. This simple subjective rating scale, however, does not take into 
account the fact that dyskinesias may occur intermittently. Marsden & 
Schachter (1981) suggested the rating of dyskinesias at each body site not 
only for their severity, but also for the frequency (occasional, frequent or 
continuous). The severity factor is then multiplied by the frequency factor 
to give an overall dyskinesia score for each body site.
Multi-item rating of dyskinetic movements has resulted in the publication 
of a number of rating scales (Crane, Ruiz, Kernohan, Wilson & Royalty, 
1969; Kennedy, Hershon & McGuire, 1971; Escobar & Kemp, 1975; 
Simpson, Zoubok & Lee 1976; Smith, Tamminga &  Haraszti, 1977; Simpson, 
1977; Barnes &. Kidger, 1979).
Videotaping has been used as a method of recording examination for 
abnormal movements in a number of studies (Gerlach & Thorsen, 1976; 
Itoh, Miura & Yagi, 1976; Gerlach, 1979). Whilst videotaping can record 
and sometimes reveal movements not observed at the time the examination 
is conducted (Gerlach, 1979), it does reduce three-dimensional movements 
to two dimensions, making movements such as undulations of the tongue 
harder to see (Gardos, Cole & La Brie, 1977). The merits and demerits of 
videotaping or filming are shown in Table 3.2. Techniques of measuring 
abnormal involuntary movements are described in the following section.
Table 3.2
AUDIOVISUAL RECORDINGS IN THE ASSESSMENT OF DYSKINESIAS
Advantages Disadvantages
Permanent record Cost of apparatus
Opportunity for repeated assessment 
by several observers
Time needed to set up apparatus 
and record
Observers can be truly ignorant 
of treatment and side-effects
Difficulty in distinguishing 
normal from abnormal movements 
or speech
Sequences can be randomised 
to ensure blind rating
Impossible to prolong observation 
period in case of doubt.
Sequences can be used to train 
raters and validate rating scales
Impossible to ask patient to under­
take tasks which may resolve 
ambiguities or provoke dyskinesias.
Visual recording in two dimensions 
only.
Source: Marsden & Schachter, 1981.
OBJECTIVE ASSESSMENT
A number of techniques for measuring the severity of tardive dyskinesia 
have been described. Electro-myography, in which muscular activity is 
recorded by the use of electrodes, has been successfully employed. 
Villeneuve, Jus & Jus (1973) placed electrodes on the right and left sides of 
the upper and lower lip, and used an electroencephalograph to record 
changes. The same authors were able to differentiate tardive dyskinesia 
which disappeared during sleep from the rabbit syndrome which persisted 
(Jus, Jus & Villeneuve, 1973). A modification of this technique in which a 
pneumatic transducer was connected to a small inflatable balloon placed 
inside the patient’s mouth, whilst sensitive to changes was, nevertheless, 
stressful to patients (Casey & Denney, 1975). Similar findings were 
recorded by Chien, Jung, Ross-Townsend & Stearno (1977) who showed high 
correlations with clinical ratings but experienced difficulties in patient 
co-operation.
An ultrasound system for measuring patients' activity and disorders of 
movement was reported by Haines & Sainsbury (1972), and the authors 
were able to differentiate categories of depression and mania in terms of 
movements. The apparatus has been subsequently adapted to record and 
quantify disorders of facial movement with particular reference to tardive 
dyskinesia (Resek, Haines & Sainsbury, 1981). Serial measurements of 
tardive dyskinesia over five months revealed striking individual 
consistency.
Chorea of the upper extremities was measured photographically using small 
pocket torches attached to each hand, with the patient being required to 
hold his arms out in front of himself (Klawans, 1973; Klawans & Rubovits, 
1974). A quantitative acceleration profile using triaxial vector
accelerometry providing a graphic display of the motion characteristics of 
a particular anatomical site has been described by Fann, Stafford, Malone, 
Frost & Richman (1977). The technique was evaluated in a group of normal 
subjects and the authors hypothesised that characteristic differences would 
be apparent in the motion profiles of patients developing drug-induced 
movement disorders and that the findings would be useful in diagnosing 
emerging symptoms and monitoring treatment-related changes.
A technique for the differential diagnosis of tremors, in which a jugular 
pressure recorder is reversed and strapped to the back of the patient’s 
hand, has been described by Griffiths &  Good (1981). An adapted 
phonocardiograph machine produced traces after amplification of the 
signal produced. The pattern and frequency of tremor and the ratio of 
postural to resting tremor frequency provided a positive diagnosis in most 
cases.
The unpredictability of most dyskinesias and most of their considerable 
variability from moment to moment have not encouraged extensive use of 
objective methods. Technical advances in the future may improve the 
reliability and sensitivity of objective methods of recording abnormal 
involuntary movements, but at the present clinical pharmacologists rely 
upon subjective assessment, perhaps coupled with very simple timing tests 
(Marsden & Schachter, 1981).
SELECTION OF RATING PROCEDURE
3.4.1 Objectives
A major section of this thesis involves a study of abnormal 
movements in 500 elderly subjects. It was necessary therefore to
decide upon an assessment procedure that would give a high 
probability of observing the majority of involuntary movements and 
their degree of severity in each subject within a limited period of 
examination.
3.4.2 Examination Procedure
The standardised examination procedure devised at the U S 
National Institute of Mental Health (AIMS, 1976) has gained 
universal acceptance (Smith, Kucharski, Oswald & Waterman, 
1979a & 1979b; Kane & Schooler, 1980; Smith, Burke & Moon, 
1981; Rey, Hunt & Johnson, 1981; Marsden & Schachter, 1981). 
This procedure has been varied slightly by Gaind & Kidger (1977), 
who commenced the examination by placing a text on a lectern and 
asking the subject to study the text. This distracting manoeuvre 
helped in unmasking dyskinetic movements.
In view of the wide acceptance of the AIMS examination, this 
procedure was adopted with minor modifications, the most 
important of these being the use of a composite picture of a series 
of animals that had been cut from Christmas cards, instead of the 
text described above. This was found to be very popular with 
elderly subjects, and their immediate attention was focussed on to 
the picture and abnormal movements, particularly in the orofacial 
region were quickly unmasked. The examination procedure is 
described in detail in Appendix 1 and the position of the subject is 
shown in Figure 3.1.
FIGURE 3.1
3.4.3 Rating Procedure
Several rating scales are currently available (Chapter 3, para 3.2) 
and the one developed at the Rockland State Hospital (Simpson, 
Zoubok & Lee, 1976) and subsequently revised (Simpson, Lee, 
Zoubok & Gardos, 1979) appears to be one of the most popular 
(Mackay & Sheppard, 1979).
The original Rockland Scale consisted of 33 items of movement 
abnormalities, and in order to simplify the rating it was decided to 
use the Abbreviated Rockland Dyskinesia Scales (Simpson, Lee, 
Zoubok & Gardos, 1979) which covered 13 items of abnormal 
movements. A further modification to this Abbreviated Scale was 
made by reducing the range of severity from 1 to 6 down to 0 to 4, 
omitting the one point on the Scale which fell between 1 (absent) 
and 3 (mild). The reason for this further modification was that the 
Abbreviated Rockland Dyskinesia scale gives a score of 1 where no 
movements are observed under each item listed on the scale. Thus, 
a patient with no abnormal movements under each of the 13 items 
listed would have a total score of 13 and yet have no dyskinesia. 
The Abnormal Involuntary Movement Scale (AIMS) (Task Force,
1980) uses a score of 0 denoting no movements under each item 
listed on the scale, and it was decided to follow a similar pattern. 
The Abbreviated Rockland score of 2 under each item denoting a 
questionable movement was also omitted with the aim of being 
more precise in observation. Thus, mild movements were rated 1, 
moderate movements 2, moderately severe movements 3 and 
severe movements 4. The total score for each patient consisted of 
the addition of all of the scores for each individual item. The 
modified scale is shown in Appendix 2. Definitions of the various 
items of abnormal movements are set out in Appendix 3.
ASSESSMENT OF ABNORMAL MOVEMENTS BY USE OF VIDEO TAPES
3.5.1 Materials and Methods
A preliminary study was undertaken in which three psychiatric 
patients from the Abraham Cowley Unit at St Peter's Hospital, 
Chertsey, and 4 patients from Horton Hospital, Epsom, were 
selected for examination. All 7 patients had been observed by 
ward staff to have exhibited abnormal involuntary movements over 
a period of several months, including the week prior to 
examination.
3.5.2 Ethical Consent
Approval for the study was obtained from the Consultant 
responsible for each patient. Individual patients were invited to 
participate in the procedure after it had been explained to them 
in detail. An assurance was given that the videotapes were to 
be used only for research purposes.
3.5.3 Recording of Abnormal Movements
In order that manifest movements could be observed under 
standard conditions, patients were seated on a firm, straight- 
backed, armless chair with feet placed firmly on the floor and 
slightly apart. The hands were rested unsupported on the knees in 
order that manifest movements could be observed.
The patients were taken through the procedure described in 
Appendix 1 and the entire examination was recorded using a 
videocamera which had been set up previously. The operator had 
been instructed to record any observed movements, with particular 
attention being given to the orofacial region.
3.5.4 Assessment of Abnormal Movements
Two raters, AJB and CMB, simultaneously observed the playback of 
the videotape and independantly recorded their interpretation of 
the type and severity of abnormal movements of each patient, 
using the abnormal involuntary movements rating scale (Appendix 
2).
3.5.5 Results
Due to the small sample of patients and the number of zero 
movement scores, it was impossible to calculate the Intraclass 
Coefficient (ICC) (Bartko & Carpenter, 1976) for each individual 
item of the AIMS examination. The overall ICC was calculated and 
indicated a reliability between the 2 raters of 0.90 (p<0.001). An 
ICC of 1 indicates perfect agreement, and thus that obtained 
between the two raters would be classified as good (Bartko & 
Carpenter, 1976).
In comparing the intra-rater reliability of rater AJB, an ICC of
0.93 (p<0.001) was achieved, showing that agreement between 
successive ratings by the same rater was good (Bartko & 
Carpenter, 1976).
3.5.6 Discussion
Within the limitation of a small sample of patients it has been 
possible, using a standard method, to show that there is 'good1 
consistency in both inter and intra-rater assessments of abnormal 
involuntary movements using the AIMS rating procedure, and 
recording movements on the Rockland Research Institute Scale.
The high number of zero movements scores, 286 out of 364, 
reduced the amount of data available for subsequent analysis.
ASSESSMENT OF ABNORMAL MOVEMENTS IN A SMALL GROUP OF
ELDERLY SUBJECTS
3.6.1 Materials and Methods
Fifty five residents, the total population of one home for the 
elderly in Surrey, were included in the study. These were 13 males 
and 42 females with ages ranging from 67 to 100 years (mean 85.5 
years).
3.6.2 Ethical Consent
Approval for the study was obtained from both the Social Services 
Department of Surrey County Council and the General 
Practitioners responsible for the medical care of the subjects (See 
chapter 5, para 5.2.2).
3.6.3 Recording of Abnormal Movements
Residents were examined individually under standard conditions. 
They were seated on a firm, straight-backed, armless chair with 
feet placed firmly on the floor and slightly apart. The hands were 
rested on the knees in order that manifest movements could be 
observed. The residents were taken through the procedure in 
Appendix 1.
3.6.4 Assessment of Abnormal Movements
Two raters, AJB and CMB, simultaneously observed the residents 
and independently recorded their interpretation of the type and 
severity of abnormal movements of each resident using the 
abnormal involuntary movements rating scale (Appendix 2). The
scores were subsequently analysed to test for inter^rater 
reliability.
6.5 Results
Thirty eight of the 55 residents examined had no observed 
abnormal involuntary movements.
Forty one of the 46 readings (89.1 per cent) excluding zeros agreed. 
Of these, 43.9per cent would be expected due to chance, hence the 
difference between observed and chance agreement is 45.2 per 
cent. The very high chance agreement is due to the fact that most 
of the scores are either 1 or 2 here, compared with a larger spread 
of readings in the previous group (para 3.5.5).
The Intraclass Correlation Coefficient (ICC) for this data is 0.88 
(p<0.001) which is very close to the corresponding results from the 
previous work para (3.5.5). The ICC for the individual items of the 
AIMS examination is shown in Table 3.3
6.6 Discussion
As in the previous work (para 3.5), within the limitations of a small 
sample of subjects it has been possible, using a standard method, to 
show ’good1 consistency in inter-rater assessments of abnormal 
involuntary movements using the AIMS rating procedure and 
recording movements on the modified Rockland Research Institute 
Scale. A high number of zero movements scores, 1338 out of 1430, 
reduced the amount of data available for subsequent analysis. The 
high correlations in both of these reliability studies may be
TABLE 3.3
INTER-RATER RELIABILITIES FOR THE ABNORMAL INVOLUNTARY 
MOVEMENTS RATING SCALE -  TWO RATER SCORES
ITEM I.C.C. N
Facial and oral movements
1. Periocular area (blinking of eyes, tremor 
of eyelids (1.00) 2
2. Movements of the lips (pouting, 
puckering and smacking). 1.00 7
3. Chewing movements .71 8
4. Sweet in mouth sign (1.00) 2
3. Tongue protrusion 1.00 6
6. Tremor and/or choreoathetoid movements 
of the tongue. .58 12
Neck and Trunk
7. Axial hyperkinesis (patient standing) - 0
8. Rocking movements - 0
9. Torsion movements (1.00) 2
Extremities
10. Movements of fingers and wrists (1.00) 4
11. Movements of ankles and toes - 1
12. Stamping movements - 0
Entire body
13 Akathisia (1.00) 2
I.C.C. = Intraclass Correlation Coefficient 
= Movement absent
N = The correlations were based on 17 subjects; the numbers in this
column indicate the number of subjects in which the movement 
was present.
0 = Numbers too small to draw conclusions
partially due to the fact that the two raters had worked together 
on a number of occasions and had carried out training sessions with 
films and videotapes of dyskinetic patients.
Other authors have reported good consistency in inter-rater 
reliability using the AIMS rating procedure. Using 4 raters, Smith, 
Oswald, Kucharski & Waterman (1978) achieved inter-rater 
reliability on the total score ranging from 0.84 to 0.93. Where 2 
raters were employed, reliabilities of 0.77 and 0.78 were obtained 
by Gardos, Cole &  La Brie (1977) , 0.92 by Moore & Bowers (1980) 
and 0.80 by Smith, Burke & Moon (1981). Problems can occur on 
rater bias, and Smith, Kucharski, Oswald & Waterman (1979b) 
noted that even with well-trained raters consistent differences can 
occur, and whilst 3 of their raters were in fairly good agreement, 
the 4th rater rated significantly higher on several scale items.
In this study it has not been possible to investigate further the 
effect of stress, food intake, circadian rhythm, time of day, time 
in relation to administration of drugs and other factors, on the 
severity of movement disorder. It is strongly recommended that 
where within patient ratings are undertaken on successive 
occasions, the examination procedure should be conducted at the 
same hour of day each time. Location of the examination should 
also be constant.
SUMMARY
The differentiation of tardive dyskinesia from other movement disorders is 
outlined and both subjective and objective assessment techniques discussed. 
A simple examination and rating procedure aimed to give a high probability 
of observing the majority of involuntary movements and their degree of
severity is described. This method was then validated for inter, and 
intra-rater reliability both from videotaped examination of patients and 
during actual examination sessions. Good consistency in inter-rater and 
intra-rater assessments of abnormal involuntary movements were obtained.
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4.1 INTRODUCTION
Uhrbrand &. Faurbye (1960) were the first to observe that tardive 
dyskinesia is more frequent in the elderly and in patients with organic brain 
diseases. Many mentally handicapped patients have congenital or 
long-standing brain damage and, because of the increasing life span, the 
geriatric population of mentally handicapped individuals is increasing so 
that between 10 per cent and 24 per cent of patients in most long-stay 
hospitals are over 63 years. Thus, surveys for abnormal movements in 
these patients should therefore yield fruitful results, although such surveys 
will challenge diagnostic skills, as by no means will all the movement 
disorders be tardive dyskinesia; the involuntary movements of the cerebral 
palsies must be distinguished (Bicknell & Blowers, 1980b).
Having selected an examination procedure to assess abnormal movements, 
a pilot study was undertaken to establish the prevalence of tardive 
dyskinesia in a small population of elderly female patients in a hospital for 
the mentally handicapped because there would be many movements to 
observe, and to establish whether there were any differences between 
those who had received antipsychotic medication during the past seven 
years and those who had not.
MATERIALS AND METHODS
4.2.1 Clinical Population
Forty-one female patients, the total population available from one 
ward at Botleys Park Hospital, Chertsey, were included in the 
study* Ages ranged from 42 to 87 years with a mean age of 63.49 
years. Time spent in the present hospital ranged from 2 to 50 
years with a mean of 31.6 years. Most of the patients had spent a 
lifetime in institutions, including periods of time in other than the 
present hospital. Examination of past records revealed that some 
had been certified as moral defectives of dull intelligence but with 
no clear history of brain damage. Their current intellectual status 
ranged from a mental age of less than 5 years in 8 patients, to 
normal intelligence (IQ above 75) in 5 patients. Many patients had 
probably functioned at a higher level in the past, but their present 
rating had been affected by years of living in hospital, increasing 
age and the handicaps of progressive visual and hearing loss 
associated with the older age groups.
4.2.2 Ethical Consent
Approval for the study was given by the consultant responsible for 
the ward, who was herself one of the raters (DJB). The 2 ward 
sisters explained the procedure to each patient as far as was 
possible, bearing in mind levels of impaired mental function, and 
patients were given the opportunity to decline to participate, 
should they so wish.
4.2.3 Assessment of Abnormal Movements
The patients were examined individually under standard conditions 
using the examination technique described in Chapter 3 (para 
3.4.2). Rater 1 (AJB) took the patients through the procedure with 
appropriate sympathetic encouragement and Rater 2 (DJB) 
recorded details of abnormal involuntary movements on the 
abbreviated dyskinesia rating scale of the Rockland Research 
Institute (Appendix 2).
4.2.4 Drop-outs
One patient aged 70 years who had a dyskinetic movement score of 
30 was excluded from the study as her medical records showed that 
when she was admitted to the hospital in 1936 she was observed to 
have ’’tremor of the head". Other abnormal movements were noted 
in her records before antipsychotic drugs were available as 
therapeutic agents.
RESULTS
Abnormal movements indistinguishable from tardive dyskinesia were seen 
in 34 (85 per cent) of the 40 patients remaining in the study. Severity was 
considered to be mild (Abbreviated Rockland scores of 2 or less) in 15 
patients (37.5 per cent) and moderate 41* greater (Abbreviated Rockland 
scores of 3 or more) in 19 patients (47.5 per cent).
Patients were then assigned to 1 of the 2 groups - group A which 
included those who had no antipsychotic medication in the past 7 years and 
group B which included those who had received antipsychotic medication
during the past 7 years. In the 31 patients who had not received 
antipsychotic medication, 25 had abnormal movements noted, and in the 9 
patients who had received antipsychotic medication, all patients had some 
abnormal movements.
Each group was subdivided into those below 65 years and those above 
65 years, the mean dyskinetic scores were calculated and the standard 
errors obtained. The results are shown in Tables 4.1 & 4.2.
The age distribution is similar for the 2 groups (mean age of 65.3 for 
Group A and 65.7 for Group B). Differences between the 4 mean scores 
are not statistically significant at the 5 per cent level, but there is a trend 
for the scores to be greater in Group B, than in Group A, and a trend for the 
score to increase with age, but neither trend was very pronounced.
A variety of abnormal movements were seen in patients in both groups 
(Table 4.3). Most of the abnormalities seen were in the orofacial region. Of 
the 31 patients with abnormal movements all had 1 or more movement in 
the orofacial region. Tremor and/or choreoathetoid tongue movements were 
most frequently seen (15 patients) closely followed by movements of the 
lips (14 patients). Two patients had symptoms more typical of a cerebellar 
disorder and they had received no medication in the last 7 years. Two 
patients had Parkinson’s disease, one was arteriosclerotic and the other 
post encephalitic, the latter improving with L-dopa. Two patients were 
epileptic and were on anti-con vulsants. Three were receiving treatment 
for depression or anxiety and 2 maintained euthyroid with thyroxine 
therapy. Four patients received iron for anaemia, and 2 received 
analgesics for osteoarthritis.
TABLE 4.1
MEAN DYSKINETIC SCORES IN 31 PATIENTS NEVER 
EXPOSED TO ANTIPSYCHOTIC MEDICATION (GROUP A)
Age
No. of 
Patients
Mean Dyskinetic 
Score S.E.
<65 13 2.69 0.59
£65 18 3.78 0.86
All ages 31 3.32 0.56.
TABLE 4.2
MEAN DYSKINETIC SCORES IN 9 PATIENTS WITH 
HISTORY OF ANTIPSYCHOTIC MEDICATION (GROUP B)
Age
No. of 
Patients
Mean Dyskinetic 
Score S.E.
<65 4 5.25 1.65
) 6 5 5 5.20 1.56
All ages 9 5.22 . 1.06
TABLE 4.3
INDIVIDUAL ABNORMAL MOVEMENTS OBSERVED (40 PATIENTS)
MOVEMENT
"With anti­
psychotic 
medication 
(n = 9)
Without anti­
psychotic 
medication 
(n = 31)
All patients 
(n = 40)
Periocular area 1 3 4
Movement of lips 4 10 14
Chewing movements 1 4 5
Bonbon sign 1 0 1
Tongue protrusion 5 7 12
Tremor and/or 
choreoathetoid 
tongue movements
3 12 15
Axial hyperkinesis 0 0 0
Rocking movements 2 0 2
Torsion movements 0 0 0
Movement of fingers 
and wrists 1 6 7
Movements of ankles 
and toes 1 0 1
Stamping movements 0 1 1
Body akathisia 0 1 1
Eight patients were mildly hypertensive and obese, and were controlled by 
diuretics and anti-hypertensives. The average dyskinetic score in this 
group receiving treatment for hypertension was 2.3, which was lower than 
for any of the defined groups. The reason for this was not apparent.
Of the 9 patients who had received antipsychotic preparations during 
the past 7 years, 5 had received thioridazine alone, one haloperidol 
followed by the addition of thioridazine and flupenthixol, and one haloperidol 
followed by thioridazine. In addition, these 9 patients had received 
antidepressants (5 prescriptions), antiparkinsonian drugs (5 prescriptions), 
minor tranquillisers (5 prescriptions) and barbiturates (2 prescriptions).
DISCUSSION
The examination to observe dyskinetic movements was brief, easy to 
conduct, and hearing, visual or intellectual impairment in the patient 
sample proved no major obstacle. The patients appeared to enjoy the 
procedure and co-operation was easy to obtain. The possibility of anxiety, 
provoked by the examination, masking abnormal movements was reduced 
by the fact that both raters were known to the patients.
Whilst it is generally accepted that tardive dyskinesia occurs as a result of 
long-term antipsychotic medication, there is evidence to suggest that the 
disorder can occur in persons who have never received these compounds 
(Brandon, McClelland & Protheroe, 1971; Crane, 1973; Crane & Smeets, 
1974). This aspect is dealt with in greater detail in Chapter 2 (para 2.7.6).
Whilst the results in this pilot study point to a high prevalence rate of 
abnormal movements in a selected group of elderly, long-stay, female, 
mentally handicapped patients, they are similar to those obtained by Jus, 
Pineau, Lachance, Pelchat, Jus, Pires & Villeneuve, (1976) who, with careful 
screening, eliminated abnormal movements found in other neurological 
disorders, and showed a prevalence rate of 60 per cent in the 50 to 69 years 
age group, and in those of 70 years and above the rate had risen to 75.6 per 
cent. The prevalence rate in this study was 84 per cent in those up to 69 
years of age, and 86.7 per cent in the 70 years and above age group. These 
findings may possibly be related to the sex of the patients, their increasing 
age and the frequency of brain damage. The failure to establish a 
significant link with antipsychotic medication may be due to the overall 
high frequency of abnormal movements.
Of the 9 patients who had received antipsychotic medication, the 2 showing 
the highest dyskinetic movements were receiving haloperidol, whereas 
those receiving thioridazine produced lower scores. In fact in the treated 
group the 2 patients showing the least dyskinetic movements (score of 2 
and 1) were from patients who had received thioridazine for 7 years (total 
intake 255gm) and 17 years (total intake 679gm) respectively. The 
possibility of thioridazine causing less dyskinetic movements is considered 
further in Chapter 5 (para 5.3.2).
SUMMARY
Forty-one female patients in a hospital for the mentally handicapped were 
examined for abnormal movements characteristic of tardive dyskinesia. 
Whilst mild abnormal movements of the tongue, lips, jaws and hands were 
found in 37.5 per cent and more obvious movements in a further 47.5 per 
cent, there was no significant relationship to intake of antipsychotic 
medication during the last 7 years nor to chronological age. The trend, 
however, was for increased prevalence of movements with a history of 
antipsychotic medication and increasing age. The examination protocol 
was found to be easy to administer and patient co-operation quickly 
obtained despite limited cognitive abilities.
CHAPTER 5
PREVALENCE OF TARDIVE DYSKINESIA IN THE ELDERLY
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INTRODUCTION
By definition the term "tardive dyskinesia" implies an iatrogenic disease 
caused by chronic antipsychotic drug therapy (Klawans, Goetz & Perlik, 
1980). A number of epidemiological studies have been conducted to 
establish the frequency of the disorder and the significance of such factors 
as age, sex, and type of underlying psychiatric disease (Villeneuve, Lavallee 
& Lemieux, 1969; Brandon, McClelland & Protheroe, 1971; Crane 1973). 
Other factors additional to age and sex have been studied including length 
of hospitalisation, history of antipsychotic drug-induced extrapyramidal 
syndromes and type of schizophrenia (Jus, Pineau, Lachance, Pelchat, Jus, 
Pires & Villeneuve, 1976). No established patterns have emerged to clarify 
these epidemiological issues, and it appears that these are not significant 
factors in the development of tardive dyskinesia.
The occurrence of involuntary movements similar to tardive dyskinesia in 
elderly subjects who have never been exposed to antipsychotic medication 
has also been reported (Marsden & Parkes, 1973; Crane &  Smeets, 1974; 
Bourgeois, Bouilh, Tignol & Yesavage, 1980; Blowers & Bicknell, 1980.)
In discussing the aetiology of tardive dyskinesia and advocating an open- 
minded attitude, Tarsy & Baldessarini (1976) suggested that more work 
should be done to study the possible relationships of drug effects and the 
tardive dyskinesia syndrome. They also suggested that more 
epidemiological studies in countries where drugs are still not generally 
available would be helpful.
The availability of a large population of elderly subjects in the care of a 
local authority presented an opportunity.of conducting a detailed study to 
determine the presence of abnormal involuntary movements with a view to 
establishing prevalence rates of antipsychotic drug-induced tardive 
dyskinesia and spontaneous dyskinesia. As drugs other than antipsychotic 
agents have been reported to have caused tar dive dyskinesia, additional 
objectives would be to examine individual drug histories with a view to 
ascertaining which drugs and what other physical factors may contribute to 
the presence of dyskinetic movements.
MATERIALS AND METHODS
5.2.1 Clinical Population
Five hundred elderly subjects, 138 males and 362 females, who 
were resident or receiving short term or day care in 12 local 
authority residential homes for the elderly were included in the 
study. Ages ranged from 59 - 102 years with a mean age of 82.6 
years (male mean age 81.4 years, female mean age 83.1 years). 
Five subjects had ,been admitted as short-stay holiday residents, 
14 subjects were attending the homes on a continuing day-care 
basis, and the remaining 481 subjects had been resident in this type 
of accommodation for a period of between 2 months and 17 years 
(mean 3.3 years). Additionally, 49 of these subjects had spent 
periods of their lives in other institutional care in psychiatric or 
mental handicap hospitals for periods of between 3 months and 38 
years (mean 10.4 years). The total period of institutional care for 
the entire sample ranged from 2 months to 39 years (mean 4.3 
years). During their period of care 122 (24.4 per cent) of the total
population in the study had been treated with antipsychotic drugs. 
There were no significant age differences between the group who 
had received antipsychotic drugs and the group who had never 
been exposed to this class of drugs (Table 5.1)
5.2.2 Ethical Consent
Approval for the study was first sought through the Social Services 
Department of Surrey County Council. At a joint meeting with the 
Area Specialist in Community Medicine and the Deputy Director of 
Social Services the project was outlined and formal approval 
obtained. Letters and a study protocol were then sent to the 
General Practitioners who were responsible for the provision of 
medical services for residents of Homes for the Elderly in Surrey, 
informing them of approval given to the project. The General 
Practitioners' consent was sought and obtained in writing in order 
that medical records and drug histories could be searched 
subsequent to the examination for abnormal movements (Appendix 
4).
A protocol of the proposed study was submitted to the Secretary of 
the Surrey Local Medical Committee and subsequent questions 
answered. In view of the widespread involvement of General 
Practitioners in the care of the elderly, 500 copies of the letter 
(Appendix 4) were sent to all GPs who were practising within the 
area covered by the Surrey Family Practitioner Committee. 
Letters were then sent to Officers in Charge of the Homes for the 
Elderly within the County of Surrey giving them details of the 
study and informing them of a planned presentation on how the 
work would be carried out in their respective Homes (Appendix 5).
TABLE 5.1
AGE AND SEX DISTRIBUTION OF THE 500 SUBJECTS
Male Female Male & Female
Total Population 138 362 500
Mean Age (yrs) 81.4 83.1 82.6
Antipsychotic 
Treated Group 30 92 122
Mean Age (yrs) 81.0 82.8 82.4
NonAntipsychotic
Group 108 270 378
Mean Age (yrs) 82.9 83.2 82.6
Individual residents were invited by care staff to participate in the 
examination procedure, without creating an anxiety situation as far 
as that was possible. Where any patient expressed reluctance they 
were not included in the study. In all 12 establishments involved in 
the project a total of 8 residents declined to take part.
.5.2.3 Assessment of Abnormal Movements
The residents were examined individually under standard conditions 
described in Appendix 1. Rater 1 (AJB) took the residents through 
the procedure with appropriate sympathetic encouragement. The 
composite picture of the animals was a source of immediate 
interest and the resident was reassured by being told that this was 
a very simple memory test. The finger to thumb exercise was 
introduced by indicating that it was a simple check for arthritis, 
and whilst this often brought forth a history of arthritic 
development, the widespread acceptance of the manoeuvre was 
justified.
Rater 2 (CMB) recorded details of abnormal movements on the 
abnormal involuntary movements rating scale (Appendix 2). 
Dyskinetic movements were considered in two categories for 
determination of prevalence rates. Global AIMS scores of 1 and 
above were all categorised as having abnormal involuntary 
movements, and those with an AIMS global score of 3 and above 
were considered to have tardive dyskinesia, or where there was no 
recorded history of antipsychotic medication, to have dyskinesia 
indistinguishable from tardive dyskinesia. The AIMS score of 3 is 
considered indicative of true tardive dyskinesia (Smith, Kucharski, 
Oswald & Waterman, 1979b; Borison, 1981).
5.3 RESULTS
5.3.1 Association of Tardive Dyskinesia with Antipsychotic Drugs
Abnormal involuntary movements (AIMS score of 1 or more) were 
observed in 180 (36 per cent) of the 500 subjects who were 
examined. Orofacial involvement was present in 140 of the 180 
subjects with abnormal movements.
In the 122 subject (24.4 per cent) who had received antipsychotic 
drugs for a minimum period of 3 months, abnormal involuntary 
movements were present in 58 (47 per cent), and in the 378 
subjects (75.6 per cent) who had no recorded history of anti­
psychotic medication, abnormal movements were present in 122 (32 
per cent). The Chi Square test (Kirkwood, 1981) indicated that the 
difference in the prevalence of abnormal movements between 
subjects who had received antipsychotics and those who had never 
been exposed to these compounds was statistically significant 
(p -40.001), thus confirming the association of dyskinetic 
movements with antipsychotic medication.
The prevalence figures using an AIMS score of 3 and above were 
lower, and a total of 77 (15 per cent) of the 500 residents showed 
dyskinetic movements. In the 122 residents who had a history of 
antipsychotic medication, dyskinesias were present in 27 (22 per 
cent) as compared with 50 (13 per cent) in the 378 residents who 
had never received antipsychotics. This difference between the 2 
groups was statistically significant (p 4.0.001) (Table 5.2).
TABLE 5.2
ASSOCIATION OF TARDIVE DYSKINESIA WITH 
ANTIPSYCHOTIC MEDICATION
AIMS SCORE
1 or more 3 or more
Total Population 500 180 (36%) 77 (15%)
Antipsychotic 
Treated Group 122 58 (47%) 27 (22%)
Non Antipsychotic 
Group 378 122 (32%) 50 (13%)
Twelve residents in the antipsychotic-treated group had AIMS 
scores of between 5 and 9 inclusive, and a further 3 residents had 
scores of 11, 15 and 15 respectively. In the non-antipsychotic- 
treated group, 7 residents had scores of between 5 and 9 inclusive, 
and a further 3 residents had scores of 11, 11 and 18 respectively. 
The resident with a score of 18, which was the highest score in the 
total study, was an 85 year old lady who had been admitted from 
the community 6 months previously. She had been living on her 
own and was deemed to be in need of care following a period of 
self neglect. She had never been exposed to antipsychotic 
medication during her lifetime.
5.3.2 Association of Tardive Dyskinesia with the use of Multiple 
Antipsychotics
The prevalence of tardive dyskinesia increased in residents who had 
a history of medication with more than one antipsychotic drug. In 
the 91 patients who had received one antipsychotic drug, 13 (14 per 
cent) had tardive dyskinesia. Where 2 antipsychotic drugs had 
been administered, 10 of 20 residents (50 per cent) had dyskinesia, 
and in the 11 residents who had received 3 antipsychotics, 5 (45 per 
cent) had dyskinesia (Table 5.3). The difference between the 
prevalence rate of dyskinesia in the 13 residents (14 per cent) who 
had received only 1 antipsychotic drug and the 15 (49 per cent) who 
had received 2 or more antipsychotics was statistically significant 
(p4 0.001). Bcul & Smith (1978), in a large scale study, showed that 
in a group of 576 patients those on 2 or more antipsychotic drugs 
had higher dyskinetic scores than those on 1 antipsychotic drug.
TABLE 5.3
ASSOCIATION OF TARDIVE DYSKINESIA WITH THE USE OF 
MULTIPLE ANTIPSYCHOTICS
Medication
No. of 
Patients
Patients with 
Tardive Dyskinesia
No Antipsychotics 378 50 (13%)
One Antipsychotic 91 13 (14%)
Two Antipsychotics 20 10 (50%)
Three Antipsychotics 11 5 (45%)
5.3.3 Association of Tardive Dyskinesia with Specific Anti­
psychotics
In examining the effect of individual antipsychotics, data are 
presented where 4 or more residents were on a particular compound. 
Table 5.4 shows that of the 4 most popular phenothiazines 
prescribed in these nursing homes, 3 of the 17 residents (18 per 
cent) who received promazine had tardive dyskinesia, 2 (11 per 
cent) of the 18 who had received prochlorperazine were affected, 3 
(11 per cent) of the 27 who received chlorpromazine were 
affected, but none of the 13 who received thioridazine had tardive 
dyskinesia. Table 5.5 indicates the range of dosage, the treatment 
period and the range of total intake of each of these 4 compounds, 
and it is of interest to note that thioridazine, the compound used 
for the longest period and with the highest daily range and total 
intake, is the drug which is free from the complications of tardive 
dyskinesia.
In the multiple use of antipsychotics, the highest prevalence of 
tardive dyskinesia occurred where haloperidol was used, and of the 
9 residents receiving haloperidol in their drug regimen, 5 (56 per 
cent) had tardive dyskinesia. In the 6 residents who received 
haloperidol in the multiple drug regimen plus an antiparkinsonian 
drug, 4 (67 per cent) had tardive dyskinesia.
5.3.4 Association of Tardive Dyskinesia with Antiparkinsonian Drugs
Analysis of data from drug histories of the 500 residents in the 
study showed that 48 (9.6 per cent) had received one or more 
antiparkinsonian drug during the previous 7 years. In this group of 
48, dyskinesias were observed in 17 (35 per cent) whereas in the
TABLE 5.4
ASSOCIATION OF TARDIVE DYSKINESIA WITH SPECIFIC 
ANTIPSYCHOTIC DRUGS
DRUG
No of 
Patients
Patients with 
Tardive Dyskinesia Percentage
Promazine 17 3 18
Prochlorperazine 18 2 11
Chi or promazine 27 3 11
Thioridazine 13 0 0
TABLE 5.5
DOSAGE AND TREATMENT PERIOD OF 
SPECIFIC ANTIPSYCHOTIC DRUGS
DRUG
No. of 
Patients
Daily
Dosage
Range
Total
Intake
Range
Treatment
Period
Promazine 17 25 - 150 mg 4.5 - 216 gm 6/12 - 10 yrs
Prochlorperazine 18 10 - 50 mg 1.3- 27 gm 3/12 - 9 yrs
Chiorpromazine 27 10 - 300 mg 2.7 - 401 gm 3/12 - 11 yrs
Thioridazine 13 30 - 450 mg 6 - 1751 gm 3/12 - 16 yrs
group of 452 who had never received antiparkinsonian drugs 
dyskinesias were present in 60 (13 per cent) indicating that the use 
of antiparkinsonian drugs was associated with more dyskinesias 
(p <0.001). The prevalence of tardive dyskinesia in those who had 
received antiparkinsonian drugs was higher in the group of 37 
females, where 15 (41 per cent) had AIMS scores of 3 and above, 
compared with that seen in the 11 males where 2 (18 per cent) had 
dyskinesias (p <0.001). However, in the group of 452 residents who 
had not received antiparkinsonian drugs the reverse was observed. 
In females 33 (10 per cent) had dyskinetic movements compared 
with 27 (21 per cent) in males (p < 0.001) (Table 5.6).
In the 32 residents receiving antiparkinsonian drugs in combination 
with antipsychotic drugs, 13 ( 41 per cent) had dyskinesias, whereas 
in the 16 who received antiparkinsonian drugs without anti­
psychotic medication 4 (25 per cent) had dyskinetic movements 
(p< 0.001) (Table 5.6).
It has been shown (see para 5.3.2) that the use of multiple 
antipsychotic agents produced more dyskinesias than the use of any 
single agent. Similarly, the prevalence of tardive dyskinesia 
resulting from the combination of antiparkinsonian drugs with 
antipsychotic drugs also increased with the number of anti­
psychotic drugs taken. This rose from 4 of 16 (25 per cent) where 
one antipsychotic drug was taken to 4 of 5 (80 per cent) who had 
received 3 or more antipsychotic agents.
5.3.5 Association of Tardive Dyskinesia with Benzodiazepine Drugs
One hundred and thirty of the 500 residents (26 per cent) had 
received one or more benzodiazepine during the previous 7 years.
TABLE 5.6
ASSOCIATION OF TARDIVE DYSKINESIA WITH 
ANTIPARKINSONIAN MEDICATION
DRUG POPULATION T D PRESENT
M F M & F M F M & F
Antiparkinsonian 11 37 48 2 (18%) 15 (41%) 17 (35%)
No Antiparkinsonian •126 326 452 27 (21%) 33 (10%) 60 (13%)
Antiparkinsonian
with
Antipsychotic
7 25 32 2 (29%) 11 (44%) 13 (41%)
Antiparkinsonian 
with 
No Antipsychotic
4 12 16 0 4 (33%) 4 (25%)
No Antiparkinsonian 
No Antipsychotic 102 260 362 20 (20%) 26 (10%) 46 (13%)
No Antiparkinsonian 
with Antipsychotic 24 66 90 7 (29%) 7 (11%) 14 (16%)
tardive dyskinesia was present in 24 (18 per cent) in those who had 
taken benzodiazepines compared with 53 (14 per cent) of the 370 
who had never received benzodiazepine therapy (Table 5.7). The 
fact that this difference did not reach a level of statistical 
significance is interesting in view of reports on the use of 
benzodiazepines to control tardive dyskinesia (O’Flanagan 1973; 
O’Flanagan 1975; Jeste & Wyatt, 1979).
The combination of benzodiazepines with antipsychotics was 
associated with the presence of tar dive dyskinesia in 12 of the 34 
residents (35 per cent) who had been treated with both drugs. In the 
96 residents where benzodiazepines had been administered without 
antipsychotic drugs, tardive dyskinesia was present in 12 (13 per 
cent), whereas in the 88 who were receiving antipsychotics without 
concomitant benzodiazepines 15 (17 per cent) showed dyskinesia 
(Table 5.7).
In the 280 residents who did not receive benzodiazepines or 
antipsychotics, 38 (13 per cent) had dyskinesia which is significantly 
less (0.25> p> 0.01) than in the 34 who received both compounds, 
where dyskinesia was present in 12 (35 per cent) (Table 5.7).
5.3.6 Association of Tardive Dyskinesia with Antidepressant Drugs
Seventy four residents in the total population studied received 
anti depress ant compounds and in this group tardive dyskinesia was 
present in 12 (16 per cent). In the group of 426 who did not receive 
anti depressants, 65 (15 per cent) had dyskinesia, indicating that 
these compounds did not significantly affect the presence of 
tardive dyskinesia (Table 5.8).
TABLE 5.7
ASSOCIATION OF TARDIVE DYSKINESIA WITH 
BENZODIAZEPINES
DRUG POPULATION T D PRESENT
M F M & F M F M & F
Benzodiazepine 29 101 130 6 (21%) 18 (18%) 24 (18%)
No Benzodiazepine 108 262 370 23 (21%) 30 (11%). 53 (14%)
Benzodiazepine
with
Antipsychotic
7 27 34 3 (43%) 9 (33%) 12 (35%)
Benzodiazepine 
with 
No Antipsychotic
22 74 96 3 (14%) 9 (12%) 12 (13%)
No Benzodiazepine 
No Antipsychotic 84 196 280 17 (20%) 21 (11%) 38 (13%)
No Benzodiazepine 
with Antipsychotic 24 64 88 6 (25%) 9 (14%) 15 (17%)
TABLE 5.8
ASSOCIATION OF TARDIVE DYSKINESIA WITH 
ANTIDEPRESSANTS
DRUG POPULATION T D PRESENT
M F M & F M F M & F
Antidepressant 16 58 74 3 (19%) 9 (16%) 12 (16%)
No Antidepressant 121 305 426 26 (21%) 39 (13%) 65 (15%)
Anti depress ant 
with 
Antipsychotic
6 25 31 3 (50%) 6 (24%) 9 (29%)
Anti depress ant 
with
No Antipsychotic
10 33 43 0 3 (9%) 3 (20%)
No Antidepressant 
No Antipsychotic 96 239 335 20 (21%) 27 (11%) 47 (14%)
No Anti depress ant 
with Antipsychotic 25 66 91 6 (24%) 12 (18%) 18 (20%)
The combination of anti depress ants with antipsychotics in 31 
residents was associated with dyskinesia in 9 (29 per cent), whereas 
in the group of 335 residents where neither drug had been prescribed 
dyskinesia was present in 47 (14 per cent) (Table 5.8). This was not 
statistically significant.
In the 31 residents who received antidepressants without anti­
psychotic drugs, 3 (20 per cent) showed dyskinesia, compared with 
18 (20 per cent) of the 91 who received antipsychotic drugs without 
anti depressants (Table 5.8).
3.7 Association of Tardive Dyskinesia with Hypnotic/Sedative Drugs
One hundred and twenty nine residents in the total population in 
the study were receiving hypnotics or sedatives for night-time 
sedation, and of these 27 (21 per cent) had dyskinesia. In the 371 
residents who were not treated with hypnotics or sedatives 
dyskinesia was present in 50 (13 per cent) (Table 5.9). This did not 
reach a level of statistical significance (0.1> p> 0.05).
3.8 Association of Tardive Dyskinesia with Age and Sex
The subjects were grouped by decades and 9 (32 per cent) of the 28 
residents in the 60 to 70 years decade had dyskinesia. In the 70 to 
80 decade, 25 (19 per cent) had dyskinesia and in the 80 to 90 
decade, 23 (9 per cent) were affected (Table 5.10). No consistent 
trend of increasing dyskinesias with age was observed in either 
males or females, or in the total population over the age of 70, but 
the prevalence rate of dyskinesias in the 30 subjects under the age 
of 70 years was 30 per cent (9 subjects) and in the 470 over 70
TABLE 5.9
ASSOCIATION OF TARDIVE DYSKINESIA WITH 
HYPNOTICS/SEDATIVES
DRUG POPULATION T D PRESENT
M F M & F M F M & F
Hypnotic/Sedative 
No Hypnotic/Sedative
29 100 129 
108 263 371
7 (24%) 20 (20%) 27 (21%) 
22 (20%) 28 (11%) 50 (13%)
TABLE 5.10
ASSOCIATION OF TARDIVE DYSKINESIA WITH AGE AND SEX
Population >50 760 770 >80 790 >100
M & F 500 2 28 130 242 92 6
AIMS 
3 or over 77 0 9 25 23 18 2
Percentage 0 32 19 9 20 33
Males 138 1 9 42 63 20 2
AIMS 
3 or over 29 0 3 11 7 7 2
Percentage 0 33 26 11 35 100
Females 362 1 19 88 179 72 4
AIMS 
3 or over 48 0 6 14 16 11 0
Percentage 0 31 16 9 15 0
years the prevalence rate was 14 per cent (67 subjects). However, 
this was not statistically significant (0.1> p> 0.05).
Twenty nine of the 138 males (21 per cent) in the study had 
dyskinesias (AIMS score of 3 and above) compared with 48 (13 per 
cent) of the 362 females. The difference between these two groups 
was not statistically different (0.1> p> 0.05) (Table 5.10).
There was no significant difference in the frequency of dyskinesias 
in the 31 males who had received antipsychotic drugs, where 9 (29 
per cent) had AIMS scores of 3 and above compared with 20 of the 
107 (19 per cent) who had never been exposed to antipsychotic 
medication. However, in the 91 females who had received anti­
psychotics, 18 (20 per cent) had dyskinesias, which was statistically 
significant (p< 0.001), compared with the presence of dyskinesias in 
30 (11 per cent) of the 271 who had never received antipsychotic 
drugs (Table 5.11).
DISCUSSION
Whilst Evans (1965) observed that the causal relationship between treat­
ment with antipsychotic drugs and oral dyskinesia is presumptive, but is 
likelier than other possibilities, epidemiologic studies strongly support an 
association between the use of antipsychotic drugs and the development n f  
persistent, as well as relatively transient, forms of tardive dyskinesia 
(Baldessarini, 1974).
One criticism of the concept of tardive dyskinesia is that dyskinesia 
frequently occurs spontaneously among chronic psychiatric patients, 
especially the elderly (Jeste & Wyatt, 1981).
TABLE 5.11
SEX DIFFERENCES IN THE PREVALENCE OF DYSKINESIAS
Sex Number of 
Subjects
AIMS Score 
3 or more
Antipsychotic 
Treated Group
M
F
M & F
31
91
122
9 (29%) 
18 (20%) 
27 (22%)
Non Antipsychotic 
Group
M
F
M & F
107
271
378
20 (19%) 
30 (11%) 
50 (13%)
Marsden & Parkes (1973) estimated that some 2 per cent of the inmates of 
chronic geriatric homes exhibit some spontaneous orofacial dyskinesia and 
the same prevalence rate was noted by Greenblatt, Dominick, Stotsky & 
DiMascio (1968) who examined a group of 270 patients in 2 large nursing 
homes. Pakkenberg & Fog (1974) suggested that spontaneous dyskinesia 
was treatable with drugs such as tetrabenazine and pimozide that have 
been used in the treatment of tardive dyskinesia. In a review, Jeste & 
Wyatt (1981) found 12 major studies comparing the prevalence of
dyskinesia among antipsychotic-treated and non-antipsychotic-treated 
patients. Ten of these 12 studies found a significantly higher prevalence 
of dyskinesia among antipsychotic-treated patients. Taking all 12 studies 
together, the overall weighted mean prevalence of dyskinesia for
chronically institutionalised individuals was 3.25 greater in the anti­
psychotic group than in the non-antipsychotic-treated group.
In the present study, abnormal involuntary movements (AIMS score 1 or 
greater) were present in 58 of 122 residents (47 per cent) who had a history 
of antipsychotic medication, and in the non-antipsychotic-treated group 
122 of 378 residents (32 per cent) had abnormal movements. The
difference between the 2 groups was statistically significant (p<0.001). 
Using an AIMS score of 3 or greater as being indicative of true tardive 
dyskinesia (Borison, 1981), the prevalence figures were 22 per cent in the 
antipsychotic treated group and 13 per cent in the non-anti­
psychotic-treated group. The difference was again statistically significant 
(p<D.001). From these results it seems clear that there is a level of 
idiopathic or spontaneous dyskinesia and that the administration of anti­
psychotic drugs increases the prevalence of dyskinesias.
The wide variation in prevalence rates of tardive dyskinesia is referred to 
earlier (see 2.7.3). Smith, Kucharski, Oswald & Waterman (1979a) showed 
prevalence rates ranging from 62.1 per cent using a criterion level of an 
AIMS score of 2, to 6.8 per cent using an AIMS score of 4, in a group of 377 
psychiatric inpatients. They suggested an AIMS score of 3 as being an 
acceptable criterion. In this study the prevalence rate of tardive
dyskinesia ranges from 47 per cent with an AIMS score of 1, down to 22 
per cent with an AIMS score of 3, in the group receiving antipsychotic 
medication.
In other studies age has been reported a significant factor. Marsden & 
Parkes (1973) were of the opinion that orofacial dyskinesia rarely appeared 
below the age of 40. Kane, Wegner, Stenzler & Ramsey (1980) fe lt that 
their relatively low prevalence rate of tardive dyskinesia of 4.6 per cent 
might in a large part have been due to the relatively young age of their 
population. Crane (1974), in a survey of 699 chronic hospitalised patients, 
showed that age is a major contributing factor, in that the prevalence of 
tardive dyskinesia increased sharply after 35 years of age.
The present study shows that after age 70 there were no significant 
differences found in the prevalence of dyskinesias among the various age 
groups defined by decades. However, prevalence was higher in the under 
70 years age group as compared with those over 70, although this did not 
quite reach a level of statistical significance.
The Task Force (1980) referred to the ageing brain having an increased 
likelihood of antipsychotic-related tardive dyskinesias, especially in the 
oral region. Whilst Ezrin-Waters, Seeman & Seeman (1981) reported that 
tardive dyskinesia increased directly with age, their study population of 94 
ranged in age from 19 to 65, and only 3 patients were over 60 years of age.
Sex differences are frequently referred to in published reports and although 
Crane (1974) showed that sex did not appear to play a significant role in 
the prevalence of dyskinesia, Smith, Oswald, Kucharski & Waterman (1978) 
found a significant linear trend with age for their female sample and a 
significant quadratic trend for the male sample. Smith & Dunn (1979) were 
of the opinion that female/male prevalence ratios are difficult to interpret 
without consideration of the age and sex distribution of the sample. Whilst 
Smith, Kucharski, Oswald &  Waterman (1979a) felt that the often quoted 
2:1 female/male prevalence rate is true of only the 2 oldest age groups, 
Perenyi & Arato*(1980) found tardive dyskinesia in a significantly higher 
number of men than women. Ezrin-Waters, Seeman &  Seeman (1981) found 
no sex differences in the overall prevalence rate.
In the current study, whilst there was no significant difference in the 
frequency of dyskinesias in males receiving antipsychotics and those who 
were not, the position with females was significantly different, with 
those receiving antipsychotic drugs having almost twice the frequency of 
dyskinesias than their non-antipsychotic treated counterparts.
The chronic use of anticholinergic (antiparkinsonian) drugs is to be avoided 
(Klawans, Goetz & Perlik, 1980; Task Force, 1980). Since anticholinergic 
agents clearly exacerbate already present tardive dyskinesia, it is possible 
that with chronic administration these drugs may alter the striatal 
neurochemical balance and potentiate the development of abnormal 
movements de novo (Klawans, 1973). Chouinard, De Montigny & Annable 
(1979) also showed that the central anticholinergic agent procyclidine 
exacerbated tardive dyskinesia, and they suggested that tardive dyskinesia 
might be uncovered by short-term administration of an anti-parkinsonian 
drug, and this might aid early detection and help to prevent the subsequent
development of incapacitating forms of the disorder. Bell & Smith (1978) 
reported that the administration of concomitant antiparkinsonian 
medication together with antipsychotics was only weakly related (p<0.1) 
to patients' dyskinesia scores, and patients with higher than standard dose of 
antiparkinsonian medication did not have significantly higher dyskinesia 
scores.
In this study the total use of antiparkinsonian drugs in the population was 
associated with more dyskinesias (35 per cent) than residents not receiving 
these drugs (13 per cent) (p<0.001). Residents receiving antiparkinsonian 
drugs in combination with antipsychotic drugs had a significantly higher 
rate of dyskinesias (41 per cent) than patients receiving antiparkinsonian 
drugs alone (25 per cent) (p <0.001). The 2 residents with the most severe 
dyskinesia (AIMS scores of 15) in the antipsychotic-treated group had been 
receiving orphenadrine and amantadine respectively. The use of anti­
parkinsonian drugs and "high potency" antipsychotic agents dramatically 
increased the frequency of dyskinesias.
Whilst benzodiazepines have been used to treat tardive dyskinesia 
(O'Flanagan, 1973 & 1975), and may ameliorate the condition a little (Cole 
& Gardos, 1980), this study has shown that tardive dyskinesia appears more 
likely to occur in subjects receiving a combination of benzodiazepines and 
antipsychotics than those on either of these 2 drugs administered on their 
own. Rosenbaum & De La Fuente (1979) did report an association between 
the benzodiazepines and tardive dyskinesia.
Anti depressant drugs have only rarely been reported in connection with 
tardive dyskinesia (see 2.7.5) and where they had been used in the present 
study they did not significantly affect the presence of tardive dyskinesia
The use of night-time hypnotics and sedatives in combination with 
antipsychotics produced a trend towards more dyskinesia.
SUMMARY
In a study of 500 residents in residential homes for the elderly, abnormal 
involuntary movements, indistinguishable from tardive dyskinesia, were 
found in 15 per cent. In those subjects who had received antipsychotic 
medication 22 per cent had dyskinesia, and in those who had never received 
antipsychotic medication 13 per cent had dyskinetic movements. The 
difference in prevalence of movements was statistically significant.
A trend which did not reach a level of statistically significant difference 
was observed in more dyskinesias ocurring in residents under the age of 70 
than in those over 70. No significant differences were found in dyskinesias 
among the various age groups defined by decades over the age of 70.
There was no significant difference in the frequency of dyskinesias 
between males receiving antipsychotic drugs and those who had not. 
However, women receiving antipsychotic drugs had almost twice the 
frequency of dyskinesias in comparison with those who had never been 
exposed to antipsychotics.
Dyskinesia was more prevalent where residents received more than one 
antipsychotic drug, and the use of antiparkinsonian medication in 
conjunction with antipsychotics also increased the frequencies of 
dyskinesias.
Benzodiazepines combined with antipsychotic drugs also increased the rate 
of dyskinesias to a level of statistical significance. The use of hypnotics 
and sedatives in combination with antipsychotics increased the frequency 
of dyskinesias but this did not reach significance levels. Anti depressants did 
not significantly affect the presence of tardive dyskinesia.
Analysis of the data relating to the use of individual antipsychotic drugs 
for a minimum period of 3 months suggested that those who had received 
thioridazine were least likely to develop tardive dyskinesia.
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INTRODUCTION
In reviewing all of the studies on antipsychotic drug-induced tardive 
dyskinesia published in the English literature up until August 1978, Jeste & 
Wyatt (1979) observed that there was as yet no single satisfactory method 
of treating the disorder, and that until recently most of the treatment 
studies were carried out on a small number of patients and were un­
controlled. This view has been subsequently supported (Committee on 
Safety of Medicines, 1979; Lancet, 1979; Mackay, Sheppard, Saha, Motley, 
Johnson & Marsden, 1980; British Medical Journal, 1979 & 1981).
Gardos &  Cole (1980) stated that from a public health view, the treatment 
of tardive dyskinesia was unsatisfactory. Safe, effective and specific 
treatment methods were lacking and therefore the search for newer and 
better therapeutic agents needed to be pursued relentlessly. In a treat­
ment review, Paulson (1981) did not confirm one ideal treatment among the 
dozens of therapeutic approaches that have been suggested. The many 
suggested treatment methods have been reviewed earlier (Chapter 2, para 
2.2.7).
In 1977 Smith, Tamminga, Haraszti, Pandey & Davis investigated the 
effects of dopamine agonists on tardive dyskinesia. They showed that 
apomorphine actually reduced dyskinetic movements - a finding contrary to 
predictions based on animal models. Subsequently it was suggested that 
apomorphine may have stimulated the presynaptic dopamine receptor to 
produce this improvement (Barnes, Kidger & Taylor, 1978).
The ergot derivative co-dergocrine appears to play a role in cerebral 
synaptic transmission and has been shown in vitro to displace dopamine and 
haloperidol from their specific binding sites in the caudate nucleus 
(Goldstein, Lew, Hata & Lieberman, 1978) and in vivo to produce an 
acceleration of noradrenaline turnover and a slowing of dopamine and 
serotonin brain turnover, suggesting noradrenaline antagonism, dopamine 
agonism and serotonin agonism (Loew, Vigouret & Jaton, 1979).
Co-dergocrine contains equal proportions of the mesylates of dihydro- 
ergocornine, dihydroergocristine and dihydroergokryptine. It has been in 
clinical use since 1951 and its principal indication has been in the 
treatment of the wide range of symptoms associated with mild to moderate 
impairment of mental function in the elderly (Ditch, Kelly & Resnick, 
1971; Rao & Norris, 1972; Rehman, 1973; McConnachie, 1973 & Nelson, 
1975).
In an open study in 10 patients suffering from schizophrenia of long 
standing and, additionally, cerebral arteriosclerosis and tardive dyskinesia, 
Gomez, (1977) administered co-dergocrine in dosages ranging from 2 to 3 
mg a day. Dyskinetic movements in 7 patients disappeared after 2 to 4 
weeks, and a follow-up of these patients for up to 8 months showed them to 
be free from tardive dyskinesia. The study is limited by the fact that all 7 
patients had their antipsychotic therapy discontinued or altered, and it 
would be impossible to determine how much this affected the improvement 
in dyskinetic symptoms.
A pilot study was subsequently undertaken by Hajioff (1978) in which 6 
patients who had been on long-term phenothiazine medication were given
4.5 mg co-dergocrine daily for 6 weeks, and there was no alteration to
their phenothiazine therapy. All 6 patients responded within 2 to 4 weeks, 
and by 6 weeks one had lost all symptoms of tardive dyskinesia and the 
others had mild symptoms only. Work is continuing with a placebo phase, 
and after 6 months dyskinetic movements remain abated (Hajioff, 1979). 
The author suggested that co-dergocrine may work either by correcting 
disturbed dopamine activity in the striatum or by improving the meta­
bolism of cells in the area by increased oxidation.
In a group of 9 patients with tardive dyskinesia treated with a placebo for 
1 week, followed by active co-dergocrine for 7 weeks and then by placebo 
for a final 2 weeks, all 9 patients showed highly significant improvement 
during the period of active medication. Doses were increased from 4.5 mg 
to 7.5 mg daily during the study, and there were no variations made in 
existing antipsychotic medication (Arranz Munecas, Ganoza Garcia & 
Forcadell Puyo, 1979).
The promising results obtained in these open, uncontrolled studies indicated 
the need for an evaluation of co-dergocrine under double-blind conditions.
MATERIALS AND METHODS
6.2.1 Clinical Population
Forty-three chronic psychiatric in-patients (18 male and 25 female) 
from the Herrison Hospital, Dorchester, were included in the study. 
The following criteria for admission were established:
1) The presence of persistent involuntary movements pre­
dominately in the orofacial region.
2) The movements had been present for at least 1 year and were 
considered to have resulted from antipsychotic drug 
administration.
3) Antipsychotic, drug treatment had been for a period of at 
least 18 months.
The following exclusion criteria were applied:
1. Patients with marked natural physical disabilities which 
would prevent accurate assessment of tardive dyskinetic 
signs.
2. Patients taking vasodilators, central nervous system 
stimulants, antihypertensive drugs like reserpine or any other 
drug with reserpine as a component.
3. Patients with a past history or current symptoms of brady­
cardia. (Pulse rate ^60).
Of the forty-three patients selected, case note diagnoses were 
schizophrenia (30), dementia (7), depressive psychosis (3), oligo­
phrenia (2), bipolar affective psychosis (1). Median age was 70.44 
years (range 40 to 92 ; S.D. 10.85; S.E. 1.65) and the median period 
of psychiatric hospitalisation was 25.8 years (range 1.5 to 55 
years). All patients had been treated with a variety of anti­
psychotic drugs (mean 3,8 compounds: range 1 to 9) during their 
psychiatric care. Background antipsychotic and antiparkinsonian 
medication was held constant throughout the study period.
6.2.2 Ethical Consent
Approval was given by the Ethical Committee of Herrison Hospital, 
and informed consent was obtained from patients participating in 
the study and approved by individual patients' psychiatric 
consultant.
6.2.3 Study Design
A double-blind placebo controlled, parallel group procedure was 
used. The randomisation preparation of drug supplies was carried 
out in the Research and Development Laboratories of Sandoz 
Products Limited, at Horsforth, and the randomisation code was 
held at the laboratories. A sealed envelope containing a copy of 
the randomisation code was sent to the Chief Pharmacist at 
Herrison Hospital with the instructions "To be opened only in 
emergency". The two raters, ward staff, pharmacy staff and 
patients were blind to the treatment procedure. Patients were 
randomly allocated to two groups according to their trial number, 
and received either co-dergocrine 4.5 mg tablets once daily for 6 
weeks or an identical placebo tablet for the same period.
6.2.4 Rating Procedures
Patients were examined, individually under standard conditions, 
using the examination technique described in Chapter 3 (para 
3.4.2), at approximately the same time of day on each occasion, by 
two raters (SCR and AJB). The AIMS examination (Appendix 1) 
was employed and abnormal movements were assessed using the 
abbreviated Rockland Research Institute Rating Scale (Appendix 
2). Rating procedures were carried out prior to entry into the
study, at the conclusion of the 6 week drug/placebo treatment 
period and again at 6 weeks after the drug/placebo treatment 
period to observe any possible carry over effect.
6.2.5 Drop Outs
Patient number 12 was omitted from the study as she was missing 
from the hospital on the day on which her second rating procedure 
was due to be carried out. Patient numbers 40 and 41 both died 
during the study period. Their ages were 92 and 81 respectively 
and death in both cases was considered due to pneumonia secondary 
to senile dementia, and in no way to drugs administered during the 
study.
6.2.6 Statistical Analysis
Due to limitations on availability of patients and the subsequent 
random allocation of patients to the two groups it was necessary to 
ascertain the importance of sex ratio, mean age and pre-treatment 
scores between the 2 groups. This was obtained by using 
'Generalised Linear Models' (Nelder & Wedderburn, 1972), to carry 
out the analysis on score decreases over the study period.
RESULTS
Decrease in the scores of dyskinetic movements were obtained after the 6 
week medication period in both the group receiving active medication and 
the placebo group. The improvement in the active treatment group was 
reflected in a mean reduction of 3.79 from the pre-treatment mean score
of 10.1 ( -  1.1). In the placebo group the mean reduction was 2.48 from a 
pre-treatment mean score of 8.7 ( - 0.7). At the end of the further 6 week 
period following the drug/placebo treatment phase, a small additional 
improvement in mean scores was seen in the co-dergocrine group of 0.58 
and in the placebo group of 0.66.
The comparability of the groups is set out in Table 6.1 and the comparison 
of treatments is shown in Table 6.2. Both results indicated there were no 
sex differences present in the data. However the use of the pre-drug score 
as a covariate indicates that it has a significant effect in both cases; thus, 
the higher the pre-drug score, the greater the improvement in scores 
between:
1) Pre-drug and after week 6.
2) Pre-drug and after week 12.
A significant effect was also noted when age was used as a second 
covariate (p<0.01 for pre-drug and after week 6, and p<0.05 for pre-drug 
and after week 12), indicating that the improvement (i.e. reduction) in 
scores is less as age increases. The reduction in scores in the active group 
was higher than the placebo group for both periods, but this did not reach a 
level of statistical significance.
DISCUSSION
This study has shown that under double-blind conditions improvement in 
tardive dyskinesia did not reach a level of statistical significance between 
co-dergocrine and placebo, and thus fails to confirm earlier promising 
uncontrolled open studies. A further double-blind evaluation reported after 
the conclusion of this study demonstrated superiority of co-dergocrine over
TABLE 6.1
COMPARABILITY OF THE GROUPS 
(Co-dergocrine v placebo)
Active Placebo
Overall
Means
Mean Age (i Se) 69.7 (±2.1) 70.0 (t 2.6) 69.9
Male/Female 7/12 11/10 18/22
Mean Predrug 
score (i Se) 10.1 (±1.1) 8.7 (i 0.7) 9.4
Number in group 19 21
TABLE 6.2
COMPARABILITY OF TREATMENTS 
(Co-dergocrine v placebo)
Active Placebo
Reduction of scores 3.79 2.48pre—^  first 6 weeks
Standard error 0.92 0.95
Reduction of scores 4.37 3.14pre-^-second 6 weeks
Standard error 0.95 0.82
placebo (Chien, Marder, Van Putten & Escobar, 1980). Their report, 
however, is only based on 8 patients, but it is of interest that they 
commenced their co-dergocrine dosage at 3 mg daily and increased this at 
weekly intervals to 6 mg daily. It may well be that the standard 4.5mg 
daily dosage of co-dergocrine employed in this study was insufficient. 
Insufficient dosage could possibly have accounted for the disappointing 
results experienced with deanol under controlled conditions (Simpson, 
Voitashevsky, Young & Lee, 1977; Jus, Villeneuve, Gautier, Jus, Villeneuve, 
Pires & Villeneuve, 1978), as a recent study under double-blind controlled 
conditions showed significant reduction in mean rating of dyskinetic 
movements in a group of 11 patients using a daily dosage of 2000 mg deanol 
whereas the 11 receiving 1000 mg deanol and the 11 in the placebo group 
failed to improve (George, Pridmore & Aldous, 1981).
A problem frequently encountered in the conduct of drug studies is that the 
patient sample includes those who have been previously treated for the 
indication under study. In this evaluation 3 patients had been previously 
treated unsuccessfully with tetrabenazine for their tardive dyskinesia, 3 
had been treated unsuccessfully with sodium valproate for the condition, 
and 1 had received both of these compounds and failed to show 
improvement. The separation of this previously treated group into a sub­
group did not show any significant differences from the pattern of results 
in the total population in the study.
The patient sample in this study included a high proportion of chronic 
schizophrenics, who had been in institutional care for many years. Of the 
43 patients in the study, 33 had been in psychiatric hospitals for more than 
10 years, and of those, 24 had been in for more than 20 years. Thirty-four
patients had been treated with 3 or more antipsychotic agents during their 
illness and 39 had been prescribed one or more antiparkinsonian drug for 
earlier extrapyramidal side effects. In addition 27 patients were over the 
age of 70 and it would seem unlikely that any drug would produce 
improvement in a group where tardive dyskinesia was probably irreversible.
Further studies with a longer treatment period and at a higher dosage level 
in a younger patient sample should be undertaken.
SUMMARY
In a double-blind placebo controlled study with co-dergocrine in the 
treatment of tardive dyskinesia in a group of 43 elderly chronic psychiatric 
in-patients, the reduction in dyskinetic scores in the group receiving active 
medication was slightly greater than in the placebo group, but this did not 
reach a level of statistical significance. It is suggested that further work 
could be undertaken with a longer period of treatment, and at a higher 
dosage of co-dergocrine in a younger patient sample.
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RESULTS OF THESE STUDIES
This research project has provided information on the prevalence of 
dyskinesia in a group of mentally handicapped patients. The high 
prevalence rate of 47.5 per cent observed is suggested as being related to 
the sex of patients, their increasing age and the frequency of brain 
damage.
The major undertaking has been a detailed prevalence study in 500 
residents in residential homes for the elderly. Prevalence rates of 
dyskinesia in those with a history of antipsychotic medication were, 
statistically, significantly greater than those in the group who had never 
received antipsychotic drugs.
It is suggested that dyskinesias are more likely to occur in females receiving 
antipsychotic drugs than in males, and that the use of more than one 
antipsychotic drug in the same subject is likely to produce more dyskinesias 
than where a single agent is administered.
The association of an increase in prevalence of tardive dyskinesia where 
antiparkinsonian agents are used in conjunction with antipsychotic drugs is 
identified, and there was also an increase in dyskinesias where benzo­
diazepines were given in conjunction with antipsychotic drugs.
In view of the fact that none of the 13 residents who had received 
thioridazine had tardive dyskinesia, it might be appropriate to suggest the 
use of this compound in the elderly, where agitation, anxiety and disturbed 
behaviour are manifested.
A double-blind evaluation of co-dergocrine, a drug which had given 
promising results in open studies, was also undertaken. Results were 
inconclusive but there was a trend in favour of the active drug, and further 
work is suggested in a younger, less chronic group of patients. A higher 
dosage and longer periods of treatment are also recommended.
Additional studies that could be undertaken in the 500 residents of the 
residential homes for the elderly might centre on the following:-
1. The withdrawal of antipsychotic medication to observe whether 
or not tardive dyskinesia appears in subjects who do not have 
dyskinesia at the present. This would have, ethical considerations 
in that the possibility of disturbed behaviour might result from 
the removal of antipsychotic medication.
2. A subsequent follow-up rating to observe whether the dyskinesias 
observed have shown signs of progression or not.
Further work could be carried out in respect of rating procedures. There is 
a need for standardisation of techniques and the effect of variables such as 
stress, circadian rhythms and food intake should be examined. Drug intake 
and time of administration might also be explored as, unless a steady state 
exists, the peaks and troughs of antipsychotic and sedative drugs may 
affect the severity of dyskinesias.
IMPLICATIONS FOR PSYCHIATRY OF TARDIVE DYSKINESIA
In a University Lecture to the University of Surrey entitled "Man, Health 
and Technology, the next 100 years?", Davis (1977) considered 2 models in
the projections of future population. With a 1.63 children per family 
breeding rate, mental illness rates would remain the same but there would 
be a rise in geriatric illness in the next 30 years. A 2 children per family 
breeding rate would produce a growth in mental illness of 16 per cent, and 
an increase in geriatric illness of 38.4 per cent. He drew attention to the 
reduction in the working population and the consequent problems of 
staffing hospitals and clinics, and stressed the need for better preventive 
and social medicine. Unless positive action is taken in respect of tardive 
dyskinesia the problem will increase with the rise in mental and geriatric 
illness.
Jeste & Wyatt (1981) drew attention to the fact that the rising prevalence 
of tardive dyskinesia has obvious implications for the use of antipsychotic 
drugs. They pointed out that the development of tardive dyskinesia is only 
one aspect of antipsychotic drug treatment, and that antipsychotic drugs 
have had a far greater impact than any other treatment on the 
management of schizophrenic patients. Nearly 3 decades after the 
discovery of chlorpromazine as an antipsychotic agent, there is still no 
single substitute for antipsychotics for control of symptoms and 
prevention of relapse in the majority of chronic schizophrenic patients 
(Davis & Cole, 1975).
For many years psychiatrists were reluctant to accept that tardive 
dyskinesia was a side effect of the antipsychotic drugs (British Medical 
Journal, 1979). There followed a period of intense concern as exampled in 
the popular press and in the law-review literature (DuBose, 1976) following 
an editorial on the risks versus the benefits of antipsychotic drugs 
(Baldessarini & Lipinski, 1973). In an article entitled "Maintenance 
antipsychotic therapy; is the cure worse than the disease?", Gardos & Cole 
(1976) stated that tardive dyskinesia in particular was becoming recognised 
as a major therapeutic challenge.
By the late 1970's the problem of tardive dyskinesia had produced 
considerable reaction in the USA. Some 30 law suits in which patients 
and/or their relatives sued their physicians were in process and in those 
that had been settled, patients had all been successful (Borison, 1980).
Gardos &  Cole (1976) stressed that every chronic schizophrenic outpatient 
maintained on antipsychotic medication should have the benefits of an 
adequate trial without drugs. They listed a suggested programme of 
withdrawal of antipsychotic medication. By 1980, the same authors 
referred to the fact that the response of the profession had shifted from, 
curiosity and mild concern to panic (Gardos & Cole, 1980). They drew 
attention to the likelihood of increasing litigation but accepted the 
fact that with no suitable alternatives to antipsychotic medication 
on the horizon, tardive dyskinesia was not likely to diminish but might, 
in fact, become more widespread.
More recently, attitudes have shifted from the panic situation to one of 
balancing benefits against risks. In making the point that in drug therapy 
one cannot have benefits without risks, Teeling-Smith (1981) expressed the 
view that disproportionate emphasis on the risks of medicines can itself be 
extremely harmful. This is further emphasised by Baldessarini & Lipinski 
(1981), who were concerned that excessive and unbalanced criticism may 
lead physicians, patients and their families or the courts to avoid a 
treatment with established efficacy and reasonable safety in patients with 
psychoses.
Ananth (1980), in discussing the advisability of warning patients of side 
effects of antipsychotic medication, could not imagine himself fully
explaining the side effects of antipsychotics to a highly paranoid schizo­
phrenic patient and obtaining full consent for treatment. Additionally, he 
felt that because it was not possible to predict who will develop tardive 
dyskinesia, explaining this side effect to patients such as acute schizo­
phrenics was not warranted. Where patients had insight, and long-term 
maintenance was necessary, they should be made aware of the risks and 
benefits of antipsychotic therapy.
Gelenberg (1980) felt that psychiatrists could not and should not practice 
every moment with a lawyer at the elbow, but they could and should 
remember that a doctor-patient relationship requires mutual respect and 
ongoing dialogue - and that, after all, was the best way to avoid a legal 
morass. Cole (1976) was of the opinion that the first duty was to treat the 
patients and then to go into the more remote, possible consequences of 
therapy at a later date.
One of the biggest problems has been the potential harm of overdiagnosis 
in what is a complex area, against a background of major public health, 
legal and ethical implications (Kane, Wegner, Stenzler & Ramsey, 1980). 
They felt that because investigators are all eager to identify important risk 
variables, there has been a tendency to perform rather dramatic statistical 
overkill on limited data.
In considering the current situation in regard to implications for psychiatry 
of tardive dyskinesia, the consensus viewpoint seems to be reflected in the 
comment of the Drug and Therapeutics Bulletin (1978) that the balance 
between control of psychotic symptoms and avoidance of tardive dyskinesia 
is one of the most difficult in psychiatric therapy.
DRUG TREATMENT OF TARDIVE DYSKINESIA
The treatment of established tardive dyskinesia has been considered in 
detail earlier (See 2.7.7). Attempts to treat tardive dyskinesia with specific 
agents have not been encouraging, and no single drug has emerged as the 
agent of choice (Kobayashi, 1977a). This view is supported by many 
authors (Mackay & Sheppard, 1979; Deveaugh-Geiss, 1979). Gardos & Cole 
(1980) stated that from a public health view the treatment of tardive 
dyskinesia is unsatisfactory. Safe, effective and specific treatment 
methods are lacking. This is supported by the Task Force (1980) report 
which observed that although many therapies for tardive dyskinesia have 
been evaluated, none has been either thoroughly studied or proven safe and 
effective. The same report postulates that it is possible that tardive 
dyskinesia is a heterogenous group of disorders with a variety of 
anatomical, neuropathological and pathophysiological bases, corresponding 
to the varieties of natural history and responses to treatment. No 
treatment to date uniformly benefits dyskinesias in all patients. Kobayashi 
(1977a) suggested an appropriate approach might be to challenge dyskinetic 
patients with several different categories of drugs with relatively rapid 
actions. The existence of pharmacological subtypes and the employment of 
a strategy of acute drug challenge as suggested by Kobayashi (1977a) is 
supported by Casey & Denney (1977) and Mackay & Sheppard (1979).
ADJUSTMENT OF ANTIPSYCHOTIC DOSAGE
7.4.1. Drug Holidays
The concept of drug holidays was suggested by Ayd (1970) and
Crane (1973). These can be the subject of considerable variation
such as the administration of antipsychotic drugs for 3 days during 
the week and the week-end left free from medication. An 
alternative is to stop antipsychotic medication for a period of 
several weeks after continuous administration of drugs for several 
months.
Casey (1978) suggested that the drug free interval might also 
uncover mild tardive dyskinesia symptoms which were previously 
masked by the drug. Thus, early detection could lead to early 
treatment and prevention of advanced symptoms. A further 
advantage would be the fact that with periodic termination of 
antipsychotic medication the patient might be able to go for a 
long period of time without drug therapy. Caution is advocated in 
that some patients cannot tolerate drug holidays and begin to 
relapse shortly after discontinuing their drug (Casey, 1978).
One controlled study to establish the effects of drug holidays has 
shown that after a 6 week period without antipsychotic 
medication there was no significant development or reduction of 
tardive dyskinesia, and no clinical worsening in the global severity 
of illness (Goldberg, Shenoy, Sadler, Hamer & Ross, 1981). The 
authors did draw attention to the low level of tardive dyskinesia at 
baseline in their study. Others have produced evidence that 
interrupted courses of antipsychotic medication are worse than 
continuous treatment (Jeste, Potkin, Sinha, Feder & Wyatt, 1979). 
It is suggested that repeated drug challenges may have a kindling 
effect on the development of hypersensitivity in dopamine 
receptors (Kennedy, 1980). Caution in the use of drug holidays is 
also advanced by La Bruzza (1981).
7.4.2 Discontinuation of Antipsychotic Medication
In a controlled study in 34 psychiatric patients the effects of total 
withdrawal of medication for a 10 week period were observed. 
Dyskinesia persisted throughout this period and there was a slight 
worsening in behavioural effects in 9 patients, and 6 patients were 
much worse. Whilst the results were disappointing from the 
aspect of improving dyskinesia, the authors strongly recommended 
that drugs should be kept to a minimum in patients exhibiting 
tardive dyskinesia (Crane, Ruiz, Kernohan, Wilson & Royalty, 
1969).
Lehmann (1973) suggested that the withdrawal of antipsychotic 
medication should be by means of gradual decrease to a lowest 
effective dosage level. In a double-blind study in 21 patients, 
medication was decreased in successive steps of 4 weeks duration 
to one-half, one-fourth and finally one-eighth of its initial level, 
and was then followed by a 6 month placebo medication period. 
Sixteen of the patients (76 per cent) relapsed, one during the 
period of progressive drug reduction and 15 between the 2nd and 
14th week after medication had been discontinued. In a control 
group of 11 patients who were maintained on the same dose of 
antipsychotic drug, 2 patients (18 per cent) showed signs of
deterioration. In the experimental group there was a non-
D ■■
significant increase in dyskinesia during the period of gradual drug 
reduction, and a greater increase after complete drug withdrawal 
(Branchey, Branchey & Richardson, 1981).
7.4.3 Reduction of Antipsychotic Medication
The current consensus viewpoint suggests that antipsychotic drugs 
should be used only when clearly indicated and that they be 
restricted to the lowest effective dosage. This aspect is 
considered in detail later (see 7.6).
RESEARCH STRATEGIES
7.3.1 Diagnosis of Tardive Dyskinesia
Granacher (1981) observed that for the psychiatrist, ail that 
moves in patients receiving antipsychotics may not be tardive 
dyskinesia, even though in the large majority of cases that 
diagnosis is correct. Attention must be paid to other causes of 
abnormal involuntary movements. Emphasis on the basics of 
medical description and classification may add to knowledge of 
the tardive dyskinesia syndrome. In this respect, the description 
of the disorder by Parkes (1976) is concise and less complicated 
than the Task Force description (Schiele, Gallant, Simpson, 
Gardner, Cole, Crane, Chase, Ayd, Levine & Ochota, 1973) (see 
3.1). A standardisation on diagnostic criterion in respect of an 
AIMS total score will prevent the wide variations in studies of 
prevalence rates, and should put the syndrome in true perspective.
7.5.2 Animal Models
)
After repeated administration of classical antipsychotics to the 
rat, supersensitivity of striatal dopamine (DA) receptors towards 
DA-receptor agonists can be demonstrated. This effect can be 
quantified (a) by measuring the turning response to apomorphine 
in rats with unilateral striatal lesions or (b) by measuring the 
changes induced by neuroleptics in the DA metabolism in the 
striatum of intact rats (Sayers, Burki, Ruch & Asper, 1977). Using 
the rat model Clow, Jenner, Theodorou & Marsden (1979) showed 
that the initial behavioural and biochemical evidence for striatal- 
DA-receptor blockade by trifluoperazine disappeared within a few 
weeks of starting therapy to be replaced by supersensitivity after 
6 months of drug administration despite continued drug intake. 
They suggested this might explain why drug-induced parkinsonism 
may disappear and why tardive dyskinesias may appear during 
chronic antipsychotic therapy. It was also suggested that this 
type of experiment may provide a realistic animal model for 
testing drugs for their capacity to induce dyskinesias. In the test 
system used by Sayers, Burki, Ruch & Asper (1977) thioridazine 
was shown to induce an increase in DA-receptor sensitivity which 
is significantly less intense and of shorter duration than that 
induced by haloperidol. They postulated that the tendency of a 
drug to increase DA-receptor sensitivity has been related to its 
propensity to induce tardive dyskinesia in man, and on this basis it 
may be expected that tardive dyskinesias following treatment 
with thioridazine will be rare and less intense than those seen 
after classical neuroleptics. This has been supported by clinical 
evidence (Blowers & Bicknell, 1980). Davidson (1981) observed
that the chronic cebus monkey model appears to be homologous to 
tardive dyskinesia in all respects, and the same author with 
colleagues, in unpublished work, has produced early dyskinetic 
symptoms in squirrel monkeys after 8 to 12 weeks of treatment 
with haloperidol. Two other models have been identified but not 
studied extensively, they are Fisher rats (Smith & Leelavathi, 
1978) and frontally lesioned rats (Glassman & Glassman, 1979). In 
these latter two models, spontaneous mouth movements that may 
be related to tardive dyskinesia appeared in some rats after 
approximately 2 months of chronic antipsychotic therapy. In 
a further study the potential of a drug to cause tardive dyskinesia 
was assessed by measuring adaptive changes in the striatal 
dopamine metabolism. Homovanillic-acid concentration in the 
striatum was measured after a high dose of haloperidol had 
been administered to rats pre-treated with test drugs (BUrki, 1979).
Experimental work was conducted with guinea-pigs who were given 
chronic high dosage amphetamine treatment for several weeks to 
elicit stereotyped behaviour. They were then subjected to testing 
with low doses of D-amphetamine to determine whether the 
chronic high-dosage pre-treatment altered the response to low 
doses. Data obtained suggested that chronically increased 
activity of dopamine at dopamine receptors (caused by chronic 
amphetamine administration) could alter the function of the 
striatum in such a way as to predispose the animal to stereotyped 
behaviour. This predisposition may reflect an increase in dopa­
minergic receptor sensitivity since the behavioural sensitivity to 
apomorphine was altered (Klawans, Crosset & Dana, 1974), This 
may have some implications in tardive dyskinesia. If tardive
dyskinesias are a manifestation of dopamine acting at dopamine 
receptors, they must represent altered or increased activity of 
dopamine at the involved receptors. The chronic persistence of 
tardive dyskinesia must then represent chronic increased dopa­
minergic activity at specific receptors. If this is analogous to the 
chronic amphetamine exposure described above, then allowing the 
clinical manifestations of tardive dyskinesia to persist may 
further predispose to the perpetuation of the movement 
abnormality (Klawans & Rubovits, 1975).
Further research with animal models is necessary, not only to 
clarify early impressions that there are fundamental differences 
in the propensity of existing antipsychotics to produce 
tardive dyskinesia, but also to screen newly developed anti­
psychotic preparations before they are subjected to volunteer 
studies in humans as part of the testing programme prior to the 
. issue of a Clinical Trials Certificate.
7.5.3 Human Studies
Reference has already been made to the proposition that 
uncovering tardive dyskinesia by short-term administration of an 
antiparkinsonian drug may aid in early detection and help to 
prevent the subsequent development of incapacitating forms of 
the disorder (Chouinard, De Montigny & Annable, 1979). The use 
of pharmacologic probes was suggested by Moore & Bowers (1980), 
who observed that some patients with tardive dyskinesia fit the 
cholinefgic-dopaminergic imbalance theory, but some do not. To 
study this heterogenicity further, they measured the responses of 
10 patients with tardive dyskinesia to intravenous challenge doses
of drugs that facilitate or inhibit acetylcholine transmission 
(physostigmine or benzotropine, respectively). They then measured 
the response of these patients to an open outpatients deanol trial. 
They found that the responses of half the patients followed the 
classic theory, 2 responded paradoxically and 3 responded 
inconsistently. The authors suggested that there is a subgroup of 
tardive dyskinesia patients who fit the theory but that more 
research is needed to identify the subgroups who do not. Mackay 
& Sheppard (1979) suggested that the definition of a pharmaco­
logical signature for each patient in an acute dose-response 
design seems to offer the most sensible and economical 
therapeutic approach to tardive dyskinesia at the present time. 
Correlation of pharmacological response with careful clinical 
classification may lead to the identification of clinical predictors 
and even to a better understanding of the underlying neurological 
disorder(s).
Rosenbaum, Maruta, Jiang, Auger, de la Fuente & Duane (1979) 
hypothesised that primary affective disorders are a major 
predisposing factor for the development of tardive dyskinesia and 
that patients with tardive dyskinesia have neuroendocrine 
abnormalities similar to those of patients with primary affective 
disorders. To test this hypothesis, they measured the levels of 24 
hour urinary free cortisol (UFC) and blood thyroid-stimulating 
hormone (TSH) in consecutive patients with tardive dyskinesia 
and compared these levels with those found in controls. In an 
earlier reported study, in patients with primary affective disorders, 
24 hour UFC levels were elevated (Carroll, Curtis, Davies, 
Mendels & Sugerman, 1976) but this, did not occur in schizophrenia. 
In the first mentioned study, Rosenbaum and his colleagues
showed that 13 of the 18 patients (72 per cent) had elevated UFC 
levels, which supported their hypothesis that the endocrine 
dysfunction in these patients was similar to that in patients with 
primary affective disorders. Further, patients with low TS'H 
levels tended to have elevated UFC levels, which suggested an 
inverse relationship. None of these patients fulfilled research 
diagnostic criteria for schizophrenia at the time of the authors 
evaluation. Instead, all of the patients with elevated UFC 
levels, except the manic and paranoid patients, fulfilled 4 to 6 of 
the 8 research diagnostic criteria depressive symptoms, although 
many denied a dysphoric mood. The authors suggested that their 
findings indicate that a subgroup of patients with tardive 
dyskinesia have endocrine dysfunction similar to that seen in 
primary affective disorders. They advocated further testing using 
dexamethasone suppression and thyrotropin-releasing hormone 
(TRH) stimulation, along with determination of UFC levels.
Kane, Struve, Weinhold & Woerner (1980) defined a high risk 
patient as anyone who developed presumptive tardive dyskinesia 
after less than 1 year cumulative lifetime exposure to anti- 
psychotics. A small group of "high-risk11 patients were selected. 
EEG evaluations were made and 3 of 7 patients examined showed 
an abnormal reading. Four of the 7 had the B-mitten
dysrhythmia. The authors suggested that EEG abnormalities may 
indicate an increased risk factor for tardive dyskinesia, and are 
in process of collecting further data.
In a study to determine the value of a tongue protrusion test in the 
early detection of tardive dyskinesia (Pi & Simpson, 1981), the 
test was positive in 5 of 11 possible cases of tardive dyskinesia 
and in 1 of 11 doubtful subjects. The recommendation is made for
a controlled prospective study of the evolution of tardive 
dyskinesia in subjects with an initial mild abnormal tongue 
movement.
There is clearly an area of research in which "risk" patients for 
tardive dyskinesia can be identified, either by the use of 
biochemical methods or EEG examination. Additionally, the 
selective use of drugs in the treatment of the disorder, 
particularly if specific sub-groups can be identified, has 
considerable possibilities, and may overcome the disappointing 
results obtained so far. A study in which a group of patients with 
tardive dyskinesia could be treated firstly, for example, with 
deanol, the non-responders then treated with tetrabenazine, and 
the non-responders treated with co-dergocrine, and so on, or a 
permutation on these and other drugs, might be worthy of 
initiation.
One study by Casey & Denney (1977) evaluated the effects of 
challenge doses of dopamine and acetylcholine agonists and 
antagonists on dyskinetic symptoms and found that drug responses 
formed sub-groups which divided into pharmacological mirror 
images. Dopaminergic antagonists or acetylcholinergic agonists 
reduced symptoms in group 1 but increased symptoms in group 2, 
whilst dopamine agonists or acetylcholinergic antagonists 
increased symptoms in group 1 but reduced them in group 2. 
These seemingly paradoxical results suggest that inhibitory and 
excitatory dopamine receptors might play differential roles in the 
pathophysiology of the tardive dyskinesia syndrome.
A low dosage study with the dopamine agonist bromocriptine 
might also be undertaken to investigate the long-term effect in 
treating tardive dyskinesia. An initial worsening of dyskinesia 
might well occur but subsequently a beneficial effect might be 
obtained. A Clinical Trials Certificate for the use of bromo­
criptine in tardive dyskinesia is currently in existence.
7.5.4 New Antipsychotic Compounds
In a leading article (British Medical Journal, 1979) the observation 
was made that in the long term the answer must lie in the 
development of a new class of antipsychotic drugs that will 
control schizophrenia without producing tardive dyskinesia. 
Marsden (1976a) refers to the current hypothesis that anti­
psychotic drugs possess their antipsychotic activity because they 
block cerebral dopamine receptors, not only in the striatum but 
also in areas of the mesolimbic system, brainstem and hypo­
thalamus. The unwanted extrapyramidal effects of antipsychotic 
activity are attributed to striatal dopamine receptor blockade, 
but it is generally accepted that they are not necessary for 
antipsychotic activity. The latter may depend on the effects of 
the drugs on dopamine receptors elsewhere, for example, the 
mesolimbic system. He suggested that if this assumption was 
correct, it may be possible to create antipsychotics devoid of 
striatal dopamine antagonism, and hence of extrapyramidal 
unwanted actions.
The Task Force (1980) stressed the urgent need for the develop­
ment of effective antipsychotics that do not have the risk of 
inducing tardive dyskinesia, and pointed to the requirement to
develop better drug screening tests. They suggested that 
clozapine and sulpiride are examples of experimental drugs that 
seem to be effective antipsychotic agents with little or late 
extrapyramidal effect. Whilst they refer to the discontinuation of 
trials with clozapine due to its association with agranulocytosis 
(see 2.7.7) it is understood that following clinical use of clozapine 
in a number of countries, including South Africa, its association 
with agranulocytosis is no greater than that with other anti­
psychotics.
It is planned to introduce clozapine into the United States in the 
near future. Marsden (1976b) described clozapine as a fascinating 
drug, that does not appear to cause much parkinsonism, acute 
dystonias or akathisia, and whilst most of the evidence is based on 
short-term trials, tardive dyskinesia has not been described. He 
felt that if tardive dyskinesia was not produced following long­
term administration then this crucial question may be answered.
Both clozapine and thioridazine have been shown to have a site 
specificity for blocking dopamine receptors in the limbic rather 
than the extrapyramidal system (Borison, Bauer, Havdala & 
Diamond, 1980; Borison, Fields & Diamond, 1981; Borison, 
Blowers & Diamond, 1982) and this may account for their low 
incidence of extrapyramidal side effects.
Further research on analogues of clozapine at the Sandoz/Wander 
Research Institute in Berne have produced a new compound, NB 
106-689, which has an antipsychotic profile similar to clozapine, 
but has successfully completed an agranulocytosis animal model 
screening programme. This compound is in the early stages of 
clinical trials in the United Kingdom.
RECOMMENDATIONS
7.6.1 Continuation of Antipsychotic Medication
As the search for more selective treatments for acute and chronic 
schizophrenia free of neurological'side effects progresses, the use 
of available antipsychotic agents continues to be the cornerstone 
of management of these serious and disabling mental illnesses 
(Baldessarini, 1980). Cole &  Gardos (1980) pointed to the dilemma 
faced by the psychiatrist, with dyskinesia in an ambulatory, 
socially adjusted schizophrenic with a history of overt, severe 
psychosis, doing well on maintenance antipsychotic therapy. 
Stopping the antipsychotic medication has to be seriously 
considered but may lead rapidly to relapse and rehospitalisation. 
A clinical decision has to made that takes into account the 
patient’s history of drug response and relapse. In a patient who 
clearly relapses rapidly when taken off drugs, continued drug 
therapy at the lowest possible dose seems to be the best therapy 
of the total problem. Obviously, the undesirability of the 
dyskinesia must be weighed against the hazards of psychotic 
relapse.
7.6.2 Guidelines for Antipsychotic Therapy
Various authors have listed guidelines for the avoidance and 
management of tardive dyskinesia (Task Force, 1980; Klawans, 
Goetz &  Perlik, 1980; Gardos & Cole, 1980; Jeste & Wyatt,
The following recommendations are made to effectively use
antipsychotic drugs and, at the same time, decrease the incidence
of tardive dyskinesia:-
1. Limit the use of antipsychotic drugs to those indications 
where they are absolutely necessary, e.g. acute and chronic 
schizophrenia, manic phase of manic-depressive psychosis.
2. Continue medication only when efficacy is clear, and use 
lowest effective daily dosage.
3. Use lower doses with elderly patients and children, and aim 
to achieve minimum effective dose.
4. Avoid multiple antipsychotic drug prescriptions.
5. Avoid long-term use of antiparkinsonian drugs, and only use 
when clearly indicated.
6. Advise patients (if appropriate) and families of risks and 
benefits of antipsychotic drug therapy.
7. Aim to detect tardive dyskinesia as early as possible, and 
urge nursing staff to be alert to the possible appearance of 
the syndrome.
8. Re-assess the patient on a regular basis and attempt to
reduce dosage.
9. At the earliest signs of tardive dyskinesia, lower anti­
psychotic drug dosage, withdraw medication if possible, or
switch to a less potent agent (e.g. thioridazine).
10. Treat dyskinesias with benign agents initially (e.g. deanol, 
choline, lecithin). Reinstitute antipsychotics if relapse 
occurs using minimum effective dosage.
7.6.3 The Role of Thioridazine
Klawans, Goetz & Perlik (1980) stated that where antipsychotics 
were absolutely required, they tended to switch to thioridazine. 
They indicated that their practice is based on several 
considerations. Firstly, there appears to be some relationship 
between drug-induced parkinsonism and tardive dyskinesia, and 
thioridazine has the lowest incidence of drug-induced parkin­
sonism of available antipsychotics. Evidence from animal 
experiments also suggests that some agents may be less likely to 
induce receptor hypersensitivity than others. In animals it has 
been shown that thioridazine produces a short-lived sensitisation 
of striatal dopamine receptors, whereas haloperidol and flu- 
phenazine produced much more marked and longer-lived receptor 
sensitisation (Borison, Blowers & Diamond, 1982). In their 
laboratories Klawans, Goetz & Perlik (1980) have been unable to 
produce receptor-site hypersensitivity measured either bio­
chemically or behaviouraily with chronic thioridazine, but can 
easily produce this state with other phenothiazines and 
haloperidol in equivalent doses. They stated that there was no 
human data to establish a lower incidence of tardive dyskinesia 
with thioridazine, but, because of the above consideration, they 
felt it reasonable to substitute thioridazine in this situation. The 
present study has produced some evidence to support the use of 
thioridazine in that it has been shown to produce less tardive 
dyskinesia than haloperidol (see 4.4.) and where pure culture 
groups of antipsychotic-treated subjects could be identified, those 
on thioridazine did not have tardive dyskinesia (see 5.3.3).
Further support for the use of thioridazine in patients where 
tardive dyskinesia has occurred following treatment with other 
antipsychotics is reported by Kobayashi (1977), Tarsy & 
Baldessarini (1980), Dominguez (1980) and Richelson (1980).
Gerlach & Simmelsgaard (1978) suggested that strong dopamine 
-receptor blocking antipsychotics (e.g. haloperidol) induce the 
pathological basis for tardive dyskinesia to a greater degree than 
weak dopamine-receptor blocking antipsychotics (e.g. thio­
ridazine), and Klawans, Goetz & Perlik (1980), whilst accepting 
that thioridazine can cause tardive dyskinesia, stated that they 
feel safer using it when antipsychotic treatment is necessary.
SUMMARY
The main findings of this research are outlined, including the presentation 
of data from prevalence studies of tardive dyskinesia in 40 mentally 
handicapped patients and 500 subjects in residential homes for the elderly. 
Association of tardive dyskinesia with antipsychotic drugs, antiparkinsonian 
agents and benzodiazepines is summarised. Results of a double-blind 
evaluation of co-dergocrine in the treatment of tardive dyskinesia are 
briefly discussed.
Suggestions are made for future research in the group of 500 subjects who 
were included in the prevalence study, as well as identifying areas where 
further work is necessary in rating procedures.
Implications for psychiatry of tardive dyskinesia are discussed and the 
current practices for treating the syndrome are considered. Research 
strategies are reviewed, and finally recommendations are made for both 
the attempts to limit the incidence of tardive dyskinesia and to manage the 
problem if it presents.
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APPENDIX 1
ABNORMAL INVOLUNTARY MOVEMENT EXAMINATION
Observation begins when the patient enters the room and the whole body 
movements, with particular attention to the lower limbs, are noted.
The patient is asked to sit on a firm straight-backed, armless chair, with 
feet placed firmly on the floor and slightly apart.
The hands are rested unsupported on the knees so that manifest movements 
can be observed.
The patient is invited to examine the large composite picture placed on a 
music stand in front of him, and told that he should look at the picture for 
a few minutes and then he will be asked to tell the rater what different 
animals were seen in the picture.
This distracting manoeuvre will enable the rater to make an overall 
assessment of the patient for visible abnormal involuntary movements.
At the end of 2 minutes, the patient is asked to name the species of 
animals seen. No specific importance will be attached to the answers 
given.
If  abnormal movements are observed the patient is asked if he is aware of 
them and if the movements cause him concern
The patient is asked if has anything in his mouth, e.g. a sweet or chewing 
gum.
The patient is asked if he is wearing dentures and, if so, do they fit  
properly or cause any discomfort.
The patient is asked to open his mouth as wide as he can, and the tongue is 
observed as it rests in the buccal cavity. Differentiation is made between 
normal fine tremor and the choreoathetoid movement of tardive 
dyskinesia.
The patient is then asked to close the mouth and then open it again as 
widely as possible. The tongue is again observed. Sovner (1978) stated that 
tongue movement that may not be present when the mouth is first opened 
can occur after the mouth is opened on the 2nd occasion.
The patient is then asked to close the mouth, and then to open it and stick 
out the tongue as far as possible. This manoeuvre can activate previously 
undetected tongue movements or increase the severity of movements 
already present (Sovner, 1978).
The patient is then asked to close the mouth and again open it  and stick out 
the tongue as far as possible. Observations are again noted.
The patient is then invited to participate in an activating task in which, 
firstly, the right hand is slightly extended, and each of the fingers in turn is 
touched by the thumb. This thumb touching manoeuvre is repeated three 
more times.
The procedure is then carried out with the left hand and the patient is 
urged to speed the movement up.
During this activating task which is designed as an unmasking technique, 
the patient is observed for tongue and eye movements and involuntary 
mouth movements.
The patient is then asked to put his hands down on his lap and to let them 
go loose. Muscle tone flexibility is then checked by shaking wrists and 
forearm in order to differentiate from drug induced Parkinsonian tremor.
The patient is asked to^stand and put his arms out in front, and in this 
activating manoeuvre observation is made for cho reoat he toid hand 
movements.
The arms are then returned to the patient's side and he is asked to turn to 
his side (90°) and again put out his arms in front of himself. The arms are 
again returned to the side and the patient asked to walk across the room, 
turn around, and then come back to the chair and sit down. During this 
activating test, close watch is kept on hand movements.
A minimum of 10 minutes is spent with each patient, and any subsequent 
examination should be carried out to the exact pattern of that described 
above.
Details of abnormal involuntary movements are recorded on the relevant 
sheet and in accordance with the Abbreviated Dyskinesia Rating Scale of 
the Rockland Research Institute (Appendix 2).
ABNORMAL INVOLUNTARY MOVEMENT EXAMINATION
Check List for Rating Procedure 
Observe patient as he enters room.
After patient is correctly seated, invite him to examine picture. 
Observe for 2 minutes.
Check mouth for sweets, chewing gum, ill-fitting dentures.
Open wide and close mouth twice - observing tongue.
Open mouth and extend tongue fully and observe tongue - close 
mouth - then repeat.
Slightly extend right hand and touch each finger with thumb - repeat 
4 times.
Repeat with le ft hand urging patient to speed up - observe tongue, 
eyes and mouth.
Relax hands - flex arms - observe for Parkinsonian tremor.
Stand - extend arms - and return to side.
Rotate patient 90° and repeat arm extension - observe for choreo- 
athetoid hand movements.
Ask patient to walk across room and return observe hand 
movements.
APPENDIX 2
ABNORMAL INVOLUNTARY MOVEMENT RATING SCALE
Hospital/Home Ward
Patient's Initials Age: Sex:
Date of Exam: Time: Examiners
Initials
Facial and Oral Movements:
1. Periocular area (blinking of eyes, tremor 
of eyelids
0 1 2 3 4
2. Movements of the lips (pouting, 
puckering and smacking).
0 1 2 3 4
3. Chewing movements 0 1 2 3 4
4. Sweet in mouth sign 0 1 2 3 4
3. Tongue protrusion 0 1 2 3 4
6. Tremor and/or choreoathetoid movements 
of the tongue.
0 1 2 3 4
OTHER (describe) 0 1 2 3 4
0 1 2  3 4 
0 1 2  3 4 
0 1 2 3 4 
0 1 2  3 4
0 1 2  3 4 
0 1 2  3 4 
0 1 2  3 4 
0 1 2  3 4
Entire body
13 Akathisia 0 1 2  3 4
OTHER (describe) 0 1 2  3 4
Rating 0 absent 2 moderate 4 severe
1 mild 3 moderately severe.
Neck and Trunk
7. Axial hyperkinesis (patient standing)
8. Rocking movements
9. Torsion movements 
OTHER (describe)
Extremities
10. Movements of fingers and wrists
11. Movements of ankles and toes
12. Stamping movements 
OTHER (describe)
Source: Adapted from Rockland Research Institute Abbreviated
Dyskinesia Rating Scale.
(Tick if appropriate)
Alcoholism Parkinson’s disease
Lobotomy Sydenham’s chorea
E.C.T. Encephalitis
Insulin coma treatment Syphilis
Metrazol coma Epilepsy
Mental retardation Temporal lobe epilepsy
Cerebral arteriosclerosis Abnormal E.E.G
Cerebral vascular accident Bell's palsy
Pernicious anaemia Congenital neuroLdisease
Hypothyroidism Tuberculosis
Diabetes mellitus Concussion, contusion
Uraemia Korsakoff's psychosis
Senile dementia
Other Medical History:
Antipsychotic Therapy: (list drug/drugs and length of treatment)
Anti-Parkinsonian Drug Therapy: (list drug and length of treatment)
Other Drugs Administered:
Current Medication:
Other Relevant Informations
Length of Stay in Hospital:
APPENDIX 3
ABNORMAL INVOLUNTARY MOVEMENT RATING SCALE
Definitions 
FACIAL AND ORAL MOVEMENTS
1. Periocular Area 
Blinking of Eyes
Repetitive and more or less continuous or in bursts. To be distinguished 
from tics which occur episodically.
Tremor of Eyelids
Isolated tremor, more frequently bilateral but can occur unilaterally. 
Usually seen when eyes are closed. Fine in character.
2. Movements of the Lips 
Pouting of the Lower Lip
A thrusting out of the lower lip as in solemness.
Puckering of Lips
Drawstring or pursing action of the lips.
Smacking of Lips
Brisk separation of lips which produces a sharp sound.
3. Chewing Movements
Self explanatory.
4. Sweet in Mouth Sign (Bon Bon)
Tongue movement within the oral cavity which produces a bulge in 
the cheek giving the impression the patient has a hard sweet tucked 
in his cheek. Occasionally a repetitious sweeping movement of the 
tongue over the buccal lining which also pushes out the mouth.
5. Tongue Protrusion
Clonic - a rhythmic in and out movement of the tongue.
Tonic - a continuous protrusion of the tongue.
FlyCatcher - a sudden shooting out of the tongue from the
mouth at irregular episodes.
6. Tongue Movements 
Tongue Tremor
Fine tremor observed with the mouth open and tongue within the 
buccal cavity.
Choreoathetoid Movements of the Tongue
A rolling, worm-like movement of the tongue muscles without 
displacement of the tongue from the mouth. The tongue may rotate 
on its longitudinal axis. Observed when the mouth is opened.
NECK AND TRUNK MOVEMENTS
7. Axial Hyperkinesia (patient standing)
A front to back hip rocking movement. Resembles copulatory 
movements. Differs from the rocking movement where it is the 
upper torso which has to and fro movement.
8. Rocking Movement
A rhythmic to and fro movement of the upper torso which occurs 
from a repeated bending of the spinal column in the lumbar region. 
Different from Axial Hyperkinesia where the hips move to and fro.
9. Torsion Movements
Twisting undulant movement of the upper or lower part of the trunk 
(shoulder or hip girdle) resulting from mobile, spastic movements of 
the axial and proximal muscles, The movements are not fast and 
they involve large portions of the body.
EXTREMITIES MOVEMENTS
10. Movement of Fingers and Wrists 
Choreiform Movements
In fingers, wrists, arms. Variable, purposeless, coarse, quick and 
jerky movements which begin suddenly and show no rhythmicity. 
They vary in distribution and extension.
Athetoid Movements
In fingers, wrists, arms. Continuous rhythmic, slow, writhing, 
worm-like movements. They almost invariably appear together with 
Choreiform Movements.
Rnger Counting
Rhythmic rubbing of the thumb against the middle and index finger. 
Caressing Face and Hair
Gives the impression of being absent-minded or vernous mannerism; 
has the appearance of being purposeful.
Rubbing of Thighs
Hands rub the outside or tops of thighs* Sporadic and non-rhythmic.
11. Movements of Ankles and Toes
Rotation and/or Flexion of the Ankles 
Self-explanatory
Toe Movements
Slow rhythmic, retroflexion, usually of the big toes although other 
toes can also be involved.
12. Stamping Movements 
Stamping Movements (Standing)
Weight is shifted back and forth from one foot to the other when 
patient stands.
Stamping Movements (Sitting)
Flapping or tapping of the whole foot on the floor when the patient is 
sitting, or may comprise an alternate toe and heel tapping.
ENTIRE BODY MOVEMENTS
13. Akathisia
An inability to sit or stand still.
Source: Adapted from Rockland Research Institute Tardive Dyskinesia
Rating Scale (Definitions).
County Hall,
K ingston upon Thames
O I- 546 1050
APPENDIX 4
6 March 1980 Home Telephone
BYFLEET 41017
To: General Practitioners providing services for
residents in Surrey County Council Homes for 
the Elderly.
Dear Doctor
As you will know, in the mid 1950s the tranquilliser drugs dramatically 
changed the treatment of mental illness. They have been widely used in 
psychiatric hospitals where previously physical restraint played a 
prominent part. Use has also extended to the treatment of confusion and 
agitation in the elderly.
Some years after the introduction of the tranquillisers, it  was observed that 
some of those who had been on treatment for at least six months began to 
develop involuntary muscular movements, e.g. a pronounced continuous 
chewing movement or frequent ejection of the tongue. Many people have 
tended to accept these movements as part of the illness process and, in 
fact, they can occur in people who have never received tranquillisers.
Much research has been done in psychiatric hospitals to determine the 
prevalence of these movement disorders, but very little work has been done 
to assess how much is present in the elderly as a group and how many of 
these have been on tranquillisers.
There are some 1600 residents in the County's Homes for the Elderly and as 
a PhD research student of Surrey University I am planning to carry out a 
study to obtain information that will fill these gaps in the total picture.
Approval has been obtained from the County's Social Services Department 
and the Area Specialist in Community Medicine to undertake this work in 
the Part IE Homes, and will consist of a simple test procedure which does 
not involve physical contact with the residents. '
In those residents showing abnormal involuntary movements it would be 
necessary to establish whether or not they have had any antipsychotic 
drugs in the past 7 years and I would be grateful if you would allow me to. 
obtain this information from the Officer in Charge/Matron of the 
respective homes. I appreciate there may be gaps in treatment records, 
and in this event the resident would be classified in a separate sub-group.
If you would like further information on the proposed project please let me 
know. In any event, I would be pleased to forward you a report on the 
findings of .the study.
Yours sincerely
A.J. Blowers J.P., L.I.Biol., A.I.M.L.5. 
Member Social Services Committee, S.C.C. 
and Surrey Area Health Authority.
County Hall,
K ingston upon Thames
01-546 1050
APPENDIX 5
26 March 1980 Home Telephone
BYFLEET 41017
To: Officers in Charge
Homes for the Elderly
Dear Officer in Charge,
As you may know the tranquilliser drugs have revolutionised the treatment 
of mental illness. They have been widely used in psychiatric hospitals 
where previously physical restraint played a prominent part. Use has also 
extended to the. treatment of confusion and agitation in the elderly.
Some years after the introduction of the tranquillisers, it was observed 
that some of those who had been on treatment for at least six months 
began to develop involuntary muscular movements, e.g. a pronounced 
continuous chewing movement or frequent ejection of the tongue. Many 
people have tended to accept these movements as part of the illness 
process and, in fact, they can occur in people who have never received 
tranquillisers.
Much research has been done in psychiatric hospitals to determine the 
prevalence of these movement disorders, but very little work has been done 
to assess how much is present in the elderly as a group and how many of 
these have been on tranquillisers.
As you will appreciate, there are some 1600 residents in the County’s 
Homes for the Elderly and I am planning to carry out a study, under the 
aegis of the University of Surrey, to obtain information that will fill these 
gaps in the total picture.
I would plan to explain the details of the survey to a staff meeting at your 
Home to indicate what is involved for your residents and what action will 
be required by members of staff. I should be glad to explain the results of 
a pilot study which I have already completed with a group of elderly ladies 
in a hospital setting, where there was considerable interest and 
co-operation from residents and staff alike. There is a fairly simple test 
procedure, but without your support the whole test would not be possible. 
A report on this pilot study is attached, and could be shown to your visiting 
doctors, who have been sent a letter (copy enclosed) informing them of the 
project.
Mr Lillington did write to you in March of last year indicating his 
agreement to the study being carried out in the County’s Homes for the 
Elderly, and I am now ready to commence this stage of the project and 
would hope to contact you within the next few months.
Looking forward to meeting you.
Yours sincerely
A .J. Blowers c.c. Mr B.R. Lillington 
Dr. B. West worth
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TARDIVE DYSKINESIA AND THE 
MENTALLY HANDICAPPED
D e a r  S ir ,
Most surveys have been carried out among long- 
stay psychiatric hospital populations of chronic 
schizophrenics where phenothiazines have frequently 
been used for long periods of time.
So far few studies have involved the equally long- 
stay populations of mental handicap hospitals where 
chronic shortage of staff, inadequate diversional 
activities and inappropriate environments have fre­
quently necessitated the non-specific use of anti­
psychotic medication to reduce behaviour disturb­
ances. Routine review of prescriptions in mental 
handicap hospitals has not always been adequate; it 
has been our experience that prescriptions may be re­
peated at infrequent intervals with little thought for 
their continuing need. In  the past anticholinergic drugs 
were often given routinely, and the mentally handi­
capped, because of the supervision of their drug 
taking, probably reach a high degree of compliance. 
Many mentally handicapped have congenital or long­
standing brain damage, and because of the increasing 
life span the geriatric population of mentally handi­
capped individuals is increasing so that between 
10 per cent and 24 per cent of patients in most long- 
stay hospitals are over 65 years.
Surveys for abnormal movements in these patients 
should therefore yield fruitful results, although such 
surveys will challenge our diagnostic skills as by no 
means will all the movement disorders be tardive 
dyskinesia: the involuntary movements of the cerebral 
palsies must be distinguished.
In  a small survey of the total population in one long- 
stay female ward in a mental handicap hospital 
where ages ranged from 42 to 87 years (mean of 
65 years) and time spent in hospital ranged from 
2 to 50 years (mean of 32 years) and mental ages 
ranged from less than 5 years to dull normality, 
9 had received antipsychotic medication in the past 
7 years. Obvious movements suggestive of tardive 
dyskinesia were found in 49 per cent and mild 
abnormal movements of the face, tongue, jaws and 
hands were found in a further 37 per cent. All 9 who 
had received antipsychotic medication, and 25 out 
of 31 who had not received medication had abnormal 
movements; in this small number there was no 
significant relationship to medication history, nor to 
age. This survey was primarily a pilot scheme to 
assess the level of co-operation one could expect from 
such a population. With appropriate techniques and 
much encouragement all patients in the survey 
completed the examination, based on the technique 
described by Sovner (1978), using the Abnormal 
Involuntary Movements Scale (N IM H , 1975) with 
appropriate simplification assuming low cognitive 
abilities (Blowers and Bicknell, 1979).
With the slight improvements in the mental
handicap services and the greater emphasis on daily 
activity programmes, many of the behaviour distur­
bances formerly treated by medication are being 
successfully dealt with by methods not requiring 
medication. Many mentally handicapped people are 
being maintained in the community in more appro­
priate environments than were hitherto available in 
long stay wards. Those who are admitted to hospital 
are experiencing a service that continues to improve. 
We believe therefore that further work could usefully 
be done with this group of mentally handicapped 
individuals who are with us now, as with a more 
progressive philosophy of care and increased resources 
the opportunity to study such a group should 
fortunately disappear.
D . J . B ic k n e l l  
A. J . B lo w e r s
B otleys P a rk  H osp ita l,
Chertsey, Surrey
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THE RELEVANCE OF ANTIPSYCHOTIC MEDICATION IN 
TARDIVE DYSKINESIA IN THE ELDERLY
A.J. BLOWERS+AND JOAN BICKNELL++
+Department of+^uman Biology and Health, University of Surrey, Guildford,
Surrey, U.K.; Botleys Park Hospital, Chertsey, Surrey, U.K.
INTRODUCTION
Tardive dyskinesia has been generally regarded as a complication of long­
term antipsychotic therapy. It appears to be more prevalent in the elderly.^- ^
Female patients have been considered more prone to the disorder than males^ and
8in particular chorea was more common in women than in men. Following screening 
of the adult population of a large mental hospital, some 360 patients (11%) were 
found to have symptoms of tardive dyskinesia, and, from a representative group 
chosen together with a matched control group, female patients were found to be 
over-represented.** The present study was undertaken to establish the prevalence 
of tardive dyskinesia in a small population of elderly, female patients in a 
hospital for the mentally handicapped and to observe whether there were any 
differences between those who had received antipsychotic medication during the 
past seven years and those who had not.
MATERIALS AND METHODS
Forty-one female patients, the total population available from one ward, were 
included in the study. Ages ranged from 42-87 years with a mean of 65.5 years. 
Time spent in the present hospital ranged from 2-50 years with a mean of 31.6 
years.
Assessment of dyskinetic symptoms
. . .  9The patients were examined individually using a modification of the 
technique described by Sovner*^ based on the A.I.M.S. (Abnormal Involuntary
Movements Scale) examination devised by the National Institute of Mental
11 12 Health and referred to by Gardos ejt al. Details of abnormal involuntary
movements were recorded using a modification of the Abbreviated Dyskinesia
13Rating Scale of the Rockland Research Institute. Medical and drug history 
for the past seven years were also recorded.
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RESULTS
Examination of the current medical status revealed that 3 patients had 
involuntary movements of long standing. One of these showed symptoms 
indistinguishable from tardive dyskinesia of 43 years duration. She had 
received chlorpromazine more than 7 years ago, but was excluded from the study 
as her disorder was present before phenothiazines were available as therapeutic 
agents. The other two patients had symptoms more typical of a cerebellar 
disorder and they had received no medication in the last 7 years. Two patients 
had Parkinson's disease, one was arteriosclerotic, and the other post 
encephalitic, the latter improving with L.dopa. Two patients were epileptic 
and were on anti-convulsants, and eight were mildly hypertensive and obese, 
and were controlled by diuretics and anti-hypertensives. Three were receiving 
treatment for depression or anxiety and two maintained euthyroid with thyroxine 
therapy. Four patients received iron for anaemia and two, analgesics for 
osteoarthritis.
Of the 40 patients remaining in the study, 31 patients had received no 
antipsychotic medication (phenothiazines, butyrophenones or thioxanthenes) 
during the previous 7 years.
Nine patients had received one or more antipsychotic preparations at some 
time during this period. Five had received thioridazine alone, two haloperidol, 
one haloperidol followed by thioridazine and one flupenthixol. In addition, 
these nine patients had received antidepressants (5 prescriptions), anti­
parkinsonian drugs (5 prescriptions), minor tranquillizers (5 prescriptions) 
and barbiturates (2 prescriptions).
Scoring for abnormal movement was completed for each patient who was then 
assigned to one of two groups, group A which included those who had no anti­
psychotic medication for 7 years and group B involving those who had received 
antipsychotic medication in the past 7 years. A variety of abnormal movements 
were seen in patients in both groups. Abnormalities most commonly seen were 
movements of the lips, pouting, puckering and smacking, tongue protrusion with 
abnormal movements, choreoathetoid movements of the tongue, chewing movements 
and abnormal movements of the fingers and wrists. In the 31 patients who had 
not received antipsychotic medication, 25 had abnormal movements noted and in
the 9 patients who had received antipsychotic medication, all patients had some
noted abnormal movements. Each group was subdivided into those below 65 years 
and those above 65 years, the means of scores were calculated, the standard
deviations and standard errors, tables A & B.
339
TABLE A - GROUP A (31 PATIENTS - NO ANTIPSYCHOTIC MEDICATION)
Age_______No.______ Mean______S.D.______ S.E.
^ 6 5 13 2.69 2.14 0.59
>■ 65 18 3.78 3.66 0.86
All ages 31 3.32 3.11 0.56
TABLE B - GROUP B (9 PATIENTS - ANTIPSYCHOTIC MEDICATION RECEIVED)
Age No. Mean S.D. S.E.
^  65 4 5.25 3.30 1.65
>" 65 5 5.20 3.49 1.56
All ages 9 5.22 3.19 1.06
The age distribution is similar for the two groups (mean age of 65.3 years for 
Group A and 65.7 years for Group B). Differences between the four mean scores 
are not statistically significant at the 5% level but there is a trend for the 
scores to be greater in group B, than in group A, and a trend for the score to 
increase with age, but neither of these were very pronounced.
DISCUSSION
Whilst it is generally accepted that tardive dyskinesia occurs as a result 
of long-term antipsychotic medication there is evidence to suggest that the 
disorder can occur in persons who have never received these compounds.
Naturally occurring involuntary movements might be diagnosed as tardive 
dyskinesia and this might explain the unusually high prevalence of the disorder 
in some studies of drug and non-drug treated patients.^ Over enthusiasm about 
diagnosing tardive dyskinesia has been suggested as a reason for mistaking other 
types of unusual motor activity for this condition.^
Whilst the results presented here point to a high prevalence rate in elderly
18female patients they are comparable with figures obtained by Jus et al. who, 
with careful screening, eliminated abnormal movements found in other neuro­
logical disorders, and showed a prevalence rate of 60% in the 50 to 69 years
age group, and in those of 70 years and above the rate had risen to 75.6%. The
prevalence rate in this study was 77.3% in the 50 to 69 years age group, and
80% in the 70 years and above group.
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Within its limitations this present study has shown a level of dyskinesia in
patients who have never received antipsychotic medication that is not
significantly different to that of a small group who have received antipsychotic
medication over a period of several years. Of the nine patients who had
received antipsychotic medication the two showing the highest dyskinetic
movements (Score = 9), were receiving haloperidol, whereas those receiving
thioridazine produced lower scores. In fact, in the treated group, the two
showing the least dyskinetic movements (Scores 2 and 1) were from patients who
had received thioridazine for 7 years and 17 years respectively. In animal
model experiments, it has been shown that thioridazine induced an increase in
dopamine-receptor sensitivity which was significantly less intense and of
19shorter duration than that induced by haloperidol, and the observation made 
that the tendency of a drug to increase dopamine-receptor sensitivity has been 
related to its propensity to induce tardive dyskinesia in man, and on this 
basis it may be expected that tardive dyskinesia following treatment with 
thioridazine will be rare and less intense than those seen after classical 
neuroleptics.
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ABNORMAL INVOLUNTARY MOVEMENTS 
IN THE ELDERLY
D ear  Sir ,
Following an earlier pilot study in elderly patients in 
a mental handicap hospital (Bicknell and Blowers, 
1980), we have recently carried out a prevalence study 
of abnormal involuntary movements in 12 local 
authority residential homes for the elderly. A total of 
500 subjects, 138 males and 362 females were in­
cluded in the study. They were rated individually for 
abnormal movements using a modification of the 
A IM S examination (N IM H , 1975).
Abnormal involuntary movements were observed in 
179 (35.8 per cent) of the 500 subjects. These move­
ments were mostly mild in severity, but orofacial 
involvement was present in 140 (28 per cent).
In  the 122 (24.4 per cent) subjects who had re­
ceived antipsychotic drugs for a minimum period of 
three months, abnormal involuntary movements were 
present in 59 (48.4 per cent), and in the 378 (75.6 per 
cent) subjects who had no recorded history of anti­
psychotic medication, abnormal movements were 
present in 120 (31.7 per cent). The Chi square test 
(Kirkwood, 1981), indicated that the difference in 
prevalence o f abnormal movements between subjects 
who had received antipsychotics and those who had 
never been exposed to these compounds, was stat­
istically significant (P <0.001), thus confirming the 
association of dyskinetic movements with anti­
psychotic medication.
The presence of spontaneous dyskinesia in 120 
(31.7 per cent) of the 378 subjects who had never 
received antipsychotic medication confirms an earlier 
study in which 38 (18 per cent) of 211 residents who 
had never been treated with an antipsychotic drug 
showed dyskinetic movements (Bourgeois et al, 1980).
The Task Force of the American Psychiatric Asso­
ciation (1980) reporting on late neurological effects of 
antipsychotic drugs suggested that the ageing brain 
may have an increased likelihood of antipsychotic 
related dyskinesias, especially of the oral region, and 
also drew attention to the fact that in the elderly, 
studies had shown that the prevalence of spontaneous 
buccolinguomasticatory movement abnormalities, is 
close to that found in antipsychotic treated geriatric 
patients.
Our own study has shown that in a group of elderly 
subjects, age range 59-102 years (mean 82.7 years) 
there is a considerable prevalence of spontaneous
dyskinesias, and that antipsychotic drugs do seem to 
increase the risk of developing dyskinesias during old 
age.
A. J. B lo w e rs  
Department o f Human Biology and Health,
University o f  Surrey, Guildford, Surrey
R. L. B orison
Medical College o f Georgia,
Atlanta, Georgia, USA
C. M . B lo w e rs
Maudsley Hospital, London SE5
D. J. B ic k n e l l
St George's Hospital, London S W 17 
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N e w s  a n d  V ie w s
Abnormal orofacial movements
A bnormal involuntary move­
ments, particularly in the orofacial 
region, are not uncommon in the 
elderly, and a visit to the day room 
of any home for the elderly will 
soon confirm this.
Spontaneous lingual-facial- 
buccal movements
The syndrome of spontaneous 
lingual-facial-buccal movements is 
characterised by uncontrolled 
movements of the tongue, lower 
facial (oral or buccal) muscles, and 
the jaw or masticatory muscles. The 
tongue may exhibit a choreo- 
athetoid or writhing movement, 
readily observed when the mouth is 
open, and it may be thrust out in 
either a fly-catcher movement or 
complete protraction. Lip move­
ments include smacking, pouting, 
and puckering, and eye movements 
such as excessive blinking or ble­
pharospasm may occur.
The pathophysiology of spon­
taneous lingual-facial-buccal dys­
kinesia is suggested by Weiner and 
Klawans (Journal o f  the American 
Geriatrics Society, 1973, X X I ,  
314-320) as being related to altered 
responsiveness of dopamine recep­
tor sites.
Tardive dyskinesia
Reports of persistent abnormal
Fig 1: A technique 
used for detecting 
abnormal 
movements, 
which may 
disappear under 
stress, is to 
distract the 
patient by asking 
her to look at 
pictures of 
animals and recall 
at least three 
species after the 
pictures have been 
removed. This 
will unmask them
involuntary movements associated 
with long-term treatment with anti­
psychotic medication began to 
appear in the 1950s. The dyskinetic 
movements are similar to those of 
the spontaneous syndrome, and the 
main area of involvement is the 
orofacial region. Numerous studies 
have shown a prevalence of the 
disorder ranging from 0-5 per cent 
to 56 per cent in patients treated 
with prolonged antipsychotic medi­
cation, and there is evidence to 
suggest that the movements occur
with increasing frequency with age.
A recent study undertaken by the 
author (not yet published) has 
shown that in 500 subjects who 
were resident or receiving day care 
in homes for the elderly, abnormal 
involuntary m ovements were 
present in 179 (36 per cent). In the 
122 subjects who had a history of 
antipsychotic medication 59 (48 per 
cent) had dyskinetic movements, 
and in the 378 subjects who had 
never received antipsychotic medi­
cation 120 (32 per cent) had 
dyskinetic movements. Orofacial 
involvement was present in ap­
proximately 80 per cent of those 
who had dyskinesia, whether spon­
taneous or in association with anti­
psychotic drugs.
Treatment
Most of the orofacial dyskinesias 
seen in the above study were mild, 
and the subjects were unaware of 
the presence of the movements. 
Treatment is probably inappro­
priate and, in any case, likely to be 
ineffective.
In a leading article (British Medi­
cal Journal, 1981, 282, 1257-1258) 
reference was made to the fact that 
many remedies have been tried in 
treating tardive dyskinesia, but I 
none is effective. Promising results 
in uncontrolled studies have not 
been confirmed under double­
blind conditions. Increasing the 
dosage of antipsychotic drugs only 
postpones the risk, since further, 
and perhaps more, severe dys­
kinesia may develop later. Anti­
cholinergic drugs will exacerbate 
established tardive dyskinesia, and 
their long-term use for controlling 
drug-induced parkinsonism should 
be avoided.
Prophylaxis
Preventive measures, such as 
using antipsychotic drugs only 
when clearly indicated, and using 
the lowest effective daily dosage, 
will minimise the incidence of tar­
dive dyskinesia. There appears to
be a relationship between drug- 
induced parkinsonism and tardive 
dyskinesia, and Klawans, Goetz, 
and Perlik (American Journal o j 
Psychiatry, 1980, 137, 900-908) 
suggest the use of thioridazine 
because it has the lowest incidence 
of drug-induced parkinsonism, and 
is also a much weaker blocker of 
striatal dopamine receptors than 
other antipsychotics.
Following drug withdrawal the 
syndrome temporarily worsens, 
presumably because of the better 
access of dopamine to striatal re­
ceptors, but after a few weeks it will 
diminish. In the elderly both spon­
taneous dyskinesias and drug- 
induced dyskinesias are more com­
mon and the irreversibility of the 
latter is less likely, possibly due to 
degenerative changes in the basal 
ganglia of the brain. It now seems 
generally accepted that antipsy­
chotic drugs should only be used 
when clearly indicated and the daily 
dosage kept as low as possible. 
Early detection of tardive dys­
kinesia is important and medica­
tion should be withdrawn if poss­
ible.
A  J Blowers 
Dept Hum an Biology and Health 
University o f Surrey
Table 1: Severity of abnormal involuntary movements 
with antipsychotic medication
Antipsychotic Number of Dyskinetic m ean
compound patients score
Two or more compounds 31 3-55
Trifluoperazine + tranylcypromine 1 3-00
Trifluoperazine 4 2-75
Promazine 17 2-15
Flupenthixol 2 1-50
Perphenazine + amitriptyline 4 1-50
Chlorpromazine 27 1-06
Fluphenazine + nortriptyline 2 1-00
Prochlorperazine 18 0-64
Thioridazine 13 0-27
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EPIDEMIOLOGY OF TARDIVE DYSKINESIA 
IN THE ELDERLY
A. J. B lo w e rs
D epartm ent of H um an Biology and H ealth , U niversity  of Surrey,
G uildford, Surrey. England.
Sum m ary— In a study of 500 subjects in residential hom es for the elderly, abnorm al involuntary  m ove­
m ents were found in 35.8%. In those subjects w ho had  received an tipsychotic m edication 48.4% had 
dyskinetic m ovem ents, and  in those w ho had  never received antipsychotic  m edication 31.7% had dyski- 
netic m ovem ents. The difference in prevalence o f m ovem ents was statistically  significant.
Analysis o f d a ta  follow ing the exam ination  o f d rug  h istories o f pa tien ts receiving antipsychotic m edi- 
cation  for a m inim um  period  of 3 m onths, suggested th a t those w ho had received th io ridazine were least 
likely to  develop tard ive dyskinesia.
Problem s in conducting  and  in terpreting  results o f epidem iological studies are  discussed.
Since the first reports of abnormal involuntary per­
sistent movements, often of a lingual-facial-buccal 
nature, began to appear (Ey, Faure and Rappard, 
1956; Hall, Jackson and Swain, 1956; Schonecker, 
1957) numerous prevalence studies have been under­
taken. Klawans, Goetz and Perlik (1980) in reviewing 
some of these studies, observed that the prevalence of 
tardive dyskinesia ranged from 0.5 to 56% of patients 
treated with prolonged antipsychotic medication.
A number of studies have shown that involuntary 
movements similar to tardive dyskinesia have been 
observed in elderly subjects who have never been 
exposed to antipsychotic medication (Crane and 
Smeets, 1974; Bourgeois, Bouilh, Tignol and Yesa- 
vage, 1980; Blowers and Bicknell, 1980). A prelimi­
nary report of a study of 500 subjects in residential 
homes for the elderly indicated a prevalence rate of 
dyskinetic movements of 35.8% (Blowers, Borison, 
Blowers and Bicknell, unpublished).
This paper presents further details of the prevalence 
study (Blowers et al., unpublished) and considers the 
problems in conducting and interpreting results of 
epidemiological studies of tardive dyskinesia in the 
elderly.
METHODS
V
Five hundred subjects, 138 males and 362 females, 
who were resident or receiving day care in homes for 
the elderly were included in the study. Ages ranged 
from 59 to 102 years with a mean of 82.7 years. The 
subjects were examined individually for abnormal 
involuntary movements using a modified A.I.M.S. 
examination (National Institute of Mental Health, 
1975), and these movements were rated on the Rock­
land Dyskinesia Scale (Simpson, Lee, Zoubok and 
Gardos, 1979). Medical and drug histories were also 
recorded.
RESULTS
Abnormal involuntary movements mostly mild in 
severity were observed in 179 (36%) of the 500 sub­
jects included in the study. In the 122 subjects who 
had a history of antipsychotic medication 59 (48%) 
had dyskinetic movements, and in the 378 subjects 
who had never received antipsychotic medication 120 
(32%) had dyskinetic movements.
In the 59 subjects in the antipsychotic treated 
group who had dyskinetic movements, orofacial in­
volvement was observed in 48 (81%), and in the 120 
subjects who had no history of antipsychotic drugs, 
92 (77%) had orofacial dyskinetic movements. In both 
groups choreoathetoid tongue movements were most 
frequently observed, and the individual orofacial 
movements are shown in Table 1.
Whilst the majority of subjects in the study were 
showing only mild dyskinesia, in the antipsychotic- 
treated group, 12 of 122 subjects had total dyskinetic 
scores of between 5 and 9, and 3 subjects had total 
scores in excess of 10. In the group who had not been 
exposed to antipsychotic medication, 7 of 378 had
Table 1. R ockland scale orofacial m ovem ents in an tip sy ­
chotic and  non-antipsychotic  treated  subjects
A ntipsychotic N on-an tip sycho tic  
treated  (122) trea ted  (378) 
Rockland item n % n %
O ne or m ore 
orofacial m ovem ent 
C horeoatheto id  
tongue m ovem ents 
Lip m ovem ents 
Chewing m ovem ents 
T ongue pro trusion  
Periocular 
m ovem ents 
Bonbon sign
48 39.3 92 24.3
30 24.6 44 11.6
20 16.4 25 6.6
18 14.8 27 7.1
8 6.6 16 4.2
8 6.6 9 2.4
4 3.3 8 2.1
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total dyskinetic scores of between 5 and 9, and 3 had 
scores in excess of 10.
Analysis of antipsychotic drug history has shown 
that of the 91 subjects who had received only one 
compound, the 13 who had received thioridazine had 
the lowest dyskinetic scores. In the thioridazine 
group, 10 of 13 subjects had no dyskinetic move­
ments.
DISCUSSION
In an overview of the changing epidemiology of 
tardive dyskinesia, Jeste and Wyatt (1981) referred to 
the reported rising prevalence among patients treated 
with antipsychotics. They also suggested that epide­
miological studies of drug-induced tardive dyskinesias 
should be complemented by similar work on spon­
taneously occurring dyskinesias to show that the risk 
of drug-induced illness is significantly greater than the 
baseline risk of developing dyskinesia. The present 
study in 12 homes for the elderly was conducted 
under conditions where information on drug treat­
ment was not known until after all of the residents of 
each home had been rated for dyskinetic movements. 
The Chi Square test (Kirkwood, 1981) indicated that 
the difference in prevalence of dyskinesias between 
subjects who had received antipsychotic drugs and 
those who had never been exposed to these com­
pounds was statistically significant (P <  0.001). The 
lower proportion of patients with dyskinesia in the 
study not treated with antipsychotics thus further 
confirms the relationship between tardive dyskinesia 
and antipsychotic medication, and this association 
has been strongly supported (Baldessarini, 1974).
It is suggested that some of the epidemiological 
studies that have reported a high prevalence of tar­
dive dyskinesia may reflect an increasing sensitivity to 
minor degrees of possible movement abnormality 
(Task Force, 1980). Methodological differences in­
clude diagnostic criteria, severity of dyskinesia and 
type of dyskinesia, and account for the wide vari­
ations in prevalence rates (Jeste and Wyatt, 1981)
In an earlier study (Blowers and Bicknell, 1980), 
dyskinesias seen in patients treated with thioridazine 
were less frequent and of lower severity than those 
seen in patients treated with haloperidol. The absence 
of dyskinesia in 10 of the 13 subjects who had 
received thioridazine in the current study comple­
ments results obtained from animal studies, in which 
it has been shown that the dopamine receptor sensi­
tivity produced by thioridazine is significantly less 
intense and of shorter duration than that produced by
haloperidol (Sayers, Biirki, Ruch and Asper, 1977) 
and by haloperidol and fluphenazine (Borison and 
Blowers, 1981)
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BRIEF C O M M U N IC A T IO N
Co-dergocrine (Hydergine) in the treatment of tardive dyskinesia
S U D H IR  C. R A S T O G I,1 A N T H O N Y  J. B L O W E R S 2 a n d  A L A N  C. G IB S O N 3 
From Herrison Hospital, Dorchester, Dorset
s y n o p s i s  In a double-blind, placebo-controlled study with co-dergocrine in the treatment of 
tardive dyskinesia in a group of elderly chronic psychiatric patients the reduction of dyskinetic scores 
in the group receiving active medication was slightly greater than that in the placebo group; however, 
this difference did not reach a level of statistical significance. It is suggested that further work could 
be undertaken with a longer period of treatment, and at a higher dosage level of co-dergocrine, in
a younger patient sample.
INTRODUCTION
Since reports of tardive dyskinesia associated 
with antipsychotic drugs first appeared (Ey et al. 
1956; Hall et al. 1956; Schonecker, 1957), many 
drugs have been suggested for its treatment. To 
date, no generally satisfactory treatment has 
been demonstrated (Mackay et al. 1980).
The ergot derivative co-dergocrine appears to 
play a role in cerebral synaptic transmission and 
has been shown in vitro to displace dopamine 
and haloperidol from their specific binding sites 
in the caudate nucleus (Goldstein et al. 1978), 
and in vivo to produce an acceleration of 
noradrenaline turnover and a slowing of dop­
amine and serotonin brain turnover, suggesting 
noradrenaline antagonism, dopamine agonism 
and serotonin antagonism (Loew et al. 1979).
While it might be expected that dopamine 
agonists would markedly exacerbate tardive 
dyskinesia, it has been shown that apomorphine 
actually reduced dyskinetic movements (Smith et 
al. 1977). It has been postulated that a low dose 
of the dopamine agonist, bromocriptine, may 
lead to predominant stimulation of the pre- 
synaptic inhibitory dopaminergic receptor, thus
1 Present address: Department of Psychiatry, University of 
Southampton, Royal South Hants Hospital, Southampton.
2 Present address: Department of Human Biology and Health, 
University of Surrey, Guildford, Surrey. Address for correspon­
dence: Dr Anthony J. Blowers, Chevron, Mayfield Avenue, New 
Haw, Weybridge, Surrey.
3 Present address: St Ann’s Hospital, Canford Cliffs, Poole, 
Dorset.
reducing pre-synaptic dopamine release (Barnes 
et al. 1978). It was felt that the dopamine agonist 
effect of co-dergocrine merited study in the 
treatment of tardive dyskinesia.
Results from uncontrolled studies with co- 
dergocrine in the treatment of tardive dyskinesia 
have been promising (Gomez, 1977; Hajioff, 
1978), and the present study was undertaken to 
evaluate the compound under double-blind 
conditions.
METHOD 
Clinical population
Forty chronic in-patients (17 male and 23 
female) were included in the study. The following 
criteria for admission were established: (1) the 
presence of persistent involuntary movements 
predominately in the orofacial region and 
unrelated to idiopathic or drug-induced Parkin­
sonian movements; (2) movements had been 
present for at least 1 year and were considered 
to have resulted from antipsychotic drug 
administration; (3) antipsychotic drug treatment 
had lasted for a period of at least 1 year. Of the 
40 patients selected, case-note diagnoses were: 
schizophrenia (29), dementia (5), depressive 
psychosis (3), oligophrenia (2), bipolar affective 
psychosis (1). The mean age was 69-9 years 
(range 41-91) and the median period of 
psychiatric hospitalization was 26-7 years (range
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Table 1. Comparison o f groups and treatments
Active Placebo Overall means
Mean age ( ± s.e.) 69-7 ( +  21) 70 0 (±2-6) 69-9
Male/female 7/12 11/10 18/22
Mean pre-drug
score ( ± s.e.) 101 (+1-1) 8-7 (±0-7) 9-4
Number in group 19 21 -
Reduction of scores
pre -» first 6 weeks 3-79 2-48 310
Standard error 0-92 0-95 -
Reduction of scores
pre -► second 6 weeks 4-37 3-14 3-72
Standard error 0-95 0-82 -
1-55). All patients had been treated with a 
variety of antipsychotic drugs (mean 3-8 
compounds) during their psychiatric care. Back­
ground antipsychotic and antiparkinsonian 
medication was held constant throughout the 
study.
Informed consent was obtained from patients 
participating in the study and approved by the 
patient’s psychiatric consultant.
Study design
A double-blind, placebo-controlled parallel 
group procedure was used. Patients were 
randomly allocated to two groups, one of which 
received co-dergocrine, 4-5 mg tablets once daily 
for 6 weeks, and the other received an identical 
placebo tablet for the same period. The 2 raters, 
ward staff and patients were blind to the 
treatment procedure.
Rating procedures
Patients were examined individually under 
standard conditions, at approximately the same 
time of day, by 2 raters using the AIMS 
examination (NIMH, 1975) combined with the 
abbreviated Rockland Tardive Dyskinesia 
Rating Scale (Simpson et al. 1979). Ratings were 
carried out prior to entry into the study, at the 
conclusion of the 6-week drug treatment period, 
and again at 6 weeks after completion of the drug 
treatment period to observe any possible 
carry-over effect.
Statistical analysis
Due to the random allocation of patients to the 
2 groups it was necessary to ascertain the 
importance of sex ratio, mean age and pre­
treatment scores between the 2 groups. This was
obtained by using generalized linear models 
(Nelder & Wedderburn, 1972) to perform the 
analysis on decreases in scores over the study 
period.
RESULTS
The decreases in the scores of dyskinetic 
movements were obtained after the 6-week 
medication period in both the group receiving 
active medication and the placebo group. The 
improvement in the active treatment group was 
reflected in a mean reduction of 3-79 from the 
pre-treatment mean score of 10*1 (±  1-1). In the 
placebo group the mean reduction was 2-48 from 
a pre-treatment mean score of 8-7 (±0-7). At the 
end of the further 6-week period following the 
drug treatment phase, a small additional im­
provement in mean scores was seen in the co- 
dergocrine group of 0-58 and in the placebo 
group of 0-66. The comparability of the groups 
and of treatments is shown in Table 1. Both 
results indicated that there were no sex differences 
present in the data. However, the use of the 
pre-drug score as a covariate indicates that it has 
a significant effect in both cases: thus, the higher 
the pre-drug score, the greater the improvement 
in scores between (1) pre-drug and after week 6, 
and (2) pre-drug and after week 12. A significant 
effect was also noted when age was used as a 
second covariate (P <  0-01 for pre-drug and 
after week 6, and P <  0 05 for pre-drug and after 
week 12), indicating that the improvement in 
scores is reduced as age increases. The reduction 
in scores in the active group was slightly higher 
than the placebo group for both periods, but this 
did not reach a level of statistical significance.
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In reviewing all the studies on antipsychotic 
drug-induced tardive dyskinesia published in the 
English literature up until August 1978, Jeste & 
Wyatt (1979) observed that there is, as yet, no 
single satisfactory method of treating the 
disorder, and that, until recently, most of the 
treatment studies were conducted on a small 
number of patients and were uncontrolled. This 
observation has been further emphasized by 
others (Committee on Safety of Medicines, 1979; 
Mackay et al. 1980). The present study has 
shown that, under double-blind conditions, 
improvement in tardive dyskinesia did not reach 
a level of significance between co-dergocrine and 
placebo. The patient sample in this study1 
included a high proportion of chronic schizo­
phrenics who had been in institutional care for 
many years. Of the 40 patients in the study, 35 
had been in psychiatric hospitals for more than 
10 years and 24 for more than 20 years. 
Thirty-three patients had been treated with 3 or 
more different antipsychotic agents during their 
illness, and 38 had been prescribed one or more 
antiparkinsonian drugs. Ten patients had been 
previously treated unsuccessfully with tetrabena- 
zine and/or sodium valproate for their tardive 
dyskinesia. In addition, 25 patients were over the 
age of 70, and it would seem unlikely that any 
drug would produce improvement in a group 
where tardive dyskinesia was probably 
irreversible.
In this study a'daily dosage of 4-5 mg of 
co-dergocrine was employed. A preliminary 
report of a further double-blind study, in which 
a daily dose of 6 mg of co-dergocrine was used, 
showed an impressive trend in the effect of 
co-dergocrine over placebo in the analysis of 
results in the first 8 patients who had completed 
the trial (Chien et al. 1980).
Further studies with a longer period of treat­
ment and at a higher dosage level in a younger 
patient sample should be undertaken.
We wish to express our gratitude to the doctors, nurses 
and pharmacists at Herrison Hospital for their kind 
cooperation; to M r P. Jones for the statistical 
analysis; and to Mrs R. Trumper for the preparation 
of the manuscript.
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PUBLIC HEALTH ISSUES REGARDING EXTR APYR AM I DAL SIDE EFFECTS
1. Dystonic reactions are distressing to patients and account for a large non-compliance rate in taking 
antipsychotic medication.
2. Dystonic reactions involving the laryngeal muscles produce laryngospasm which can be life 
threatening.
3. Drug-induced parkinsonism occurs in a high percentage of patients receiving piperazine 
phenothiazines or butyrophenones. The diagnosis is often missed because akinesia/bradykinesia is'the 
most common parkinsonian sign, and tremors are relatively uncommon.
4. Patients with drug-induced parkinsonism are more prone to injury by falling and food aspiration due to 
swallowing difficulties.
5. Patients with the bradykinesia of drug-induced parkinsonism are often misdiagnosed as being 
depressed (postpsychotic depression) or catatonic.
6. Akathisia is experienced as the most discomforting side effect from antipsychotic medication, and 
results in poor compliance with taking medication.
7. Drug-induced akathisia may precipitate violent behavior in patients, and may appear to worsen the 
patient’s psychosis.
8. The use of antiparkinsonian anticholinergic drugs to treat acute extrapyramidal side effects is often 
associated with an antagonism of antipsychotic action.
9. Antiparkinsonian anticholinergic drugs may promote the induction of tardive dyskinesia, and are 
commonly used as street drugs of abuse.
10. Chronic antipsychotic drug use may result in tardive dyskinesia occuring in 24-56% of patients.
11. Tardive dyskinesia is reversible in its early stages, but often becomes irreversible while being 
masked by antipsychotic medication.
12. Tardive dyskinesia can lead to life threatening respiratory and gastrointestinal complications.
13. Gait disturbances leading to falling and injury, as well as swallowing difficulties may occur as a result 
of tardive dyskinesia.
14. Tardive dyskinesia may decrease life expectancy.
PURPOSE
To determine whether antipsychotic drugs have a differential effect on the neurochemistry and functions 
of various brain areas. These effects on various brain areas account for differentiation of the side effect 
profile of various antipsychotic drugs.
METHOD
In order to demonstrate a site-specific action for various antipsychotic agents, we have conducted both 
human and animal studies. If atypical neuroleptics truly have a specific action on the limbic rather than the 
striatal dopamine receptors they should then be unable to produce a striatal dopamine receptor 
denervation hypersensitivity which occurs secondary to receptor blockade in the corpus striatum.
ANIMAL STUDIES
The behavioral effects of various antipsycotic drugs on dopamine receptor blockade was measured after 
their direct injection into discrete dopamine containing brain areas of the extrapyramidal and limbic 
systems.
□  Comparison of various antipsychotic drugs in their abilities to produce a dopamine 
receptor hypersensitivity as assessed by the preclinical model for tardive dyskinesia.
□  White male Sprague-Dawley rats were used in an animal paradigm for tardive 
dyskinesia (Tarsy and Baldessarini 1973).(32)
□  In this model animals received daily chronic administration of an antipsychotic drug 
over a 3 week period after which the animals then received daily saline injections over five 
days.
□  To assess dopamine receptor sensitization, animals were challenged with a direct 
dopamine agonist (i.e. apomorphine) in a dose which per se fails to produce behavioral 
activation.
HUMAN STUDIES
Dopamine receptor blockade in the human limbic and extrapyramidal systems assessed by radio-receptor 
assay.
□  In biochemical tests, human brain material was collected within 6 hours of death and 
areas from the limbic system including the nucleus accumbens, olfactory tubercle and 
extrapyramidal system including caudate nucleus, putamen were dissected.
□  Tissues were homogenized and prepared in a sodium phosphate buffer. Receptor 
ligand binding was carried out using (3H) spiroperidoi (Field, Reisine and Yamamura,
1977)(13) and specific binding was ascertained using butaclamol.
Preclinical model for extrapyramidal system function
The stereotyped (repetitive purposeless movements) behavior demonstrated by a rat has been used as 
an animal model for tardive dyskinesia. This behavior can be induced by chronic treatment with 
antipsychotic drugs, and like tardive dyskinesia in many animals with stereotyped behavior shows 
evidence in their extrapyramidal systems of having hypersensitive dopamine receptors.
Haloperidol and extrapyramidal dopamine receptor hypersensitivity
□  Saline
□  Haloperidol, 0.5 mg/kg
3 7 14
Days After Withdrawal
The effects of haloperidol on stereotyped behavior in rats can be observed. Animals were chronically 
treated with haloperidol, treatment was discontinued, and extrapyramidal dopamine receptor 
hypersensitivity was assessed. As can be seen, at three and seven days after stopping haloperidol 
treatment, there is a significant sensitization of dopamine receptors, as measured by stereotyped 
behavior. This hypersensitivity has normalized after fourteen days.
* p < .0 0 5  * *p < .0 0 1
Haloperidol and extrapyramidal dopamine receptor hypersensitivity at higher doses
® □  Saline
H  Haloperidol, 1 mg/kg
3 7 14
Days After Withdrawal
When the experiment was repeated with a somewhat higher dose of haloperidol, the behavioral sensitivity 
has increased in both duration and intensity.
Fluphenazine and extrapyramidal dopamine hypersensitivity
□  Saline
□  Fluphenazine. 2 mg/kg
9 14
Day» After Withdrawal
A similar response is elicited when animals have been treated with fluphenazine hydrochloride. We again 
see evidence of an extrapyramidal dopamine receptor hypersensitivity which mimics that found in patients 
with tardive, dyskinesia.
Thioridazine and extrapyramidal dopamine hypersensitivity
□  Saline
El Thioridazine. 10mgAg
Days After Withdrawal
Although thioridazine is also capable of producing a sensitivity response of dopamine receptors, it is very 
short lived. Antipsychotic drugs with potent clinical extrapyramidal side effects, such as fluphenazine and 
haloperidol, produce a longer duration of receptor sensitization when compared with thioridazine. This 
suggests that with some antipsychotic drugs there may be difficulty in reversing long term extrapyramidal 
effects.
Blockade of dopamine action in the limbic system by antipsychotic drugs
100-
Sulpiride
Clozapine
Thioridazine
Chlorpromazine
10 -
Thiothixine 
Perphenazine V
Trifluoperazine
/ • —  Haloperidol 
-•—  Fluphenazine
Pimozide
10010 1000
Rand and Average Clinical Dose for Antipsychotic Effect, mg/day
The ability of a dose of systemically administered antipsychotic drug to block the behavioral activity 
induced by the direct (bilateral) administration of dopamine into the limbic system (nucleus accumbens) of 
rat brain was plotted. These results have been compared with the daily effective antipsychotic dose of 
each drug. We see that there is a linear relationship, demonstrating that the antipsychotic actions of these 
drugs is related to their abilities to block dopamine in the limbic system.
Blockade of dopamine’s action in the extrapyramidal system by antipsychotic drugs
Sulpiride
Clozapine
Chlorpromazine
Thiothixine
PerphenazineTrifluoperazine
Haloperidol
Fluphenazine
Pimozide
1 10 100 
Rand and Average Clinical Dose for Antipsychotic Effect, mg/day
In this figure we have plotted the ability of a dose of systemically administered antipsychotic drug to block 
the behavioral activity induced by the direct (bilateral) administration of dopamine into the striatum 
(caudate-putamen nucleus) of the rat brain. These results have again been compared with the daily 
effective antipsychotic dose of each drug. A linear relationship for the majority of antipsychotic drugs was 
found, however, thioridazine, clozapine, and sulpiride, all fall to the left of the line. This demonstrates that 
these three antipsychotic drugs have much less potent effects in blocking dopamine receptors in the 
extrapyramidal system Furthermore, this demonstrates that the therapeutic antipsychotic effects of these 
drugs is not correlated to their ability to produce extrapyramidal side effects.
Comparison of extrapyramidal and limbic systems actions
caused by antipsychotic drugs in the rat brain
Extrapyramidal
Preference
•  Fluphenazine 
•
Haloperidol
•
Trifluoperazine
•  Perphenazine 
•  Thiothixine
•  Pimozide •  Chlorpromazine
•  Thioridazine
•  Sulpiride
#  Clozapine
Low
Extrapyramidal
IC50 Limbic
This figure compares the ability of antipsychotic drugs, in the rat, to block the actions of dopamine in the 
striatum or extrapyramidal system, and in the limbic system. Those drugs which fall into the upper lefthand 
corner are those drugs which are more potent in the blocking extrapyramidal rather than limbic dopamine 
receptors. Those drugs which fall into the lower right hand corner, are those compounds which are more 
potent in blocking dopamine in the limbic rather than extrapyramidal system.
Direct measurement of dopamine receptor blockade in the rat brain
3H-Spiroperidol Binding to Rat Brain Regions 
IC50 (nM)
IC50 Limbic
Olfactory Tubercle Nucleus Accumbens Caudate-Putamen IC50 Striatal
Qozapine 16 240 537 0.03,0.45
Thioridazine 20 17 50 0.40,0.34
Haloperidol 1000 80 59 59.0,1.36
IC50 Limbic/ICso Striatal:
Values less than 1 indicate a preferential binding to receptors in the limbic structures
The striatum (caudate-putamen nucleus), and part of the limbic system (olfactory tubercle and nucleus 
accumbens) was dissected from the rat brain. In receptor binding studies, using radioactivespiroperidol, a 
butyrophenone antipsychotic drug, we have measured the effects of clozapine, thioridazine, and 
haloperidol in blocking extrapyramidal and limbic dopamine receptors. The IC50 refers to the dose of drug 
needed to displace 50% of the binding of radioactive spiroperidol to the dopamine receptor. The units are 
in nanomolar concentration, which is believed to be the antipsychotic drug concentration in the brain that 
produces an antipsychotic effect. The lower the number, the more potent a drug is in blocking dopamine 
receptors. We have in the far right column compared the ICso’s of these drugs in their abilities to block 
dopamine in the limbic and extrapyramidal systems. Those values smaller than one, indicate a preference 
for blocking dopamine receptors in the limbic system. As can be seen, both clozapine and thioridazine 
produce a selective blockade of dopamine receptors in the limbic system, whereas haloperidol produces 
a preferential blockade of dopamine receptors in the striatum.
Site of action preference of antipsychotic drugs in the rat brain
ICso Limbic 
IC50 Striatal
2 - i
Preference for 
Blockade of 
Extrapyramidal 
Dopamine Receptors
Preference for 
Blockade of 
Limbic 
Dopamine Receptors
- 1-
- 2 -
Bars falling above the line indicate a preference for blocking dopamine receptors in the extrapyramidal 
system, while those bars falling below the line indicate a preference for blockade of limbic dopamine 
receptors. These results are therefore correlated with the ability of an antipsychotic drug to produce 
extrapyramidal side effects.
Direct measurement of dopamine receptor blockade in the human extrapyramidal system
Antipsychotic Drug Binding to Human Nucleus Accumbens
IC 50
Clozapine
Thioridazine
Haloperidol
Butaclamol
" T "
1.0
T
10 100
I
1000 mg0.1
Average Clinical Dose
The effect of four antipsychotic drugs to block dopamine receptors in the human caudate nucleus, which 
is an integral part of the extrapyramidal system is examined. The IC50 and y-axis again refers to the 
concentration of antipsychotic drug necessary to block 50% of the dopamine receptors (as assayed by 
displacement of radioactive spiroperidol). On the x-axis we see the average daily clinically effective 
antipsychotic dose of drugs. This graph demonstrates that butaclamol, an antipsychotic chemically 
related to haloperidol, and haloperidol, are very potent blockers of dopamine receptors in the human 
caudate nucleus. In contrast, clozapine, an antipsychotic drug formerly used in Europe, which never 
produced an extrapyramidal side effect, including tardive dyskinesia, and thioridazine, are weak blockers 
of dopamine receptors in the extrapyramidal system of the human brain.
Direct measurement of dopamine receptor blockade in the human limbic system
ICk) Antipsychotic Drug Binding to Human Caudate
10"6
1CT7
0.1 1.0 10 100 1000mg
Average Clinical Dose
The actions of the previous four drugs in their ability to block dopamine receptors in nucleus accumbens 
of the human brain obtained at autopsy can be seen. The nucleus accumbens is a part of the human limbic 
system. As compared with the previous figure, and almost straight-line relationship between these four 
drugs can be observed. This indicates that these drugs are all almost equally active in their abilities to 
block dopamine receptors in the human limbic system. Therefore, this shows that these drugs are all 
equally potent as dopamine receptor blockers in that area of the human brain where they produce an 
antipsychotic effect. Differences between these four drugs in total milligram dose administered to achieve 
an antipsychotic effect in man is NOT related to their potencies in blocking dopamine receptors in the 
limbic system but most likely due to differences in drug metabolism and distribution.
Clozapine
Haloperidol
Thioridazine
Butaclamol
Comparison of extrapyramidal system actions caused by
antipsychotic drugs in the human brain vs limbic system actions
Ratio Between 
Striatal vs. Limbic 
Dopamine Receptor Blockade 
in Human Brain 
on Autopsy
ZZHZIZIIZZ
Clozapine
These bar graphs represent the relationship of butaclamol, haloperidol, thioridazine, and closapine, in 
their abilities to block dopamine receptors in the human extrapyramidal and limbic systems. The higher a 
bar is, the more potent the drug is in its actions in blocking extrapyramidal rather than limbic dopamine 
receptors. These results show that haloperidol has the greatest activity in prefering extrapyramidal 
dopamine receptors, whereas clozapine is the least potent in this regard. This data correlates excellently 
with the fact that haloperidol and butaclamol produce many extrapyramidal side effects, whereas 
clozapine and thioridazine produce few or no extrapyramidal side effects.
Comparison of limbic system actions vs extrapyramidal actions
caused by antipsychotic drugs in the human brain
Ratio Between 
Limbic vs. Striatai 
Dopamine Receptor Blockade 
in Human Brain 
on Autopsy
Fluphenazine
Haloperidol
    -
Thioridazine : _
30 4515 60 75 900
We have taken the same data, and now represented it as the preference of an antipsychotic drug to block 
limbic system, rather than extrapyramidal system dopamine receptors. We again see that thioridazine and 
clozapine are the most potent in this regard; demonstrating that they are potent antipsychotic drugs with 
few extrapyramidal side effects. Furthermore, our dopamine receptor studies in the human brain 
demonstrate that the lack of extrapyramidal side effects is correlated to a poor blockade of dopamine 
receptors in the extrapyramidal system, and is independent of any anticholinergic properties of any of 
these compounds, as the addition of benztropine (Cogentin) fails to affect dopamine receptor binding.
The ‘Atypical’ Antipsychotic Drugs
On the feature of dopamine supersensitivity that must be considered in the attempt to evaluate animal 
models of mechanisms underlying t.D., is the differential ability of various classes of neuroleptics to 
induce supersensitivity, the recent publication of the A.P.A. task force report on Tardive Dyskinesia 
statesd1)
“Another feature of dopamine supersensitity that must be considered in the attempt to evaluate animal 
models of mechanisms underlying TD is the differential ability of various classes of neuroleptics to induce 
supersensitivity. Since certain “atypical” antipsychotic drugs (notably thioridazine, clozapine, and 
sulpiride) are relatively less likely to induce acute extrapyramidal effects in patients, or presumably 
analogous actions in animals (such as inducing catalepsy or antagonizing dopamine receptor agonists), it 
has been suggested that they may produce tardive dyskinesia less often than other neuroleptic agents. 
This prediction seems to be supported by clinical experience with thioridazine compared with many other 
antipsychotic agents, although this point has not been evaluated critically. Clozapine and sulpiride have 
not been associated with tardive dyskinesia, although they are experiemental drugs and have not yet 
been used for prolonged periods in many patients.”
The Anticholinergic Properties of Thioridazine
Even though it has sometimes been alledged that thioridazine is much more anticholinergic than other 
neuroleptics, a thorough review of the data reveals that thioridazine is not substantially more 
anticholinergic than other neuroleptics.
As an example, utilizing a standard anticholinergic cluster (blurred vision, constipation, dry mouth and 
nasal stuffiness), Galbrecht and Klett (1968)!12) found the following prevalences: fluphenazine, 15%; 
thioridazine, 19%; and chlorpromazine, 21%. Similarly, Lasky(21) et al (1962) showed prevalences for 
fluphenazine at 24%, thioridazine at 31 % and chlorpromazine at 45%.
Low Incidence of EPS with Thioridazine
Based on 22 years’ experience, and continuing review of the literature, it can be concluded that 
thioridazine has the lowest incidence of extrapyramidal reactions of any antipsychotic agent available in 
this country. It has particularly significantly fewer of these reactions than the low mg high potency 
neuroleptics. This conclusion is virtually universally accepted. <2' 5~9'14-1 6 ~ 1 8 ’ 21.22,24 ,25 ,27 ,30 ,31 .34)
CONCLUSIONS
Extrapyramidal side effects may become irreversible and even occasionally life 
threatening. Beyond medical problems, extrapyramidal side effects may interfere with 
patient compliance in taking medication. In this exhibit we demonstrate in animals and 
humans, via behavior and biochemical studies, that various antipsychotic drugs produce 
a differential blockade of dopamine receptors in the brain. Furthermore, it is 
demonstrated that this differential action in the brain accounts for the differing spectrum 
of side effects associated with antipsychotic drugs.
The low incidence of extrapyramida side effects found with thioridazine is due to its site 
specific blockade of dopamine receptors in the limbic system of the human brain. This 
results in effective antipsychotic actions, greater potential for recognition of reversible 
dyskinesias, better patient compliance and a lower incidence of recidivism.
Clinical Assessment of Dyskinesias in the Geriatric Patient
INTRODUCTION
Since the first reports of persistent, abnormal involuntary movements began to appear (Ey et al, 1956)(12) 
numerous prevalence studies have been carried out. Prevalence rates of the condition, subsequently 
classified as tardive dyskinesia, have varied from 0.5% to 56% of patients treated with prolonged 
antipsychotic medication.
Several studies have shown that involuntary movements similar to tardive dyskinesia have been observed 
in elderly subjects who have never been exposed to antipsychotic medication (Crane & Smeets, 1974;!10) 
Bourgeois et al, 1980)!4\
Most epidemiological studies agree that advanced age is an important risk factor for the development of 
tardive dyskinesia (Klawans et al, 1980; Jeste and Wyatt, 1981), and we have recently investigated factors 
related to dyskinetic movements in geriatric patients.
MATERIAL
Five hundred patients, 138 males and 362 females, in 12 British Nursing Homes for the Elderly*, were 
rated for dyskinesias using the Abnormal Involuntary Movement Scale (AIMS).
Ages ranged from 59 to 102 years with a mean of 82.6 years. Medical and drug histories were 
subsequently recorded.
*Bishops House, Shepperton, Middlesex; Weylands, Weylndge, Surrey; The Pines, Woking, Surrey; Hale End, Woking, Surrey; Healthside, Woking, 
Surrey; Birchlands, Englefield Green, Surrey; Brockhurst, Ottershaw, Surrey; Glendale, Walton on Thames, Surrey; The Manor, Old Sindsor, Berkshire; 
Shallcross, Thames Ditton, Surrey; Thames Side, East Molesey, Surrey; Rylston,Walton on Thames, Surrey.
METHODS
Patients sat in an upright, armless chair, with hands resting on the lap and feet placed firmly on the 
ground.
They were invited to look at a composite picture of animals, and told that the picture would be removed 
after two minutes. They were then asked to recall the names of at least three different animals. While no 
significance was attached to the answers, the procedure was quite useful in unmasking dyskinetic 
movements, particularly in the orofacial region.
Using an AIMS score of 3 or greater as indicative of true tardive dyskinesia, a total of 77 (15%) patients 
showed dyskinetic movement.
A higher frequency of dyskinesias (20.7%) was observed in men compared with that in women (13.6%).
There were no significant differences found in dyskinesias among various age groups defined by 
decades.
In the 122 patients who had a history of antipsychotic medication, the prevalence of dyskinesias (23%) 
was statistically significant (p<0.001) as compared with 13% in the 378 patients who had never received 
antipsychotics.
There were no significant difference in the frequency of dyskinesias between males receiving 
antipsychotics (26.5%) and those who had not (21.6%).
However, women receiving antipsychotic drugs had almost twice the frequency of dyskinesias in 
comparison with those who had never been exposed to antipsychotics (21.6% vs 11.0%).
RESULTS
Recent recommendations (Klawans et al, 1980)(20) on restricting the use of antiparkinsonian drugs to 
situations where they are clearly indicated, and then no longer than 90 days is supported in our results.
The total use of antiparkinsonian drugs in the population studied was associated with more dyskinesias 
(37%) than in patients not receiving these compounds (13.4%)
Patients receiving antiparkinsonian drugs in combination with antipsychotic drugs had a significantly 
higher rate ofdyskinesias (43.3%) than patients receiving antiparkinsonian drugs alone (22%).
The use of multiple antipsychotic agents produced more dyskinesias than the use of any single agent.
The antipsychotic drugs associated with the highest frequency of dyskinesias were haloperidol when 
used in combination with other neuroleptics, with and without an antiparkinsonian agent (55.6%), and 
trifluoperazine (40%), whereas no patient receiving thioridazine alone achieved a score of 3 on the AIMS. 
This is consistent with earlier work (Blowers and Bickness, 1980)(3) in which dyskinesias seen in patients 
treated with thioridazine were less frequenct and of lower severity than those treated with haloperidol. 
This observation was also made by Gerlach (19 7 9 )(13)
These clinical findings were similar to those of Mukherje,(23> Rosen, Cardenas, et al, who examined 153 
psychiatric outpatients, on a maintenance regimen of neuroleptics, for tardive dyskinesias and 
parkinsonism..
A IM S  > 3  For P atien ts  on S ingle  N eu ro lep tic  A gents
Drug
Patients with 
AIMS ^  3/Total 
Patients
Dosage
Range
Total
Ingestion
Length of 
Treatment 
(years)
thioridazine* —/1 3 3 0 -4 5 0  mg 6 — 1751 gm 1/4 -  16
prochlorperazine 3/18 1 0 -5 0  mg 1.3 — 27 gm 1/4 -  9
chlorpromazine 3/27 1 0 -300  mg 2.7 — 40 gm 1/4 -  11
promazine 3/17 2 5 -150  mg 4.5 — 216 gm 1/2 -  10
♦Mellaril®
AIMS>3 For Patients on Single Neuroleptic 
and an Antidepressant Agent
Drug
Patients with 
AIMS 3/Total 
Patients
Total
Dosge Range Ingestion
Length of 
Treatment 
(years)
fluphenazine 
+  nortriptyline
1/2 (fluphenazine) 1.5 mg 1 -  2 gm 2 -4
perphenazine 
+  amitriptyline
3 /4 (perphenazine) 4 - 6  mg 0 .36-17  gm Va- 8
trifluoperazine 
+  tranylcypramine
1/1 (trifluoperazine) 2 mg 3 gm 4
AIMS > 3  For Patients on No Neuroleptics, Multiple Neuroleptics
Population AIMS Population AIMS*
No neuroleptics 377 49 (13%) haloperidol+ neuroleptic(s) 9 5 (56%)
+  antiparkinsonian 18 4 (22%) + antiparkinsonian 6 4 (67%)
no antiparkinsonian 359 45 (13%) no antiparkinsonian 3 1 (33%)
Two neuroleptics 20 10 (50%)
haloperidol exclusive 0 0
+  antiparkinsonian 7 4 (57%)
no antiparkinsonian 13 6 (46%)
Three neuroleptics 11 5 (45%)
+  antiparkinsonian 5 4 (80%)
no antiparkinsonian 6 1 (17%)
•Haloperidol was included in this table since there was no record of its use as a single neuroleptic.
DISCUSSION
In this study tardive dyskinesia was significantly associated with the use of high-potency or high dosage 
neuroleptics and depot fluphenazine.
Low-potency neuroleptics were negatively correlated with moderate tardive dyskinesia.
The authors recommend that the use of neuroleptics be limited to conditions where definite indications 
and evidence of benefit exist. They recommend that the guidelines established by the A.P.A. Task Force 
on tardive dyskinesia be followed:
Suggested Guidelines for the Avoidance and Management of Tardive Dyskinesia 0)
“ 1. Consider indications for prolonged neuroleptic therapy carefully; indications (chronic 
psychosis) should be serious, with objective evidence of benefit.
2. Seek alterntive therapies in neuroses and mood and character disorders.
3. Use lower doses in elderly patients and children, strive for minimum effective doses, 
avoid multiple drugs, and remove antiparkinsonism agents as soon as possible.
4. Advise patients and families of risks and benefits; arrive at a mutual decision when use 
of neuroleptic exceeds one year. Not discussion and agreement in clinical record.
5. Examine patient regularly for early signs of choreoathetosis and orallingual dyskinesia. 
Consider alternative neurolgic diagnoses.
6. Reevaluate and document indications and response at least every three to six months 
and attempt to reduce dose.
7. At earliest sign of dyskinesia, lower the dose, change to a less potent agent, or ideally 
stop treatment; await remission as long as psychiatric status permits.
8. Treat dyskinesia with benign agents first (diazepam, deanol, choline, or lecithin in high 
doses, possibly lithium); stay alert to new experimental therapies, if only to bide for time 
and offer hope. Reinstitute neuroleptics only as an extreme measure for disabling 
dyskinesias, using lowest doses feasible.”
Gerlach and Simmelsgared reported in 1978(16) on 16 patients in a cross-over trial of thioridazine, 
clozapine, and haloperidol where they reported that haloperidol might have a greater tendency to induce 
tardive dyskinesia than thioridazine.
In a report on 44 chronically institutionalized patients(11) who had taken only one neuroleptic on a long 
term bais, DeVeaugh-Geiss found that patients on thioridazine cluster around the low AIMS scores, while 
the patients with the highest scores (30’s and higher 20’s) were taking high potency neuroleptics.
CONCLUSIONS
The results also compliment animal studies, in which Sayers et al (1977)<26) showed that the dopamine 
receptor sensitivity produced by thioridazine is significantly less intense and of shorter duration than that 
produced by haloperidol. Borison and Blowers (1981 )<3a) reported a similar pattern in respect of 
thioridazine compared with haloperidol and fluphenazine.
Our data also showed that in an elderly age group, the prevalence of idiopathic orofacial dyskinesias is 
high (13.2%), but only women show a much higher frequency of dyskinesias after antipsychotic drug 
treatment which is consistent with previous epidemiological studies.
In the age range of thegroup we studied (59-102 years) we found no trend towards increasing 
dyskinesias with age.
The use of antiparkinsonian drugs and “high potency” antipsychotic agents dramatically increased the 
frequencies of dyskinesias.
Based upon these findings, it is hoped that it will be possible to more rationally plan the treatment 
regimens for geriatric patients so as to minimize the potential risks for their development of tardive 
dyskinesias.
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